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RÉSUMÉ 
 
Contexte.  Les phénotypes ABO et Rh(D) des donneurs de sang ainsi que des 
patients transfusés sont analysés de façon routinière pour assurer une complète 
compatibilité. Ces analyses sont accomplies par agglutination suite à une réaction 
anticorps-antigènes. Cependant, pour des questions de coûts et de temps d’analyses 
faramineux, les dons de sang ne sont pas testés sur une base routinière pour les 
antigènes mineurs du sang. Cette lacune peut résulter à une allo-immunisation des 
patients receveurs contre un ou plusieurs antigènes mineurs et ainsi amener des 
sévères complications pour de futures transfusions. Plan d’étude et Méthodes.   
Pour ainsi aborder le problème, nous avons produit un panel génétique basé sur la 
technologie « GenomeLab _SNPstream» de Beckman Coulter, dans l’optique 
d’analyser simultanément 22 antigènes mineurs du sang. La source d’ADN provient 
des globules blancs des patients préalablement isolés sur papiers FTA. Résultats.  
Les résultats démontrent que le taux de discordance des génotypes, mesuré par la 
corrélation des résultats de génotypage venant des deux directions de l’ADN, ainsi 
que le taux d’échec de génotypage sont très bas (0,1%). Également, la corrélation 
entre les résultats de phénotypes prédit par génotypage et les phénotypes réels 
obtenus par sérologie des globules rouges et plaquettes sanguines, varient entre 97% 
et 100%. Les erreurs expérimentales ou encore de traitement des bases de données 
ainsi que de rares polymorphismes influençant la conformation des antigènes, 
pourraient expliquer les différences de résultats. Cependant, compte tenu du fait que 
les résultats de phénotypages obtenus par génotypes seront toujours co-vérifiés avant 
toute transfusion sanguine par les technologies standards approuvés par les instances 
gouvernementales, les taux de corrélation obtenus sont de loin supérieurs aux critères 
de succès attendus pour le projet.  Conclusion.  Le profilage génétique des antigènes 
mineurs du sang permettra de créer une banque informatique centralisée des 
phénotypes des donneurs, permettant ainsi aux banques de sang de rapidement 
retrouver les profiles compatibles entre les donneurs et les receveurs.  
Mots clés : SNPs, groupe sanguin, criblage à haut débit, antigènes mineurs 
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ABSTRACT 
 
Background. ABO and Rh(D) phenotyping of both blood donors and transfused 
patients is routinely performed by blood banks to ensure compatibility. These 
analyses are done by antibody-based agglutination assays. However, blood is not 
routinely tested for minor blood group antigens on a regular basis because of cost and 
time constraints. This can result in alloimmunization of the patient against one or 
more minor antigens and may complicate future transfusions. Study design and 
Methods. To address this problem, we have generated an assay on the GenomeLab 
SNPstream genotyping system (Beckman Coulter, Fullerton, CA) to simultaneously 
test polymorphisms linked to 22 different blood antigens using donor’s DNA isolated 
from minute amounts of white blood cells. Results. The results showed that both the 
error rate of the assay, as measured by the strand concordance rate, and the no-call 
rate were very low (0.1%). The concordance rate with the actual red blood cell and 
platelet serology data varied from 97 to 100%. Experimental or database errors as 
well as rare polymorphisms contributing to antigen conformation could explain the 
observed differences. However, these rates are well above requirements since 
phenotyping and cross-matching will always be performed prior to transfusion. 
Conclusion. Molecular profiling of blood donors for minor red blood cell and 
platelet antigens will give blood banks instant access to many different compatible 
donors through the set-up of a centralized data storage system. 
Key words: Genotyping, minor blood antigens, molecular profiling 
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INTRODUCTION 
 
1. General Introduction 
 
 Personalized medicine, Pharmacogenomics, Molecular Profiling, and Targeted 
Therapeutics are all terms describing the same ideal: identifying individual variations 
affecting drug therapies and specialized therapies. It’s well established in the 
scientific community as well as in the regulatory instances that modern medicine 
should target and understand the individual’s genomic make-up in order to increase 
the effectiveness of therapies, as well as decrease the toxicities. Many good examples 
are now reflected in modern therapies, such as Herceptin© (Trastuzumab), Gleevec© 
(Imatinib) or Iressa© (Gefitinib). These anti-cancer therapeutic agents are currently 
prescribed with a molecular profiling assay and they represent the gold standard for 
the personalised medicine approach. To extend this success to other fields of 
medicine, many pharmacogenomics studies have to be performed using state-of-the-
art genotyping technologies.  Many of these technologies are now available to help in 
the research of SNPs (Single Nucleotide Polymorphisms) that affect or influence a 
patient’s therapeutic outcome. Some of these technologies provide the ability to 
perform whole genome scanning experiments (e.g. Illumina, Affymetrix) and some 
are more suitable for focusing on specific genomic regions (e.g. SNPstream, 
Sequenom). (McLeod et al., 2004). 
Since pharmacogenomics is a fairly new field of research, most of the current studies 
are in the early stages of development. Even if some studies are more mature, most of 
them are still closely attached to the bench and more effort is required to transfer it 
into the clinic or at the bed-side. In the last two years, two projects from the Génome 
Québec and Montreal Heart Institute Pharmacogenomics Centre were successfully 
transferred from development into the clinical application. These projects entail the 
development of a molecular profiling panel for minor blood antigens that was one of 
our first projects that we transferred into a clinical process and the other project that 
is currently progressing towards a clinical application is the CVD (Cardiovascular 
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Disease) risk panel. Both projects are using cutting edge technologies available for 
such applications, and the more important thing is that the projects are developed and 
optimized for clinical grade usage. This work is already contributing to their use in 
modern therapy (minor blood antigen panel) as well as to contribute to future 
pharmacogenomics guidance. 
 
2. Genomic variations: An overview 
 
There is a real interest in documenting the amount of genetic variation in the 
human species.  This information is required by the biomedical community, who 
require detailed maps of genetic variations (i.e. SNPs: Single Nucleotide 
Polymorphisms, insertions and deletions (indels), variable number of tandem repeats 
(VNTRs), Microsatellites, Minisatellites and CNV: Copy Number Variation) in order 
to identify genes and loci associated with diseases. The ultimate goal is to 
characterize these variations to identify disease-related polymorphisms among 
patients and populations. This information is also desired by anthropologists to 
reconstruct our “Human History” and understand the role of culture and geography in 
the global distribution of human variation and migration (Weiss, 1998). These 
genomic variations are also valuable for the investigation of molecular events that 
underline evolution, genetic drift, mutation, recombination and selection (Nachman, 
2001). 
2.1. Single Nucleotide Polymorphism 
 
 The Human Genome Project has identified that the most common form of 
variation in the human genome is the single nucleotide polymorphism (SNP). A SNP, 
by definition, is a stable substitution of a single base with a frequency of 1% in at 
least one population.  Single nucleotide polymorphisms are distributed throughout the 
human genome at an estimated frequency of one every 1900 bp.  Up to now, more 
than six million SNPs have been mapped and are accessible in public databases. At 
the chromosome level, SNP densities appear to be constant across the human genome 
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with the only exception being sex chromosomes (Sachidanandam et al., 2001). SNPs 
can occur in different places within the genome and this can result in multiple effects 
on gene function and expression. For example, SNPs can occur in the non-coding 
5’UTR, non-coding 3’UTR, intergenic regions, introns and exons. SNPs that occur in 
exonic regions may be nonsynonymous, coding for an amino acid change (eg. 
GluAsp) as well as synonymous, coding for no amino change (eg. GluGlu). 
2.2. Satellites, Microsatellites, Minisatellites and CNVs 
 
 In 1993, Daniel Tautz was the first researcher to distinguish between satellites, 
microsatellites and minisatellites. He concluded that satellites are composed of 
repeats of several thousand base pairs with frequencies of 103 to 107 at each genomic 
locus and they are located in heterochromatin, mainly in the centromeres. 
Minisatellites and microsatellites are more broadly dispersed throughout the genome 
and they have a moderate degree of repetition; microsatellites typically made up of 
<10 base pair repeats whereas the minisatellites usually contain between 10 to 100 
base pairs (Debrauwere et al., 1997). Since the mini and microsatellites are highly 
polymorphic, these genomic variations have been used to support genomic fine 
mapping as well as to support the forensic investigations. More recently it has been 
discovered that the structural diversity of humans is much greater than previously 
expected. This new finding combined with affordable cutting-edge technologies, has 
led to the creation of a new research area, copy number variation (CNV) mapping 
(Goidts et al., 2006). CNVs define regions of copy number polymorphisms in the 
genome and are responsible for a significant amount of structural variation. One of 
the most examined CNVs is the segmental duplication, these are low-copy number 
repeats of DNA blocks ranging from a few kilobases to several hundred kilobases in 
length (Goidts et al., 2006). 
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2.3. Genetic variation and human diseases 
 
 Generally SNPs have been studied for their impact on defects in biological 
processes; consequently research has concentrated on SNPs that alter the function or 
the expression of the genes. From many studies of complex diseases it has been 
suggested that multiple variants confer the susceptibility, but it’s not clear yet 
whether rare (<1%) or common polymorphisms are determinants that are the most 
responsible. Based on SNP maps, it has been estimated that there could be between 
50,000 and 250,000 functional SNPs (Risch, 2001). Over time, many less common 
single nucleotide variants have been discovered, these do not occur at a high enough 
frequency to be considered as a SNPs (at least 1% frequency), however, they 
nonetheless have been associated with biological defects and other clinical 
importance (Pritchard, 2001). It is well established that an amino acid substitution 
caused by a SNP may interfere with the protein function. Likewise, gene expression 
can also be affected by SNPs positioned in a critical regulatory site. The famous 
example of the CFTR (Cystic Fibrosis) gene illustrates perfectly the deleterious effect 
of a variation that changes an amino acid which results in altered gene function, so 
much so that more than 60 different exonic variants are routinely screened in the 
clinic as a phenotype screening test (Moskowitz et al., 2008).  
 It is also important to take note that SNPs located in promoter regions can 
adversely affect gene expression and infer deleterious phenotypes, such as SNPs 
located in the promoter region of the genes that coordinate the immune response, 
namely variations in TNFα, IL4, IL6 and IL10 have been associated with a range of 
autoimmune and infectious diseases (McGuire et al., 1994). Additionally, it has been 
demonstrated that the -439T>C SNP located in the promoter region of the Duffy 
antigen receptor gene encoding the chemokines FY can completely abolish 
expression when it is present, the same study also demonstrated that this 
polymorphism is mainly present within African populations and leads to a protective 
phenotype against the malaria parasite Plasmodium Vivax (Iwamoto et al., 1996).  
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 Historically the intergenic and intronic regions have been less well examined and 
are infrequently associated with changes in phenotype.  Recently however, intergenic 
and intronic SNPs have been of interest and are no longer associated with “Junk 
DNA” (Zuckerkandl, et al., 2007). To illustrate this, a recent study involving the 
CYP2D6 cytochrome enzyme has demonstrated that the single nucleotide 
polymorphism G>A located in the intron 6 at the position 2988 has a direct impact on 
the mRNA level and also on protein expression. Further mechanistic experiments 
have demonstrated that conversion from G to A destabilizes the splicing events and 
therefore reduces the amount of mature CYP2D6 containing exon 6 (Toscano et al., 
2006). This recently described polymorphism is known as *41 and represents one of 
the main deleterious components of CYP2D6 gene and therefore affects greatly 
human body detoxification.  
 Variations in regulatory regions are typically associated with mRNA expression 
levels, and consequently the resulting protein levels.  Polymorphisms found in the 
promoter regions can also be predictive for human diseases. The UGT1A1 gene 
illustrates the importance of such polymorphisms in a non-coding region. The variant 
UGT1A1*28 is well described in literature to affect the downstream regulation of the 
enzyme consequently leading to the impaired elimination of the bilirubin and 
subsequently causing Gilbert Syndrome (Roden et al., 2006). 
 Since 1993, microsatellites and minisatellites have been well characterized and 
are associated with human diseases that have dominant mode of inheritance.  The 
diseases are classified into two groups, the first represents the size of repeats in the 
coding or regulatory genomic regions affecting gene expression and leading to 
aberrant or toxic proteins (Sutherland et al., 1995). The second group is associated 
with familial heredity defects and cancers. These types of variation are often located 
in very unstable repeat regions. Taken together more than a dozen well known and 
characterized diseases have been recorded. Huntingdon disease, muscular dystrophy 
and fragile X syndrome are some of the most examined pathologies related to 
minisatellites. Typically, the numbers of repeats are directly connected with the age 
of the disease onset (Fu et al., 1991). With new research in the CNV area, many 
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Figure 1: copied from Roden et al., 2006
different associations have been made regarding disease susceptibility. A great 
example of the utility of such mapping is the case of the HIV, where CNVs have 
been highly associated CCL3L1 gene duplications and the susceptibility to acquire 
AIDS (Gonzalez et al., 2005). 
 
2.4. The Promises of Pharmacogenomics 
 
  Between 1909 and 1923, the physiologist Archibald Garrod, was the first 
person to propose that common genetic factors might underline the error of 
metabolism and the variability in drug response (Roden et al., 2006).  Today, the 
outcome of drug therapy is often well understood, but still sometimes unpredictable, 
varying from beneficial effects to lack of efficacy to very serious adverse drug 
reactions. Recent statistics have demonstrated that more than 100,000 deaths annually 
in the US are attributable to adverse drug reactions. Up to 7% of all hospital 
admission in North America and Europe are related to ADRs (adverse drug reactions) 
(Manolopoulos, 2007). 
The concept that genetic variation contributes to disease phenotypes and drug 
response is commonly accepted in the scientific community. In 2003, the 
International Human Genome Sequencing consortium declared the Human project 
had been completed, giving 
expectation for clinical 
applications in the near future. 
The field of pharmacogenomics 
promised the end of the “one 
drug fits all” trial and error drug 
selection system, and was 
predicted to be part of the first 
clinical application of the Human Genome Project (Swen et al., 2007). Understanding 
the genetic contribution to the variability in drug response provides a new tool in 
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drug development with the hope of decreasing the risk of toxicity and identifying the 
patients that will beneficially response to the medication (Roses, 2004).  The terms of 
“Pharmacogenomics” and “Pharmacogenetics” are broadly used in different scientific 
discussions as well in many literatures and reviews.  Both terms are intimately 
connected since they are referring to the exact same endpoint. Pharmacogenetics 
focuses on the large clinical effect of single gene variants in a small number of 
patients, whereas pharmacogenomics examines many genomic loci including large 
biological pathways such as lipid-lowering agents (Liao, 2002) and hypertension 
(Dedenus, 2004), as well as the whole genome (Iakoubova et al., 2008) to identify 
variants that together determine the variability in therapeutic outcomes (See figure 1). 
Even if pharmacogenomics and pharmacogenetics are quite recent research areas, the 
literature abounds with studies that involve different genes and different therapeutic 
fields. In the current clinical practice at least five known drugs are prescribed with 
pharmacogenetic tests (Sheffield et al. 2009). In early 1990, some studies 
demonstrated that women with breast cancer having HER2 over expression had very 
poor prognosis. In the same decade Genetech developed a monoclonal antibody 
directed drug against the HER2 protein conferring for those women real 
improvement in clinical outcomes. Pharmacogenomics gained in popularity when 
Herceptin© (Trastuzumab) was prescribed with a pharmacogenomics pre-screen test. 
Today, testing for HER2 over expression is a standard practice to detect candidates 
for Herceptin© (Trastuzumab) treatment among women suffering from breast cancer 
(Swen et al., 2007).  Also, one of the most studied pharmacogenomics tests is for 
Warfarin. Since this drug is the most widely prescribed oral anticoagulant drug and 
there is greater than 10-fold interindividual variability in the dose required to attain 
the therapeutic response, the need of a pharmacogenomics clinical test to determine 
the optimum starting dose was urgent.  The genes CYP2C9 and VKORC1 have been 
identified as the two major contributors for the interindividual response to warfarin. 
Today, many retrospective and prospective studied tend to demonstrate that the 
genomics markers *2 and *3 of CYP2C9 gene and -1639 G>A of VKORC1 gene, 
contribute at least at 40% of the interindividual variability in dose requirement (Van 
Schie et al., 2009). Other current examples of pharmacogenomics being applied in 
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Figure 2: Copied from: Taylor et al., 2001
the clinic include irinotecan, a colorectal anticancer agent, Abacavir, an antiviral and 
Tamoxifen a breast cancer treatment, are routinely prescreened for UGT1A1, HLA-B 
and CYP2D6 respectively (Roden et al., 2006 and Swen et al., 2007). 
2.4.1. Gene selection: Direct and Indirect approaches 
 
 With these numerous successes, many other therapeutic areas are on the way 
to identifying key genomics-based elements correlated with either drug efficiency or 
toxicity. Among these therapeutic areas, the antihypertensive, lipid-lowering, 
anticancer and neurologic disorder drugs are the most advanced in the identification 
of potential pathways that underline genes and markers that could infer specific risk 
of drug toxicity or poor drug response. The current effort put in these different 
studies is identifying more and more complex pathways and polygenic problems. For 
instance, lipid lowering therapies implicates the very complex Mevalonate pathways 
and indirectly related pathways such as the isopranoids and glycosylation pathways 
as well as the intracellular signaling pathways (Hanai et al., 2007). This has led to the 
identification of more than 500 related and less related genes and more than 50,000 
potential clinically relevant markers. To investigate this, two genotyping strategies 
can be employed; the candidate gene approach (direct approach) and the whole 
genome scan approach 
(indirect approach). The 
two approaches have 
specific advantages and 
disadvantages. The 
candidate gene approach 
refers to the selection of 
genes that are part of 
known pathological 
pathways as well as part 
of a genetic association 
hypothesis. This strategy can be extremely powerful for studying the genetic make-up 
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of complex traits and pin-point the rare variants. Nevertheless, the candidate 
approach is greatly limited as it relies on existing knowledge about the presumed 
biological pathways and biological concept, and unfortunately most of the biological 
attributes remain unknown (Zhu et al., 2007). In contrast, the whole genome scan 
approach proceeds without any presupposition regarding biological knowledge, 
which leads to an unbiased approach. The main advantage of this approach is a 
greater coverage of all pathways including unknown loci that possibly underline the 
drug toxicity or inefficiency. The biggest disadvantages of this technique are the high 
cost related to such experiments, which needs expensive technologies and reagents 
and the relative high number of individual needed to reach statistical endpoint value. 
Also, since the whole-genome scan approach relies mainly on Hapmap data, it can 
only identify pre-described loci, so a candidate approach will be necessary to further 
map and isolate the causative markers (The International HapMap consortium, 2003). 
Figure 2 illustrates the concept of candidate genes and whole genome scan 
approaches and the downstream processes involved in defining the clinical 
application (Taylor et al., 2001).  Over the past few years the whole genome 
approach has held great interest for the pharmacogenomics studies. Since the clinical 
drug response is not only reflecting the intrinsic properties of target cells or 
pathways, but also metabolic properties, drug-drug interactions, pharmacokinetic, 
pharmacodynamic as well as the population and gender. Consequently the whole-
genome scan approach enables the highest degree of possible associations to be 
identified. Also, with the completion of the Hapmap project in 2003, the availability 
of Hapmap data for different populations have permitted a better evaluation of 
population and gender effects on drug toxicity (Zhang et al., 2008).   
 
2.4.2. Selection of markers: Candidate genes and HapMap 
resources 
  Traditionally when a pharmacogenomics study design uses a candidate gene 
approach, most candidate markers are selected from both literature and public 
database (eg dbSNP and OMIM) search. For the candidate gene approach, the 
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Figure 3: Copied from HapMap project 
 
Figure 5 : Copied from Jones et al., 2007 
 
Figure 4  
markers are selected based on their known association with specific diseases as well 
as their pharmacogenetic clinical importance. Most of the time the list of markers is 
complemented with markers that have unknown function but could potentially 
modify the target protein (e.g. variants located in the exons, promoter and intronic 
splicing sites).  The HapMap data resource has greatly improved SNP 
selection. Briefly the 
HapMap resources have 
elucidated the common 
patterns of DNA 
sequence variation in 
the human genome, 
leading to well 
characterized SNPs, 
their frequencies in multiple populations, and the extent of linkage disequilibrium 
between them. Linkage 
disequilibrium is 
explained by the fact that 
each disease-causing 
mutation arises on a particular copy of the human genome and bears a specific set of 
common alleles in cis at nearby loci, termed a haplotype (figure 3). Because the 
recombination rate is 
low [~1 crossover per 
100 megabases (Mb) per 
generation], disease 
alleles in the population 
typically show 
association with nearby 
marker alleles for many 
generations, a 
phenomenon termed linkage disequilibrium (LD) (Altshuler et al., 2008). The linkage 
disequilibrium has the great practical advantage to allow selection of only the most 
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relevant SNPs (tagSNPs) that will provide enough information to predict the 
frequency and incidence of the remaining common SNPs, thus only “tag SNPs” are 
required to be part of a genotyping panel and for subsequent analysis in further 
experiments (figure 3) (The International HapMap consortium, 2003). The 
combination of tagSNPs and well characterized functional markers permit the highest 
possible gene coverage, making possible the functional marker-phenotype association 
as well as a haplotype based association (see figure 4). A recent study (Jones et al., 
2007) has demonstrated the use of a combined strategy, which is the use of candidate 
genes complemented with HapMap resources, giving more strength for finding the 
associated markers. They demonstrate that the use of HapMap markers and a 
candidate gene approach have led to identification of the well established TPMT 
polymorphism (719 A>G), which is linked with the clinical loss of TPMT activity 
and consequently higher drug related toxicity (see figure 5). 
2.4.3. Towards clinical translation 
  Despite the accumulation of publications in pharmacogenomics showing the 
clinical benefits for many biological processes, the translation towards the clinic is 
not in its optimal phase. The lead 
reason that explain the slow 
translation of pharmacogenomics to 
clinical practice is the absence of 
important randomized studies using 
pharmacogenetics markers that 
show positive clinical outcomes 
(lest negative clinical events, better 
drug response and less drug 
toxicities). The main steps for 
clinical implementation of 
pharmacogenomics include (See 
figure 6): A) execution of large 
prospective clinical studies showing the benefit of pharmacogenomics; B) developing 
 
Figure 6: Copied from Swen et al., 2007 
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Figure 7: Copied from Van Rooij et al., 2008 
robust and validated tests to support the specific molecular profiling assays; C) 
development of specific clinical guidelines; D) education of clinicians and other 
health care professionals who interact with patients; E) creation of ethical guidelines 
(Manolopoulos, 2007). The lack of approved diagnostic tests and the lack of robust 
genetic assays are the two most critical technical issues today. However, recent 
improvements in the technologies that support the analysis of variant alleles that 
underline the ADR or drug inefficiency have resulted in a number of potentially 
commercial assays.  With the recent advancement of available robust and accurate 
technologies combined with the recent introduction of FDA-approved clinical assays, 
such as the Amplichip from Roche and the Invader UGT1A1*28 assay, the 
translation to the clinic is on the way to common use. However, one of the major non-
technical issues for the integration of pharmacogenomics into the clinic is still 
education of health 
professionals. A common 
perception of 
pharmacogenomics is that 
it represents an additional 
burden and complication 
regarding the therapeutic 
decision-making process. 
The implementation of 
pharmacogenomics 
training at undergraduate and postgraduate levels as well as continuing medical 
education will help inform professionals how to apply pharmacogenomics in modern 
medicine. In order to facilitate the integration of pharmacogenomic results into 
clinical application, some researchers have started to initiate the development of a 
pharmacogenomic clinical informatics systems (see figure 7). This application will 
bridge the gap between the current pharmacogenomic research and the reality of 
clinic application. The clinical translation will facilitate the incorporation of 
pharmacogenomics testing by informing the clinician about available 
pharmacogenomics tests, facilitate the transfer of relevant pharmacogenomics 
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information between the lab and clinical site and provide clinical guidance on drug 
prescriptions and relevant dose based on lab results (Van Rooij et al., 2008). 
 
3. Genotyping and cutting edge technologies 
 
The detection of causative polymorphisms that have the potential to impact 
protein expression or activity has always been of great interest among the scientific 
community.  Before the arrival of PCR (polymerase chain reaction) in the mid 1980s, 
the first genotyping technique to be used to detect a single base mismatch was the 
hybridization of allele-specific oligonucleotides (ASO) and was first described in 
1979 (Wallace et al., 1979). The technique was then used for the first time in 1983 to 
detect the sickle-cell mutation in the β-globin gene (Conner et al., 1983).  With the 
invention of PCR, a broad spectrum of different genotyping techniques was 
developed. One of the first PCR-based genotyping techniques that was developed 
was SSCP (single-stranded conformation polymorphism) detection, where both 
alleles are separated on a non-denaturing polyacrylamide gel and detected following 
their migration patterns (Shi, 2001). This technique was relatively popular excluding 
the fact that it is labor intensive and low throughput. Another widely employed PCR-
based genotyping technique was called PCR-RFLP. This involved PCR amplification 
followed by restriction enzyme digestion and became one of the most popular 
techniques in the 1980s and is still used today. This technique utilizes highly specific 
restriction enzymes that cleave specific DNA sequences. If the polymorphism creates 
or removes a restriction enzyme site present in the PCR fragments then the 
polymorphism will result in a specific digestion pattern that can be visualised using 
gel electrophoresis (Shi, 2001). The PCR-RFLP based genotyping technique, despite 
being low-throughput, remains today extremely popular and has been utilized in 
many recent studies and clinical applications. For instance, this technique is currently 
used in the clinic to detect variability in the HLA region (Human leukocyte antigen) 
(Doxiadis et al., 2003) as well as some cytochrome P450 variations (Jannetto et al., 
2004). However these PCR-gel based strategies are mainly used for single gene 
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Figure 8A: Copied from Brennan et al., 2001 
analysis in a low throughput context, and with the growing interest for polymorphism 
detection in polygenic diseases, such strategies are not viable.  
Over the past 10 years, an impressive number of different non-gel-based high-
throughput technologies have been developed in order to support large diseases-based 
genetic polymorphism association studies as well as for supporting large-scale 
pharmacogenomics studies.  Two main categories of technologies have been 
developed, the medium-high-throughput and very high-throughput technologies. 
Each category of technologies has been developed to support different needs. In 
general, the medium-high-throughput technologies are most suitable for a large 
number of samples (>384) to be screened for a few genetic polymorphisms (~12 to 
50), whereas the very-high-throughput technologies are most suitable for a large 
amount of genetic polymorphisms (~1536 to 1,000,000) for a low number of samples 
(<96).  
 
3.1.Medium-High-Throughput technologies 
 
This category of technology primarily utilizes a PCR-based strategy, but instead of 
identifying the genetic polymorphisms using gel electrophoresis, the detection is 
performed using either 
the incorporation of 
fluorescence or mass-
based changes in the PCR 
amplicons. These are then 
analysed using different 
types of DNA array 
matrices. Typically, this category of technology can multiplex between 12 and 50 
different genomic regions in a single PCR reaction and can analyse 384 samples 
simultaneously. In general, the size of the PCR amplification containing the genetic 
variation is limited to ~100 to 200 bp in order to amplify uniformly all of the 
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Figure 8B: Copied from Brennan et al., 
genomic regions and reduce amplification competition among the PCR reactions 
within the same tube.   
From the multiplex PCR reaction, depending on which technology the downstream 
genotyping process is processed; the detection of the polymorphic sites is typically 
achieved using either SBE (Single base extension) or ASE (Allele specific 
extension). Single base extension tends to be more robust and accurate than the ASE 
technique since the SNP detection is based on the high accuracy of nucleotide 
incorporation by the DNA polymerase (Syvanen et al., 2001) (see figure 8A). 
Basically the same extension probe is hybridized to the pre-amplified PCR template 
and then the SNPs are extended by one base using a modified DNA polymerase and 
nucleotides. Since the extension probe for a specific polymorphism has the same 
affinity for all different alleles, the reaction conditions remain similar giving robust 
and reliable genotyping 
results. On the other 
hand, the ASE technique 
(see figure 8B) utilizes 
two different extension 
probes to detect a specific 
genetic polymorphism, 
then the genotyping 
specificity is driven by the affinity of both extension probes for the PCR template. 
Since precise and accurate hybridization is required for specific allele extension of 
the probe, most of the time this technique requires rigorous optimisation to allow for 
uniform and similar annealing hybridization to accurately discriminate both alleles. 
This is more complex when multiplexing is involved. However, both genotyping 
techniques are represented among the most cited technologies. SBE is the method of 
choice for many known medium-throughput technologies as such as, SNaPshot from 
Applied Biosystems (Foster City, CA), SNPstream from Beckman Coulter (Fullerton, 
CA) and MassArray from Sequenom (La Jolla, CA), whereas the ASE detection is 
utilized by Taqman from Applied Biosystems (Foster City, CA), Tag-It from 
Luminex Molecular Diagnostic (Austin, TX) and Infinity from Autogenomics 
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(Carlsbad, CA) (Syvanen, 2001 and King et al., 2008). For all these technologies, the 
detection method depends on specific PCR amplification of the genomic region 
encompassing the genetic polymorphism. Specific PCR amplification is required to 
precisely and quantitatively amplify the desired genomic region to a degree where the 
detection method can adequately distinguish between homozygotes and 
heterozygotes for the SNPs of interest. The difficulty of designing and performing 
multiplexed PCR reactions is an important factor that limits the throughput of SNPs 
within each reaction.  
These technologies have been used for many medium sized studies as well as to 
support clinical assays. In the context of fundamental research applications, these 
technologies have been utilized to support the fine SNP mapping of the associated 
genomic loci or to validate associated SNPs in a replicate cohort (Sladek et al., 2007). 
Since these technologies are completely customizable and give accurate results, 
diagnostic and clinical applications utilizing them are possible.   
 
4. Blood antigens: Red blood cells and platelet antigens 
 
 Blood group antigens are proteins, glycoproteins or glycolipids that are located 
on the exofacial surface of the RBC (red blood cell) and platelet membranes. They 
are known to be genetically polymorphic. Inheritance of these variations results in 
variability in the structural characteristics of an individual’s blood cells. For red 
blood cells, there are 30 blood group antigen systems whereas for platelets there are 
24 antigens. The genetic bases of the carbohydrate–dependent blood groups are 
established by variation in glycosyl-transferase DNA sequences expressed by the 
erythroid and platelet cells, which are known to affect the enzyme specificity or the 
efficacy of polysaccharide synthesis occurring in the Golgi compartment (Avent et 
al., 2007).  The most clinically relevant RBC antigen systems are related to the 
structural erythrocyte membrane proteins: ABO (ABO), RH (D, cC, eE), Duffy-
DARC (Fyab), Kidd-JK (Jkab), Kel and XK (kK and Kapab), MNS- GPYA-GPYB 
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(MN, sS), Colton-AQP1 (CO) and Dombrock-ART4 (DO) (Avent et al., 2007). 
These proteins have different functions in the cell, such as; transporters and channels 
(RH, JK, CO), structural functions (GPYA and GPYB), chemokine receptors (FY), 
and membrane-bound proteins (KEL and DO). The most relevant platelet antigens 
are HPA1-ab, HPA2-ab, HPA3-ab, HPA4-ab, HPA5-ab and HPA15-ab.  
 The cells carrying a particular antigen can, if introduced into the circulation of 
patient with difference minor blood cell antigens, produce an immune response. The 
antibodies produced by the patient against the foreign antigens can result in problems 
in transfusion incompatibility, maternal-fetal incompatibility and autoimmune 
hemolytic anemia (Reid, 2003). In many countries, only major blood antigens ABO 
and D are routinely tested for in patients receiving infrequent blood transfusions, 
however chronically transfused patients that are suffering from sickle cell diseases, 
thalassaemia, autoimmune hemolytic anemia and plastic anemia need closer 
monitoring of their RBC and platelet antigen profiles (Polin et al., 2008). 
Additionally, it has been described by the National Heart, Lung and Blood institute 
that the incidence rate for alloimmunization for patients suffering from sickle cell 
disease and receiving blood, is 20 percent or higher compared to 5 percent in the 
other transfusion-dependent patients (Reid, 2007).  The major blood antigens, ABO, 
are rarely involved in HDN (hemolytic disease of the fetus and newborn), in contrast 
the minor antigens Rh, Kell, Duffy and Kidd are seriously implicated in neonatal 
alloimmunization. In the case of platelets, limited numbers of platelet transfusion-
dependent patients develop HPA antibodies; however the HPA profile is often 
required in the case of neonatal alloimmune-mediated thrombocytopenic purpura 
(Beiboer et al., 2005). 
 
4.1.Goodbye hemagglutination, welcome DNA based assays 
 
Traditionally, hemagglutination has been the principal analytical tool of 
immunohematology to determine blood antigens. This technique was used for the 
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first time by Karl Landsteiner in 1901 when he discovered the major ABO blood 
antigens and was then modified by Coombs, Mourant and Race when they discovered 
many other minor blood antigens. The principal of hemagglutination is the antibody-
mediated clumping of particles that express antigens on their surface. Basically, 
serum containing a known antibody is added to a suspension of RBCs and if the cells 
carry the equivalent antigen they are agglutinated, if no agglutination appears the 
cells are lacking the antigen (Anstee, 2005). More recently, 29 of the 30 blood group 
genes have been cloned that encode more than 300 blood group antigens. This has 
paved the way toward the development of DNA molecular based testing, especially 
for the minor blood group antigens where the majority of genetic bases are associated 
with only one SNP. However the genetic basis of the major blood group (ABO) 
antigens are quite complex, since more than 15 SNPs have to be typed to correlate the 
current hemagglutination test. Robust, reliable tests and reagents have been optimized 
for the major blood antigens (ABO and D) over the last twenty years, but at the same 
time the hemagglutination technique has shown a lack of robustness and reliability 
for the minor blood antigens. Even if the hemagglutination tests, when appropriately 
performed, have the sensitivity and specificity to support clinical needs, the technique 
has demonstrated limitations for many important clinical aspects such as unreliable 
prediction of a fetus at risk to develop hemolytic disease of newborn (HDN), 
difficulty to correctly type the RBCs of patient who recently received a blood 
transfusion, as their blood cells are coated with antibodies, and it does not predict D 
zygosity in D+ patients (Reid, 2003). In addition, only relatively small numbers of 
donors can be typed because of reagent shortages in reliable antisera due to limited 
availability of antigen-specific antisera inventories. Also it has been reported that 
many antibodies are not well characterized and some antibodies are weakly reactive 
or simply unavailable (Reid, 2003). This is also true for the platelet antigens where 
only the HPA1 assay has a specific monoclonal antibody available, whereas the other 
important HPA antigens can only by typed using fastidious human antisera-based 
assays (Reid, 2007). Because of the poor availability and poor performance for some 
of these reagents, the hemagglutination technique has been severely limited while at 
the same time being the accepted standard for worldwide blood-typing for the entire 
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20th century. With the challenges and inefficiencies of the hemagglutination assay 
coming to light and the advent of new genomic technologies, now is the time to 
change the paradigm and to evaluate the effectiveness of antigen specific genotyping 
as a tool for clinical blood banking. 
 
5. Scientific interest and global objectives 
 
Since it is widely accepted that genetic variation contributes to variability in 
disease phenotypes and drug responsiveness, the development of DNA based 
molecular profiling assays has become more established and has led to the promise of 
personalized medicine. From the drive to develop many meaningful genetic assays, 
many different techniques and technologies have been developed to support the 
identification of genetic variants and therefore contribute to the association between 
DNA makeup, diseases and xenobiotics responses. Historically, because of technical 
issues and statistical power, the interaction of diseases or drug response with DNA 
composition has only evaluated one gene at the time for a limited number of genetic 
markers. With the recent advancement in genotyping technologies, reduction in costs, 
the capacity to multiplex many genes and the ability to screen many markers in a 
single reaction, the use of genetic biomarkers in clinical research has been greatly 
accelerated. With the numerous possible applications brought on by these cutting-
edge technologies, we have set out to develop many different DNA based panels to 
support pharmacogenomic needs in the context of the clinical environment. The 
actual worldwide interest for personalized medicine has increased significantly since 
the development of new DNA-based technologies but, up to now, only a few 
clinically approved DNA-based assays are available and used for specific 
applications. In that context, along with the development of clinical grade 
pharmacogenomics assays, we have created a unique Canadian Clinical Centre 
environment dedicated to pharmacogenomics research. One of the goals of our 
Centre to is to set the standards for pharmacogenomics panel development and 
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operations.  Our Centre is presently working to become recognized as supporting 
clinical research under GLP (good laboratory practice) standards and to become 
accredited by the College of American Pathologist (CAP and CLIA). Until we reach 
this accreditation, we are developing and validating all DNA-based assays following 
rigorous clinical guidelines in order to support pharmaceutical development projects 
or clinical trials, as well as biotechnology companies and hospital network projects.  
Since using the traditional hemagglutination techniques to screen blood 
banking donors for compatible blood can be very problematic and sometimes 
impossible, and because, as described earlier, hemagglutination is the main technique 
used to type the worldwide blood reserve. As part of my thesis research, we wanted 
to develop a clinical grade genetic panel that could improve on the efficiency and 
cost of the hemagglutination assay and that would support the creation of a minor 
blood group antigens electronic database for donors from Héma-Québec. Using 
knowledge of DNA-based panel development previously acquired at the 
Pharmacogenomics Centre, we plan to create a unique pharmacogenomics panel of 
11 DNA markers that could infer the phenotypes of 22 of most clinically-relevant 
minor blood group antigens using a medium-high-throughput technology. The 
development process will consist of a development phase followed by a clinical 
validation phase. Once the validation phase is completed and accepted by Héma-
Québec, we will develop a set of clinical laboratory standard operational procedures 
(SOPs) that will permit the integration of the pharmacogenomics minor blood group 
antigen genotyping panel into Héma-Québec’s clinical processes. We will then 
conduct a proof of concept project to evaluate how the use of this genotyping panel 
and the creation of a database of molecularly profiled donors can improve Héma-
Québec’s operations. The proof of concept study will consist of the screening of 
22,000 patients in order to create the first North America blood bank electronic 
register for minor blood antigens. 
The molecular profiling data in the database will be used to: 
• Help assign appropriate donors to patients requiring frequent blood 
transfusions  
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• Identify a fetus at risk for HDN 
• Detect weakly expressed antigens (e.g., Fyb with the FyX phenotype); where 
the patient is unlikely to make antibodies to transfused antigen-positive 
RBCs 
• Replace antibody hemagglutination assays that are weak or not available,  
• Distinguish an alloantibody from an autoantibody 
• Identify molecular basis of unusual serologic results, especially Rh variants 
• Permit large scale screening of antigen-negative donors to create an 
inventory of donors whose RBCs lack a high-prevalence antigen 
• Detect genes that encode weak antigens 
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MATERIALS AND METHODS 
 
 
1. Gene and marker selection 
The nine genes and eleven markers presented in table 1 were selected by the 
clinical and the development departments of Héma-Québec (HQ). Briefly these 
variations were selected on the basis of the clinical requirements of regulatory 
agencies (Canadian, American as well as European) as well as the specific Quebec 
requirements regarding frequencies (above 5%) and relevance of these antigens in the 
population. 
Table 1: Genes, markers and antigens details 
 
This table describes the genotyping minor blood antigen panel content. For each 
antigen the table shows their public database IDs (related genomic marker), 
nucleotide variations and the downstream amino acid changes.  
 
 
2. DNA sources 
Panel Development: DNAs from 96 Caucasian, 96 African-American and 89 
Asian unrelated healthy individuals were obtained from the Coriell Institute for 
Medical Research (Camden, NJ) following completion of the appropriate assurance 
and research statement forms. All samples were thawed at room temperature and 
8.3µL (all original samples concentrations were around 300ng/µL) of all samples 
were transferred into three 96-well plates. The volumes were completed to 200µL 
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with PCR grade water to yield a final concentration of ~12.5ng/µL. FTA cards with 
blood were also received from Héma-Québec for testing the punching and DNA 
extraction techniques, as well as the genotyping conditions. 
Panel Validation: Peripheral blood samples were collected from 618 randomized 
volunteers from the province of Québec after signature of an informed consent form 
approved by Héma-Québec’s Research Ethics Committee. Samples consisted of a 
blood drop applied on an FTA card. All samples were anonymized and the FTA cards 
were sent to Génome Québec in Montreal for genotyping.  These samples were used 
for the genotyping blood antigen panel (GBAP) validation since a good proportion of 
these blood samples were also phenotyped at Héma-Québec for the typical minor 
blood group antigens using standard serology techniques. 
 
3.  DNA extraction from FTA cards 
DNA was extracted from the FTA cards using the GENERATION DNA 
purification technology (Qiagen, Mississauga, ON). To test which FTA paper punch 
size generated the highest extracted DNA yield, 2mm, 3mm and 4mm punches were 
made using a Harris Uni-Core Puncher and distributed in a standard 96-well plate 
containing 1µL of PCR grade water whereas the  6mm punches were distributed in a 
deep well plate containing 1µL of PCR grade water. Three blank punches were 
generated between each sample to clean the puncher. During the validation steps only 
the 2mm punch size was used. To remove haemoglobin contained in the FTA card, 
150 µL of Buffer 1 (DNA purification solution; G1-1000) was added to each well 
using a 12-channel pipette and then incubated at room temperature for 20 minutes. 
All samples were mixed three times using a 12-channel pipette with an up and down 
action and the coloured mixture was discarded. Two more washing cycles were 
performed with the Buffer 1 and Buffer 2 (DNA elution solution; G2-500). All 
remaining purification solution was completely removed. To extract DNA from the 
FTA card punch, 25 µL of Buffer 2 was added to each sample and incubated at 99⁰C 
for 15 minutes. After the incubation, the plates were pulse centrifuged and the entire 
contents of each well (without the FTA card) were transferred to a new 96-well plate. 
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The extracted DNAs were quantified with the Nanodrop system using 2 µL of 
undiluted mixture. The DNAs were also quantified using Picogreen (Invitrogen, 
Carlsbad, CA) diluted from 200X to 1X in TE buffer and the Varioskan 
(ThermoFisher, Waltham, MA) (Biotechniques, 1996).  
 
3.1. Long PCR amplification on DNAs extracted from FTA cards 
CYP2D6 (chromosome 22, positions 40853647 to 40855434) was amplified 
using PCR oligos 2D6_Prd7-F 5’ CTGGAATCCGGTGTCGAAGTGG 3’ and 
2D6_Prd7-R 5’ CGGCCCTGACACTCCTTCTTG 3’ at 0.5 µM final concentration. 
The PCR master mix contained 1X PCR buffer, 1.5 mM MgCl2, 0.4 mM dNTPs, 5% 
DMSO and 0.3 U/µL of Platinum Taq (Invitrogen, Carlsbad, CA). 2 µL of DNA 
extracted from FTA cards was mixed with 8 µL of the master mix and amplified 
following the initial denaturation at 95⁰C for 2 minutes then 2 cycles of 92⁰C x 1 
min., 59⁰C x 1 min., 68⁰C x 6 min. and 35 cycles of 92⁰C x 30 sec., 59⁰C x 30 sec. 
and 68⁰C x 6 min. 5 µL of the PCR amplification buffer and 3 µL of the 1 kb ladder 
(Invitrogen, Carlsbad, CA) were mixed with 10 µL of PCR grade water and loaded 
on a 1% agarose gel for band analysis.  
APOE (chromosome 19, positions 50100128 to 50101071) was amplified using 
PCR oligos rs449647-PCRU3 5’ GCATCATACTGTTCCCACCCCTC 3’ and 
rs440446_PCRL2 5’ CCGCTCCTCCTCTCCCCAAG 3’ at 0.45 µM final 
concentration. The PCR master mix contained 1X PCR buffer, 1.5 mM MgCl2, 0.1 
mM dNTPs, 1X Qsolution and 0.06 U/µL of Qiagen HotStart  Taq (Qiagen, 
Mississauga, ON). The amplification was obtained using 2 µL of DNA and 3 µL of 
master mix and amplified with the initial denaturation at 95⁰C for 15 minutes then 12 
cylces of 95⁰C x 30 sec., 66⁰C x 45 sec. (-0.5⁰C/cycle), 72⁰C x 45 sec. and 30 cycles 
of 95⁰C x 30 sec., 60⁰C x 45 sec., and 72⁰C x 45 sec. 5 µL of the PCR amplification 
buffer and 3 µL of the 1 kb ladder (Invitrogen, Carlsbad, CA) were mixed with 10 µL 
of PCR grade water and loaded on a 1% agarose gel for band analysis. 
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4. Genotyping 
                   
4.1. Primer Design 
DNA sequences flanking each SNP were tested for the presence of repeats or 
duplicated regions and masked if needed using the BLAT program 
(http://www.genome.ucsc.edu). All DNA sequences, except for c/C, e/E, M/N and 
s/S antigens, were formatted using the appropriate SNPstream and Sequenom 
oligonucleotide design software programs. For the first phase of development, the 
PCR and extension primers were designed using the Autoprimer 
(http://www.autoprimer.com) and Sequenom AssayDesign software for SNPstream 
and Sequenom technologies respectively. For the SNPstream technology, the 
program selects PCR primers that will generate products ranging between 80 and 200 
bp and an optimized single base-pair extension primer 5’ to the SNP site and 
assembles them into panels of 12 SNPs of the same extension type (i.e. G/A or C/T 
extension mixes). Also, the Autoprimer program added a unique tag address of 20 
bases at the 5’ of each extension oligo in order to make the hybridization possible 
onto the microarray SNPware plate (Bell et al. 2002).  Similar to the Autoprimer 
program, the AssayDesign software designs PCR primers that will generate 
amplicons ranging from 80 to 200 bp. The software also suggests the appropriate 
single base-pair extensions ranging in size from 18 bp to 35bp in order to separate 
them from the extended SNPs according to their respective masses. The AssayDesign 
software also adds 10 extra bases (ACGTTGGATG) at the 5’end of the PCR oligo to 
increase the total mass above 10,000 Daltons. This brings the detected PCR oligo 
masses outside of the analyzed window (3500 to 9000 Daltons) in the mass spectrum.  
Both the autoprimer and AssayDesign software are dedicated to design only one 
oligo set per SNP at a time (one set meaning two PCR oligos and one extension 
primer). Since the minor blood group antigen genotyping panel design required 
assays for both DNA directions, the second extension primers were designed using a 
modified input file that directed the extension oligo design in the opposite direction 
of the initial set. The PCR and extension oligos of c/C, e/E, M/N and s/S antigens 
were manually designed to overcome genomic challenges and SNPstream platform 
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specific issues respectively. The output design was then submitted to blast analysis 
(http://www.ncbi.nlm.nih.gov/) and to inSilico PCR (http://www.genome.ucsc.edu) 
to ensure the uniqueness of all PCR oligos and expected amplicon sizes.  Since all 
PCR oligos and extension primers need to work in a unique multiplex reaction, all 
oligo sequences were assayed for secondary structures and for possible self and inter-
oligo priming issues using the software FastPCR 
(http://www.biocenter.helsinki.fi/bi/Programs/fastpcr.htm). In subsequent design 
rounds, modifications were made to the PCR and extension primer compositions to 
resolve genomic related problems, PCR amplification specificities, and lack of 
extension performance. 
 
4.2. Multiplex PCR amplification 
Twelve-plex PCR reactions were performed in 384-well plates (MJS BioLynx, 
Brockville, ON) in a 5 μL volume using 2 μL of ~12.5 ng/μL of Coriell Institute of 
Medical Research (Camden, NJ) DNAs and 2 μL of extracted DNA from the FTA 
cards. The remainder of the volume consisted of 75 μM dNTPs, 4.5 mM MgCl2, 
0.5 U Hotstart DNA polymerase (Qiagen, Mississauga, ON), and the 24 PCR primers 
at a concentration varying from 50 nM to 100 nM each in 1 X PCR buffer (refer to 
tables 2 and 3 for PCR oligo details). Thermal cycling was performed using 
GeneAmp PCR system 9700 thermal cyclers (Applied Biosystems, Foster City, CA) 
with the following program: initial denaturation at 95°C for 15 min. followed by 45 
cycles of 95°C for 30 sec., 55°C for 55 sec., and 72°C for 30 sec. After the last cycle, 
the reaction was held at 72°C for 7 min. Following multiplex PCR using SNPstream 
oligos and plates were centrifuged briefly and 3 μL of a mixture containing 0.67 U 
Exonuclease I (USB Corporation, Cleveland, OH) and 0.33 U Shrimp Alkaline 
Phosphatase (USB Corporation, Cleveland, OH) were added to each well. Following 
the multiplex PCR using Sequenom oligos, 2 µL of Sequenom Shrimp Alkaline 
Phosphatase mixture was added to each well.  The plates were sealed and incubated 
for 30 min. at 37°C and at 95°C for 10 min. During the panel validation only the 
SNPstream and Sequenom PCR oligo mixes versions 2 and 1 were used (Table 2). 
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Table 2: SNPstream PCR oligos mix details 
 
Version one, except for the antigens M/N, s/S, c/C, c/C-intron and e/E where they were manually designed, represents the automatic 
SNPstream PCR oligo output results obtained after the initial design phase using the Autoprimer software. The nucleotides highlighted 
in white for version 2 represent the manual changes applied on the initial design to increase the specificity and quality of the 
genotyping results. In both versions, the oligos were mixed together and volumes increased to 1.0 mL with PCR grade water to reach a 
PCR oligo mix final concentration of 1 µM .  
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Table 3: Sequenom PCR oligos mix details 
 
Except for the antigens M/N, s/S, c/C, c/C-intron and e/E where manual designed was performed, the table represents the automatic 
Sequenom PCR oligo output results obtained after the initial design phase using the AssayDesign software. This version of the PCR 
oligo design was used to cross-compare and validates the genotyping results with the SNPstream panel. The oligos were mixed 
together and volumes were increased to 1.0 mL with PCR grade water to reach a PCR oligo mix final concentration of 1 µM. 
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4.3.  Single-Base multiplex extension reaction and genotyping scan 
 
SNPstream technology: Genotyping extension reactions and hybridizations to the 
SNPware 12-plex microarray plates were carried out as described by Bell et al., 2002. 
Briefly, the extension mixes were prepared in a 7 µL volume using 3.77 µL of 
SNPware extension mix diluents (Beckman Coulter, Fullerton, CA), 0.2 µL of the 
SNPware 12-Plex extension mixes GA and TC, containing two dideoxynuclotides 
labelled with either BODIPY-Fluorescein or TAMRA dye (Beckman Coulter, 
Fullerton, CA), 2.95 µL of PCR grade water, 0.017 µL of SNPware DNA polymerase 
(Beckman Coulter, Fullerton, CA) and 0.06 µL of GA and TC multiplex extension 
oligo mixes (refer to table 4). These mixes were added to each well of the previous 
multiplex PCR reactions. Thermal cycling was performed in GeneAmp PCR system 
9700 thermal cyclers (Applied Biosystems, Forster City, CA) using the following 
program: initial denaturation at 96°C for 3 min. followed by 45 cycles of 94°C for 
20 sec. and 40°C for 11 sec. The SNPware 12-plex microarray plates were 
conditioned three times with buffer 1 (1X of non-stringent) prepared as per the 
manufacturer recommendations, and partially dried using a vacuum system.  8 µL of 
hybridization mixture containing 7.56 µL of SNPware hybridization Solution and 
0.44 µL of SNPware hybridization additive were added to each well of the extension 
reaction plates. After mixing up and down each samples ten times, 15 µL of mixture 
was transferred to the conditioned SNPware 12-plex microarray plate following the 
same sample-plate layout (A01 to A01...B01 to B01...). The transferred mixture was 
then uniformly distributed throughout all wells by gently tapping the corner of the 
microarray plate. The plates were then placed into a hybridization oven at 42⁰C for 
two hours in a humid container. After two hours, the microarray plates were washed 
out three times using ~20 µL of buffer 2 (1X of stringent buffer) prepared as per the 
manufacturer recommendation (Beckman Coulter, Fullerton, CA). The plates were 
dried out as much as possible with the vacuum system and then placed upside-down 
into the centrifuge for 5 min at 3000 RPM. The plates were read using the 
GenomeLab SNPstream Array Imager (Beckman Coulter, Fullerton, CA) and 
fluorescence intensity was measured with help of the SNPstream Imager software. 
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Intensity was plotted and genotypes were called by the GetGenos software. After 
visual inspection of the clusters, manual adjustments were made for some of the 
assays. 
 
Sequenom technology: The extension mixes were prepared in 2 µL using 0.2 µL of 
iPlex buffer 10X (Sequenom, La Jolla, CA), 0.2 µL iPlex terminator mix containing 
four dideoxynuclotides modified with a unique mass component (Sequenom, La 
Jolla, CA), 0.76 µL of PCR grade water, 0.041 µL of iPlex DNA polymerase 
(Sequenom, La Jolla, CA) and finally 0.804 µL of multiplex extension oligos mixes 
(refer to table 5). Both 2 µL extension mixes were added to each well of the previous 
multiplex PCR reactions. Thermal cycling was performed in GeneAmp PCR system 
9700 thermal cyclers (Applied Biosystems, Foster City, CA) using the following 
program: initial denaturation at 94°C for 30 sec. followed by 200 cycles of 94°C for 
5 sec., 52°C for 5 sec., and 80°C for 5 sec. followed by a final extension of 3 min. at 
72°C. 15 µL of PCR grade water and 6 mg of chelating resin were added to each well 
of the extension reaction plates. The plates were sealed, incubated for 15 min. by 
rotation at room temperature and spun down.  The plates were then placed onto the 
nanodispenser deck (Sequenom, La Jolla, CA) and ~ 15 nL of the extension reactions 
and calibrator were spotted on the SpectroChip (Sequenom, La Jolla, CA). The chips 
were read using the Sequenom MassArray Maldi-TOF system (Sequenom, La Jolla, 
CA) and the different extended mass intensities were measured with the help of the 
Sequenom MassArray Imager software. Intensities were plotted and genotypes were 
called by the SequenomTyper software. After visual inspection of the clusters, 
manual adjustments were made for some of the assays. 
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Table 4: SNPstream GA and TC Extension oligo version details 
 
For version one, except for the antigens M/N, s/S, c/C, c/C-intron and e/E where the oligos were manually designed, the extension 
oligos were designed using the automatic Autoprimer software. The oligos nucleotides highlighted in white represent the manual 
changes applied on the initial design to increase the specificity and quality of the genotyping results. In both versions, the extension 
oligos for both ”GA and CT” reactions were mixed together with PCR grade water in two separate tubes in a final volume of 1.0 mL 
to reach extension oligo mixes of 5 and 10 µM final concentrations, respectively. 
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Table 5: Sequenom Forward-Reverse Extension oligos details 
 
 
Except for the antigens M/N, s/S, c/C, c/C-intron and e/E where manual designs were obtained, the table represents the automatic 
Sequenom Extension oligo output results obtained after the initial design phase using the AssayDesign software. This version of the 
PCR oligo design was used to cross-compare the genotyping results with the SNPstream panel. The extension oligos of “F and R” 
were mixed together with PCR grade water in two separate tubes to a final volume of 1.0 mL.  
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4.4. Detailed Genotyping procedure using the Beckman Coulter SNPstream 
technology 
 
As illustrated in figure 9, the SNPstream platform is a medium-high-throughput 
technology multiplexing up to 12 or 48 SNPs and for up to 384 samples at the time. 
The technology is only capable of multiplexing, in a single tube, the same variant 
types at any one time (GA or CT or CA or GC or TA or GT) and it combines single 
base extension (SBE) and the quantification of specific fluorescent-labelled probes 
captured on 384-well format array plate. Each multiplexed PCR amplicon has been 
designed to amply the SNPs of interest (Figure 9, Step 1), unincorporated nucleotides 
and primers are removed enzymatically and a mixture of extension mixes and 
extension probes are added to the cleaned-up PCR reactions. The extension probe is 
hybridized to specific amplicons in the multiplex reaction, one base 3’ of the SNP 
site (Figure 9, Step 2). The extension probes are single-base extended in a patented 
two-dye system by incorporation of a fluorescent-labelled chain terminating 
acyclonucleotide. The 5’ end of the extended probes contain an extra unique 10 bases 
(Tag) and are specifically hybridized to one of the twelve complementary Anti-Tag 
sequences arrayed in each of the 384-wells (Figure 9, Step 3-A). The two-color 
detection allows determination of the genotype by comparing the signals from the 
two fluorescent dyes.  The arrayed Anti-Tag captures the extended products and 
allows laser-based detection of each of the SNP allele signals (blue and green) 
(Figure 9, Step 3-B) and final SNPs calls are automatically and computationally 
generated (Figure 9, Step 3-C). Two extra self-extending control oligonucleotides are 
included in each extension mix and are extended during the probe extension. The 
Anti-Tags arrayed in the 384-wells include three positive controls (XX, XY and YY) 
and one negative control.  
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Figure 9: Detailed genotyping flow using Beckman Coulter SNPstream platform 
 
  Step 1 
Step 2 
Step 3 
Blue :   
G allele 
Green :  
A allele 
Genotype : 
GG 
A 
BC 
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4.5. Detailed Genotyping procedure using Sequenom MassArray system 
As seen in figure 10, the MassArray platform is a medium-high-throughput 
technology multiplexing up to 40 SNPs on up to 384 samples at the time. The 
technology allows multiplexing in a single tube, and all variant types can be queried 
in a single reaction (GA, CT, CA, GC, TA, GT). This platform technology combines 
single base extension (SBE) and quantification of specific MassExtend probes 
detected and analysed by a time-of-flight mass spectrometer.  Briefly, after multiplex 
PCR, the amplicons contain the SNPs of interest (Figure 10, Step 1), unincorporated 
nucleotides are removed enzymatically, a mixture of extension bases and extension 
probes are added to cleaned-up PCR reactions and the extension probes are 
hybridized to a specific template in the multiplex reaction one base 3’ of the SNP site 
(Figure 10, Step 2). The extension probes are single-base extended by the 
incorporation of a specific mass terminating acyclonucleotides, resulting in an allele-
specific difference in mass between extension products. The final extended mixture is 
desalted using a chelating based resin and then spotted onto a maldi-SpectroCHIP 
(Figure 10, Step 3-A). The SpectroCHIPS are placed into the Maldi-TOF mass 
spectrometer and the mass difference correlating to the genotype is determined in real 
time (Figure 10, Step 3-B). This mass difference allows computational data analysis 
by interpreting the difference in mass for each of test SNPs alleles present in the 
multiplex reaction (Figure 10, Step 3-C). 
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Figure 10: Detailed genotyping flow using Sequenom MassArray system
Step 2 
Step 3 
Step 1 
 
 
 
A 
C 
 
Genotype: AG
B
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4.6. Sequencing 
M/N antigen: Simplex PCR reactions were performed in 384-well plates (MJS 
BioLynx, Brockville, ON) in a 5 μL volume using 2 μL of ~12.5 ng/μL of selected 
Coriell Institute of Medical Research (Camden, NJ) DNAs, 140 μM dNTPs, 1.5 mM 
of MgCl2, 0.3 U of Hotstart DNA polymerase (Qiagen), and 0.1 μL of PCR primers 
(forward oligo GYPA_PCRU2: 5’ CACGCTTTATCTGTAAACCTCTGCTATG 3’ 
and reverse oligo GYPA_PCRL1: 5’ TGGCTGCATATGTGTCCCGTTTGT 3’) at a 
concentration of 50 nM each in 1 X PCR buffer. Thermal cycling was performed in 
GeneAmp PCR system 9700 thermal cyclers (Applied Biosystems, Foster City, CA) 
using the following program: initial denaturation at 95°C for 15 min. followed by 45 
cycles of 95°C for 30 sec., 60°C for 55 sec., 72°C for 45 sec. with a final extension of 
72°C for 3 min. Following simplex PCR, 3 μL of a mixture containing 0.67 U 
Exonuclease I (USB Corporation, Cleveland, OH) and 0.33 U Shrimp Alkaline 
Phosphatase (USB Corporation, Cleveland, OH) was added to each well. The plates 
were sealed and incubated for 30 min. at 37°C and at 95°C for 10 min. To each well, 
containing cleaned-up PCR product, 1 μL of sequencing oligos 5 μM 
(GYPA_SEQU-L_1: 5’ CTGTGAGATATTTCAGAGGCAAG 3’) was added and 
mixed. The plate was then sent to the sequencing platform of the Génome Québec 
Innovation Centre (Montreal, QC) and sequencing was performed on a sequencing 
instrument 3730XL (Applied Biosystems, Foster City, CA) according to the 
manufacturers instructions. The sequencing results were then analyzed using 
PhredPhrap software (http://www.phrap.org/phredphrapconsed.html).     
Whole GBAP content: Samples NA17175, NA17275, NA17223, NA17284 
NA17294 and NA19007 from the Coriell Institute of Medical Research (Camden, 
NJ) were sequenced to validate the genotyping results obtained during the 
development phase. These samples will now be used as internal controls during the 
future clinical genotyping processes. The PCR and sequencing method is the same as 
the one described above for the M/N antigen section except for the PCR and 
sequencing oligos (table 6). 
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Table 6: PCR and sequencing oligos used to sequence the whole genotyping blood antigen panel contents.  
 
 The table represents the PCR oligos and the sequencing oligos used to sequence six control DNAs from the Coriell Institute of 
Medical Research (Camden, NJ) (NA17175, NA17275, NA17223, NA17284, NA17294 and NA19007) to cross-validate the 
genotyping results obtained during the development phases. These validated samples will now be used subsequently as internal quality 
controls in all clinical genotyping experiments. 
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5.     Clinical blood antigen genotyping assay procedure 
Once the minor blood group antigen genotyping panel was optimised for 
robustness and accuracy levels needed for clinical applications, two SOPs (Standard 
Operating Procedure) and two LIMS (Laboratory Information Management System) 
protocols were developed to transfer the blood antigen genotyping panel from R&D 
into clinical application. All steps in the SOPs were mediated and tracked by a LIMS 
(Ocimum Bioscience, Hyderabad, India). Please refer to the Annexes A and B for the 
complete details on the SOPs PGx-PR012-V2.0 (Automated DNA extraction of 
blood spots from FTA cards using Generation DNA purification technology) and 
PGx-PR-013-V2.0 (Héma-Québec Genotyping Assay panel#1 on SNPstream 
Platform).  Briefly these SOPs describe in detail all steps that encompass the entire 
process flow from the blood sampling on FTA micro cards to DNA extraction and 
genotyping on the SNPstream instrument, along the process of reporting the results 
back to Héma-Québec (Figure 11).   
5.1.     Blood sample collection at Héma-Québec 
Frequent blood donors (≥ 3times per year) who had recently donated were 
selected through a new application from the Héma-Québec IT department. In total 
22,000 frequent donors, having pre-determined interesting blood antigen combination 
profiles were requested to join the Héma-Québec blood antigen database registry. 
Peripheral blood samples were collected from these donors after signature of an 
informed consent form approved by Héma-Québec’s Research Ethics Committee. 
5.2.     Sample management 
Refer to the Annexe A sections 9.1 and 9.2 for the complete sample management 
procedure. Briefly, every month ~ 2,000 barcodes were pre-generated from our LIMS 
and sent to Héma-Québec. 120 µL of blood from selected donors were spotted onto 
FTA micro cards (GE Health Care/Whatman, Piscataway, NJ) and samples were 
stored at room temperature for a minimum of three hours in order to fully dry the 
cards (Figure 11-A). Both barcodes, the one generated by Héma-Québec and the one 
generated from our LIMS, were placed on every FTA card (Figure 11-B). The FTA 
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cards were then organized as a batch of 100 samples per storage box and 500 samples 
every two weeks were sent at room temperature to the Pharmacogenomics Centre. 
Upon arrival, the sample list provided by Héma-Québec was downloaded from our 
secure share website folder and pasted into the “sample checker” tool (Figure 12-A). 
To match the FTA cards samples against the list sent by Héma-Québec, the HQ 
barcode is scanned first and immediately a notification appears as either “Passed or 
Failed” based on the original submitted sample list. Then the LIMS barcode is 
scanned to make the final link between the HQ and LIMS barcodes (Figure 12-B). 
The final file containing all sample-related information is created only if the previous 
step was completed with 100% “Passed” comments. The file is then uploaded into 
the LIMS (Figure 12-C).  
Figure 11: Process flow overview of the clinical blood antigen genotyping assay
 
A
C 
D 
E
B
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Figure 12: Clinical FTA blood sample management flow 
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5.3. DNA plate management and DNA extraction 
Refer to Annexe A sections 9.3 and 9.4 for complete details on the DNA 
management and extraction procedure. Briefly, 88 Héma-Québec FTA samples and 1 
Blank FTA were retrieved and pooled together to create one 96-well DNA extraction 
plate (the remaining positions H6 to H12 were reserved for 1 water negative control 
and 6 known genotype positive controls DNAs). All remaining FTA samples were 
retrieved and pooled together following the same extraction plate layout. 
Using a Duet 600 (BSD Robotics, Brisbane, Australia), 2mm punches were 
automatically punched out of each FTA card sample and deposited into a standard 
full-skirt 96-well plate (Bio-Rad, Hurcules, CA) containing 1 µL of PCR grade water 
(Figure 11-C). Prior to performing the punch, the Duet 600 robot scanned each 
sample barcode in order to match the DNA plate extraction layout previously created 
and only perfect matches allowed the system to move forward.  The DNAs were 
extracted using exactly the same procedure described in section 3 above but were 
automated and adapted onto the BiomekFX liquid handler (Beckman Coulter, 
Fullerton, CA) to maximize the sample extraction throughput. A total of 6 plates of 
89 samples were extracted in a single run (Figure 11-D). Once the DNAs were 
extracted the plates were stored at -20⁰C until needed. The DNA samples were single 
use and ready-to-use since no quantification is required. 
 
5.4.  PCR oligos and extension oligo mixes batches preparation 
Please refer to Annexe B, appendices PGx_PR-012_APP-3 and PGx_PR-
012_APP-5 for complete oligo mix preparation methodologies. 
 
5.5.  Multiplex PCR master mix batch preparation 
Refer to Annexe B, appendices PGx_PR-012_APP-4 for details on the multiplex 
PCR master mix preparation. 
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5.6.  Genotyping process 
The Annexe B section 8.1 to 8.8, describes in detail the complete genotyping 
process of one assay plate for 192 different samples in both DNA directions, for a 
total of 384 total reactions (Figure 11-E). The same flow and SOPs are applied to 
genotype two or more assay plates at the same time.  
The known DNA control preparation is detailed in the Annexe B appendix 
PGx_PR-012_APP-1. 
The PCR, extension as well as the hybridization plate layouts are described in the 
Annexe B appendix PGx_PR-012_APP-2. 
5.7. Data acquisition 
Please refer to the Annexe B appendix PGx_PR-012_APP-7 for complete details 
on the Raw Data acquisition using the SNPstream platform. 
5.8. Data Analysis and reporting 
Please see Annexe B appendix PGx_PR-012_APP-8 for data analysis and 
reporting methodologies.  Briefly, the data analysis and data reporting are supported 
by two different tools, SHERPA and Area51. Both software tools were developed at 
the Pharmacogenomics Centre, led by Michal Blazejczyk and Marc Bouffard 
respectively. Both applications have different roles but are complementary to each 
other (See Figures 13-A and B).  
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Figure 13: Data analysis and reporting flow 
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RESULTS 
 
 
1. Assay development and optimisation 
 
 
1.1. Bioinformatics analysis of the genes and markers of interest 
A major factor affecting genotyping assay design efficiency, especially in the 
context of multiplex PCR, is lack of knowledge of the genomic complexities that 
surrounding the regions of interest. These complexities will ultimately alter the 
quality and accuracy of the PCR and extension oligo designs. Consequently, prior to 
primer design, each target gene and marker’s genomic sequence was analysed 
bioinformatically for possible gene homology, repeat structures, and neighbouring 
polymorphisms. In addition, all homologous genes were aligned using ClustalW 
alignment software.  
For example, the gene Kel encompassed two markers of interest, Kap a/b 
(rs8176059) and k/K (rs8176058). The gene is located on chromosome 7 (7q34), 
and it is positioned from between 142348323 to 142369625 (genome sequence Build 
35). Using the University of California, Santa Cruz (UCSC) genome browser view  
showed that the Kel gene was not located in a highly repetitive region (Figure 14-A), 
some localized regions, particularly within the introns were repeated. Since both 
antigen SNPs of interest were located in the exons 7 and 5 respectively the gene was 
initially considered not problematic for assay design.  The gene was then subjected to 
a BLAT analysis and no homologous genes were identified (Figure 14-B). The 
BLAT analysis found more than 50 matches but all of them matched only a few 
hundred bases out of 23,000 total bases. Only one perfect match was found and it was 
associated with the gene of interest. According to the NCBI dbSNP build 126, more 
than 450 SNPs were found within the gene and the majority of them were mainly 
located in the introns (Figure 14-A). In order to narrow down the analysis of the 
markers of interest, approximately 200 bp upstream and downstream of the antigens 
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Kap a/b (Chr7:142361476) and k/K (Chr7:142364880) were submitted to BLAT 
and neighbouring SNP analysis. Following the BLAT analysis, no homology was 
found for homologous chromosome regions or additional genes, and only the regions 
of interest matched perfectly (Figures 14-C and D; highlighted lines). The genomic 
regions around both SNPs were also analyzed for repeat elements and neighbouring 
SNPs.  No repeats elements were found in the surrounding sequences, whereas only 1 
and 3 neighbouring SNPs were found for rs8176059 and rs8176058 respectively 
(Figures 14-E and F). The same exercise was performed for all test markers and four 
of them (rs7682260-M/N, rs7683365-s/S, rs1053344-c/C and rs609320-e/E) were 
identified as highly problematic (Table 7).  The problems were specifically identified 
as regions of high gene homologies around the test marker DNA sequences. 
Following these findings, the gene GYPA was aligned with GYPB and GYPE and the 
gene RHCE were aligned with RHD (Figures 15-A to D). The highly homologous 
regions found for these four genes led to the need for manual PCR and extension 
oligo designs for the markers within these gene regions, whereas the designs of the 
other markers were produced automatically using the Autoprimer software (Beckman 
Coulter, Fullerton, CA) and the AssayDesign software (Sequenom, La Jolla, CA).   
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Figure 14.  Bioinformatics analysis of the gene Kel  
A) Graphical representation of the gene Kel with its respective exon and intron 
structure (1). The middle part of the picture represents the polymorphism content 
for the whole gene based on dbSNP build 126 (2). The blue rectangle highlights 
the repeat elements throughout the whole gene (3) and the arrows are pointing 
the respective gene location for each repeat section.  
 
B) BLAT results of the entire Kel gene (23,300 bases) using the UCSC BLAT tool. 
The blue rectangle highlights the main homology results. The “Score” represents 
the total number of bases that match the genome, the “Start” and “End” represent 
the start and end base positions that match the genome, the “Qsize” is the total 
size submitted as query, the “Identity” represents the % of identity between the 
query and the match results, the “Chr” represents on which chromosome the 
query matches, and the “Span” represents how many consecutive bases are 
found within the genomic regions. 
 
C) BLAT results of a 356 bp DNA sequence that surrounds the marker rs8176059 
using the UCSC BLAT tool.  
 
D) BLAT results of 356 bp DNA sequences that surround the marker rs8176058 
using the UCSC BLAT tool.  
 
E) Neighbouring SNP annotation of 200 bp downstream and upstream of the 
marker rs8176059. The base highlighted in yellow represents the marker 
rs8176059 (C>T) and the bases highlighted in pink represent the flanking SNPs. 
 
F) Neighbouring SNP annotation of 200 bp downstream and upstream of the 
marker rs8176058. The base highlighted in yellow represents the marker 
rs8176058 (G>A) and the bases highlighted in pink represent the flanking SNPs.
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>chr7:142361276-142361676  
TGGAGTCAGAGACAGAATGAAAAGGTATTAAGGGCACTAGGAGGAAGAAGGAAAGGAGGT 
AATGTTTGAGAGGAAGATCCCCATGCCCACAGTCTTCTGGCCCCCAGTTCCAGGCACCTT 
GAGCTGGTCgATAGTGACCATCTGGAAGAGCTTGCCCTGTGCCCGCCGCTGCTCCAGGGG 
CCTCAGAAACTGGAAcAGCCgTGAAGTGATGGAGATTGACAAGGAAGAGTGTTCTTGCAC 
CTTGCTTGGGTCTCCTCCCAGCAAGGTTCCCAGCTGATTCAGGTAAGTCAGGTATTCCCG 
AAAGATCTGGAGGAAGGAAATGTCAGTCACAGGTGCCAGAGGTCCCTGCTTTTCTCCTGG 
CCTCAGAGGGCAGGGCCTTTGTCCATGTGCCATCTTACCTG 
E 
F 
   
>chr7:142364900-142365330  
TTCCCTTAAGGTAGGGTTGTTTCCTATATCACACAGGTGTCCTCTCTTCCCAACCTGCAA 
CCTTCCTCTAAGGGATGATTGGCTAGAGTTGGAGGCAGGCCAGGTCCAACTGTGTCTTCG 
CCAGTGCATCCCTCACCTGGATGACTGGTGTGTGTGGAGAGGCAGGATGAGGTCCTAGGT 
AGGCTCTGAAGAAAGGGAAATGGCCATACTGACTCATCAGAAGTCTCAGCgTTCGGTTAA 
AGTTTAAGGAAGTCCATTTACCAGAGATGCGCCAGCCTCCAAGCTTTAAAGGAGAGAGAG 
gGGGCTGAGCATAAGGATCcGTGGAGCCCATCCCCcATTGTCTGGATCGGCTCTTACACA 
GCTGCTACTGCCTGACCTCTGCCCTGCGCCCTTCGATTCCTCTAGGAAGCCACATCTATC 
CTTTTTTATCT 
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Figure 15.  Bioinformatics analysis of the genes GYPA, GYPB and RHCE. 
 
A) Alignment of 400 bp of GYPA, GYPB and GYPE genes using the ClustalW 
software tool. The bases in turquoise are the mismatched nucleotides and the 
base in green represents the marker rs7682260-M/N.  
 
B)  Alignment of 400 bp of GYPA, GYPB and GYPE genes using ClustalW. The 
bases in turquoise are the mismatched nucleotides and the base in green 
represents the marker rs7683365-s/S. 
 
C) Alignment of 400 bp of RHCE and RHD genes using ClustalW. RHCE-c and 
RHCE-C represent the sequences of both RHCE small c and RHCE big C 
alleles. The bases in turquoise are the mismatched nucleotides and the 
nucleotide in green represents the marker rs1053344-c/C. 
 
D) Alignment of 400 bp of RHCE and RHD genes using ClustalW. RHCE-e and 
RHCE-E represent the sequences of both RHCE small e and RHCE big E 
alleles. The bases in turquoise are the mismatched nucleotides and the 
nucleotide in green represents the marker rs609320-e/E. 
 
 
 
 
52
 
 
 
 
 
 
 
 
 
 
  
A 
B 
 
 
 
53
D 
C 
 
 
 
54
Table 7: Qualitative representation of the DNA sequence complexity at the gene and marker levels 
 
 
 
 
 
 
The table represents a summary of qualitative result of complexity of the test genes and markers DNA sequences. These results were 
obtained after performing the same process flow described for the gene Kel and its related markers. The evaluation of the repeat 
elements and the polymorphic sites was achieved using the UCSC genome browser view. The homology was evaluated using the 
BLAT tool from UCSC and confirmed by the alignment of DNA sequences using ClustalW. 
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1.2. SNPstream and Sequenom minor blood group antigen genotyping panel 
assay design 
 
After the completion of the bioinformatics analysis, 200 bp sequences upstream 
and downstream of the non-problematic markers (Kap a/b-rs8176059, HPA1 a/b-
rs5918, HPA2 a/b-rs6065, Fy a/b-rs12075, Jk a/b-rs1058396, k/K-rs8176058 and 
HPA5 a/b-rs10471371) were submitted for an automatic “Standard” assay design to 
the Autoprimer and the AssayDesign software for the SNPstream and Sequenom 
platforms respectively. In general, the software programs more than adequately 
designed the genotyping assays using the same pipeline process, where for each 
marker a pair of PCR oligos that encompassed the target markers and an extension 
oligo ending one base (5’) next to the test marker were generated. In order to reduce 
the amplification competition within the multiplex PCR reaction, all output PCR 
oligos were designed to generate PCR amplicons ranging from 80 bp to 200 bp. The 
software also generated oligos with minimal self-priming and dimer-dimer 
interactions within the multiplex pools (PCR as well as the extension pools). Since 
both software programs designed only one “set of designs” per marker (two PCR 
oligos and one Extension oligo), the submitted DNA sequences were subsequently 
modified to force the output results to also design assays for the opposite DNA strand 
in the reverse direction. The automatic output oligo designs are represented in Tables 
2 to 5 (Version 1 column) in the Materials and Methods. 
The problematic markers (s/S-rs7683365 and M/N- rs7682260) were manually 
designed from the aligned sequences using the standard procedure for both platforms. 
The markers (c/C-rs1053344 and e/E-rs609320) were subjected to a non-standard 
oligo design using the aligned sequences. For both platforms the manual PCR oligo 
design for s/S-rs7683365 and M/N- rs7682260 were meticulously performed to get 
the highest specificity in the 3’ end regions whilst maintaining a GC% content 
between 40 and 60%, and a Tm of 50 to 60⁰C (Figure 16-A and B).  
On the SNPstream, the assay designs for the markers c/C-rs1053344 and e/E-
rs609320 were developed using the “nonstandard” design approach since on this 
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platform only the same allele type (C/T or G/A or C/A or T/G or T/A) can be 
analysed as a single multiplex extension reaction. So one of the obstacles in the 
“Standard” creation of this panel was the e/E antigen pair, which is encoded by a G/C 
variation, whereas all other antigen pairs (Jk a/b, Fy a/b etc.) were G/A or C/T 
markers. To address this problem and since the genotyping blood antigen panel was 
expected to be developed in both DNA directions (G/A and C/T), we decided to 
interrogate one allele at the time, where the G nucleotide was detected in the C/T 
genotyping panel and the C nucleotide was detected in the G/A panel (Figure 17-A).  
By combining both genotyping results, the final genotyping calls (GG, GC or CC) 
can be inferred (Figure 17-B and C).  
Another problem encountered during the creation of the “Standard” SNPstream 
minor blood group antigen genotyping panel design was the antigen c/C, where very 
high homology was found between the genes RHD and RHCE, and especially near 
the c/C-rs1053344 region (Figure 15-C). In addition, the alleles RHCE_C and the 
gene RHD have close to 100% homology to each other but are completely different 
from the RHCE_c allele. The high homology of the RHCE_C and RHD alleles 
considerably increased the complexity of these oligo designs and the requirement for 
highly specific PCR. As previously reported by (Poulter et al. and Tax et al.), the 
insertion of 109 bp into intron 2 of the RHCE gene is strongly associated with the 
presence of the RHCE_C allele. Consequently, we decided to interrogate the allele 
RHCE_C and RHCE_c independently in two different PCR and extension reactions 
(c/C for RHCE_c and c/C-intron for RHCE_C). The assay c/C discriminated for the 
presence of RHCE_c antigen over RHCE_C/C individuals where the PCR oligos 
were designed to uniquely amplify the RHCE_c allele (Figure 18-A), and the assay 
for the c/C-Intron looked for the presence of the insertion of 109 bp which is 
associated with the presence of RHCE_C (Figures 18-B and C).  The results obtained 
using the assay for the c/C-intron facilitated the isolation of the C/C carriers from the 
c/C carriers, and when both c/C and c/C-intron assays are combined  the heterozygote 
individuals and c/c carriers are easily identified (Figures 18-D and E). 
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For the Sequenom assay design, the platform can support the detection of all 
allele types in a single assay reaction. Only the antigen c/C-rs1053344 assay required 
a “Non-Standard” design. As this assay was considerably complex in the context of 
multiplex genotyping, the same assay developed for the SNPstream was transferred 
to the Sequenom panel. The PCR and extension oligos of the antigen e/E-rs609320 
were then manually developed similarly to the technique describe in Figure 16 with 
respect to the specificities of the RHCE gene. 
After completing the manual designs for the standard and non-standard SNPs, 
the PCR oligo sequences, except for the c/C-Intron design, were submitted to the 
inSilico PCR tool (UCSC) to ensure the specificity and uniqueness of the 
amplification. Also, since the manually designed oligos were not evaluated for dimer-
dimer and self-priming potentials, the manually designed oligos were combined with 
the ones obtained automatically from both Autoprimer and AssayDesign and were 
submitted to FastPCR software for analysis. No conflicting oligo interactions were 
identified from these two quick analyses where all amplicons were compatible with 
the UCSC inSilico tool, and no major interaction was found within the PCR and 
extension oligo pools. The measured self-priming and dimer-dimer Tm ranged from 
10 to 35 ⁰C with minimal interactions from the 3’ end of the primers.  
Following the assay designs and quick quality control tests, the PCR oligos and 
extension oligos shown in Tables 2 and 4 (version 1 column) were the oligos used in 
the first step of the SNPstream panel optimisation. The oligos designed for Sequenom 
were not optimized, since this assay is used essentially to validate the SNPstream 
panel. All further results will focus on the optimisation and validation of the 
SNPstream assay. 
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Figure 16: Standard manual PCR and extension oligo designs for 
SNPstream and Sequenom platforms. 
 
A) Details of the manual design of M/N antigens marker (nucleotide highlighted 
in green) using the aligned DNA sequences. The turquoise nucleotides 
represent the variation between homologous genes. The pink highlighted 
sequence represents the forward PCR oligo design for the SNPstream 
platform and the red highlighted sequence represents the reverse PCR oligo 
for both SNPstream and Sequenom platforms. The forward oligo for 
Sequenom is represented in gray.  The extension oligos for both the forward 
and reverse allele detection are represented in bold-underlined format. The 
gray letters are specific to the Sequenom platform since shorter sequences 
are needed to fit into the mass spectrum window. Both designs interrogate a 
standard C/T or G/A (in the reverse direction) marker. 
B) Details of the manual design of the s/S antigen marker (nucleotide 
highlighted in green). The turquoise nucleotides represent the variation 
between homologous genes. The sequences highlighted in pink represent the 
forward and reverse oligo designs for the SNPstream platform, whereas the 
sequences in dark orange and bold-italic-underline purple represent the 
forward and reverse oligos respectively for Sequenom. The sequences in red 
represent the forward and reverse extension oligos for SNPstream and the 
bold-italic segment represent the forward extension oligo design. Both 
designs interrogate either a C/T or G/A marker (in the forward or reverse 
direction). 
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Figure 17: SNPstream specific non-standard PCR and extension oligo design 
for the antigen e/E. 
A) Detailed oligo design strategy for the non-standard polymorphism e/E-
rs609320 (nucleotide in green). The sequences highlighted in pink represent 
the manual PCR oligo designs that are specific to RHCE. The sequences 
highlighted in red represent the extension oligos used in the extension pools 
GA and CT. The same extension oligo is used in both the GA and CT single-
base extension reactions, but only the ddG-BODIPY-Fluorescein and the 
ddC-TAMRA are respectively incorporated, leading to a non-standard 
analysis of a G/C variation. 
 
B) Graphical representation of the blue and green fluorescence in logarithmic 
mode (Polar View). The genotyping cluster illustrates the ddG* detection 
(GA extension pool) of the non-standard design of the polymorphism e/E-
rs609320. The cluster in blue represents the positive ddG* extension, 
therefore it reflects the presence of G allele. Individuals located in this cluster 
are either G/G (E/E) or G/C (E/e), whereas the individuals in the green cluster 
are all C/C (e/e). 
 
C) Genotyping cluster that illustrates the ddC* detection (CT extension pool) of 
the nonstandard design of the polymorphism e/E-rs609320. The cluster in 
green represents the positive ddC* extension, therefore it reflects the presence 
of the C allele. Individuals located in this cluster are either G/C (E/e) or C/C 
(e/e), whereas the individuals in the blue cluster are all G/G (E/E).  
 
  
 
 
 
61
  A 
B C
 
 
 
 
62
Figure 18: Non-standard PCR and extension oligo designs for the antigens 
c/C. 
 
A) Detailed design of the nonstandard polymorphism c/C-rs1053344 (nucleotide 
in green). The sequences highlighted in pink represent the manual PCR oligo 
designs that are specific for the RHCE_c sequence allowing for the precise 
amplification of the specific amplicon containing the RHCE_c antigen. The 
sequence highlighted in red represents the extension oligos used in the 
extension pool GA. In the reaction only the ddA-TAMRA is incorporated, 
leading to a non-standard analysis of A/- detection. The same design logic is 
applied for the reverse complement assay, where in the extension pool CT the 
ddT-TAMRA is incorporated.  
 
 
B) Detailed design of the nonstandard assay for the c/C-Intron. The sequence in 
yellow represents the 109 bp insertion that is only present in the RHCE_C 
allele. The sequences highlighted in pink represent the manual PCR oligo 
designs, and only individuals with the insertion have a positive amplification 
of 155 bp. The sequences in green, bold and underline represent the extension 
oligos used in the extension pool GA and CT. Since the interrogated 
nucleotides (highlighted in green) are not SNPs, only the ddG-BODIPY-
Fluorescein and ddC-TAMRA are incorporated during the extension reaction, 
leading to a non-standard analysis of G/- and C/- respectively.  
 
C) Generation of 155 bp amplicon bands using the PCR oligos design detailed in 
section (B). After completing the PCR cycling, 5 µL out of 10 total µL of 
PCR reaction were mixed with 10 µL PCR grade water and loaded on a 4% 
agarose gel (50 bp mass ladder). Only individuals with the 109 bp insertion 
have a positive amplification of 155 bp. 
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D) Polar genotyping cluster view that illustrates the ddA* detection (GA 
extension pool) of the non-standard assay design for the polymorphism c/C-
rs1053344. The cluster in green represents the positive ddA* extension, 
therefore it reflects the presence of the A allele, and since the PCR 
amplification is only specific to RHCE_c, the individuals located in this 
cluster are either A/G (c/C) or A/A (c/c), whereas the individuals in the blue 
cluster are not RHCE_c carriers, leading to C/C. The same logic is applied for 
the design in the reverse direction using the CT extension pool (ddT* 
detection). 
 
E) Polar and Cartesian genotyping cluster views that illustrate the ddG* 
detection (GA extension pool) of the non-standard designs of the 
polymorphism c/C-Intron. Since the PCR amplification is only possible in 
individuals with the 109 bp insertion, the ddG* detection reflects only the 
“presence” of the insertion and is translated in the genotyping clusters. The 
blue cluster represents the positive ddG* extension, therefore it reflects the 
presence of the G nucleotide and individuals located in this cluster are either 
c/C or C/C, whereas the individuals in the green cluster are non-extended with 
ddG* (no carrier of insertion) and have the presence of RHCE_c/c allele. 
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1.3. SNPstream minor blood group antigen genotyping assay optimisation 
To evaluate the quality of the SNPstream design (PCR and extension oligos 
version 1), a total of 44 Coriell Institution of Medical Research (Camden, NJ) DNAs 
(15 Caucasians, 15 African American, 14 Asians) were genotyped. In addition, since 
the ultimate source of DNAs for the clinical genotyping is expected to be from the 
FTA cards, DNAs from forty different FTA sample were also tested. The genotyping 
results were evaluated following five different parameters; 1- the clustering quality, 
which shows how well the three expected clusters are separated (homozygote AA, 
heterozygote AB and homozygote BB), 2- the call rate percentage, referring to the 
number of samples that were successful genotyped  Vs. the number of samples that 
failed, 3- the genotyping concordances of results obtained in both DNA directions 
(Panels GA and CT), 4- the comparison of allele frequency (Minor Allele 
Frequencies; MAF) with the expected values published by dbSNP, and 5- the Hardy-
Weindberg (HW), which is a statistical value that reflects the normal allele 
distribution in a non-related population. The three first parameters are key indicators 
of the assay robustness whereas the last two parameters are mainly an indicator of 
assay design deficiency in relation to the genomic background.  
1.3.1. Phase I assay optimisation 
To know which FTA punching techniques will be further applied in the 
genotyping experiments, a total of 200 FTA punches were performed following five 
different punching size techniques. All the punches were then diluted 5, 10 and 20 
times in water and tested for multiplex PCR amplification using the SNPstream PCR 
oligos version 1. Analysis of PCR products on a 4% agarose gel indicated that the for 
Coriell DNA, the 1.2 mm punches (one and two spots) and the 2 mm (one spot) were 
the samples that were amplified with the highest yield, whereas the 2.0 mm (two 
spots) and the 3 mm (one and two spots) showed the weakest amplification, 
especially when the DNAs were diluted (Figure 19-A). The lack of PCR 
amplification when the DNAs were titrated down was a clear indication that the limit 
of detection had been reached for these punching techniques. The extracted DNAs 
from the different punching techniques were also tested for a complete genotyping 
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analysis and as per the results previously observed on a 4% agarose gel, the DNAs 
extracted from the 2 mm (two spots) and 3.0 mm (on and two spots) did not reach the 
required yield to generate good clustering and results were not interpretable (Figure 
19-B). Based on these results, the DNAs from 2mm punches (one spot) were further 
tested for integrity using two PCR amplifications (APOE and CYP2D6) known in-
house to be problematic on degraded or poor quality extracted DNAs. Figure 19-C 
illustrates clean and perfect PCR amplification for all ten samples for both PCR 
amplifications, indicating that DNAs were extracted in a high quality manner. The 
DNAs were also tested for Picogreen and Nanodrop quantification and reliable 
results were not obtained due to the presence of high background possibly due to 
DNA levels that are below detection (results not shown). No further investigations 
have been performed for quantification and we decided to use the DNAs directly 
from the extraction for the subsequent genotyping assay optimisation.  
The genotyping results obtained are categorized into two groups which are 
“markers failed optimisation” and “markers passed optimisation”. Within the group 
that needs further optimisation; two action plans are required which are “PCR 
condition modification” and “assay redesign”. After the phase 1 genotyping 
optimisation on 84 total samples (44 Coriells and 40 FTA cards) for a total of 24 
markers (12 markers in the two DNA directions), only five markers needed 
improvement (see Table 8). In summary, all markers that passed the phase 1 
optimisation, for over 2,000 genotyping calls we found to have a 97% call rate in 
both extension pools, which represented failure of only one sample or less, and more 
than 99% of the genotyping results were concordant in both extension pools. Also, 
perfect matches with the expected allele frequencies and Hardy-Weindberg 
equilibrium was observed (Figure 20-A). In the group of markers that needed 
improvement, the marker k/K-rs8176058 showed good results for all different quality 
control steps, but clear lack of sensitivity was observed in the GA extension mix 
using the DNA extracted from FTA cards. This result suggested that the problem was 
not related to the PCR amplification since both CT and GA extensions share the same 
PCR amplification fragment but highlighted that the GA extension oligo was not 
sensitive enough using low DNA concentration as template. Cautionary Hardy-
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Weindberg values were also obtained for both the GA and CT extension pools for the 
k/K-rs8176058 marker only in the genotyping of FTA samples. These results are 
likely because the FTA samples were compiled by Héma-Québec based on 
interesting phenotypes, therefore the samples selection may not be completely 
unbiased (Figure 20-B). For the marker Jka/b, a clear PCR amplification problem 
was observed since in both the GA and CT extension pools very low and poorly 
defined clusters were achieved. The same results were obtained using either the DNA 
from the Coriell samples or from the 2 mm FTA cards, confirming that the problems 
resided mainly at the PCR level. After reviewing the assay designs, the Autoprimer 
had generated a pair of oligos that amplified a 301 bp DNA sequence, which 
correlated perfectly with the PCR amplification problems, as the longest amplicon is 
always under-favoured in a multiplex PCR amplification (Figure 20-C).    
The markers M/N in the GA and CT extension pools had failed genotyping 
results because of Hardy-Weindberg (HW) and the allelic frequency failures (Figure 
20-D). For this marker the MAF is expected to be around 50% and only 27% was 
observed, also a HW value of 22 was observed, which represents a major allele 
distribution failure (normal = 0 to 5). Without the Hardy-Weindberg values, the 
problem would not have been identified, as good clustering separations and call rates 
were initially observed with the SNPstream software calculation ( Figure 20-D, blue 
circles). After closer examination of the clustering there was evidence of two 
heterozygote clusters, one less abundant (all African American samples; cluster 1) 
and one more abundant (all Caucasians; cluster 2) and a manual re-clustering was 
performed (the actual blue, orange and green clusters). Following the manual re-
clustering, the HW values and allele frequencies were normal, indicating that the 
double heterozygote clusters were the basis of the problem. Additionally, the problem 
is clearly associated with a specific population genetics issue since heterozygote calls 
from African American and Caucasian populations were split into two different 
clusters.  Considering the same problem was observed in the GA and CT pools, it 
indicated that the issue was linked mostly with the PCR design and not with the 
extension probe designs. In order to pinpoint the problem and modify the designs 
accordingly, twelve samples were selected from the sub-clusters 1 and 2 and were 
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sequenced for the M/N marker DNA sequence region. In Figure 20-E, the sequencing 
results indicated that all samples were heterozygous, and as well as the M/N marker 
(position 233), two more SNPs were observed, one upstream of the M/N variant at 
position 254 and one downstream at position 221. The SNP located at 221 was 
equally present for all samples from both cluster 1 and 2 whereas the SNP located at 
position 254 was only present for samples located in cluster 1 (African American 
specific). Sequencing analysis was then performed for the DNA sequences that 
encompassed the forward and reverse PCR oligo sequences. No differences were 
observed for all tested samples for DNA sequences that encompassed the forward 
oligo design (position 320 to 340), but a G/A SNP (rs4867) specific to cluster 1 
(African American) was observed at position 199 of the surrounding reverse PCR 
oligo DNA sequence (start position = 180, end position = 199) (Figure 20-F). This 
finding was in direct line with the observed genotyping issues since the underlying 
SNP is specifically associated with the outlier samples (African Americans), and it 
was located in the 3’ end of the reverse oligo which is known to affect amplification 
of the non-matching allele. In this case, the A allele (position 199) seems to be tightly 
linked with the A allele of the M/N variation since the outlier samples were found 
with the A signals.    
 
1.3.2. Phase II assay optimisation 
Based on these observations, appropriate actions were taken to create 
improved PCR and extension oligo designs for version 2. For the phase II 
optimisation, a total of 192 samples (32 Caucasian, 32 African American, 32 Asians 
and 96 FTA) were genotyped. In the case of the marker k/K, to overcome the lack of 
sensitivity when low DNA template was used, the GA extension pool oligo was 
increased from 5 µM to 10 µM. Also, after reviewing the PCR and extension 
sequence annotation, appropriate modification of the first base located at the 5’end 
was performed on the forward PCR oligo. As pictured in Figure 21-A, the GA assay 
sensitivity is now comparable to the CT extension oligo. Both assays (GA and CT) 
now have a call rate of more than 99.5% and 100% genotyping concordance. Perfect 
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HW and MAF values are now observed.  The PCR oligos of Jk a/b were manually 
redesigned to diminish the amplicon size. With respect to Tm, GC% and multiplex 
PCR compatibility, the amplicon size was then cut from 301 bp to 194 pb. Also, the 
GA extension oligo was modified to correct a mistake in the sequence. Following 
these modifications, both GA and CT genotyping clusters were perfectly separated 
with high intensities and the observed call rates were equal to 100%. A concordance 
of 100% was also achieved when genotyping results from both extension pools were 
compared. A warning regarding the HW value was obtained, but similar to the 
explanation for k/K during phase I, the HW values deviate from reality only in the 
FTA samples, which were pre-selected by Héma-Québec (Figure 21-B). Both 
forward and reverse PCR oligos of M/N-rs7682260 were modified to avoid any 
underlying SNPs that could ultimately contribute to a bad cluster distribution. The 
forward oligo was moved approximately 60 bp upstream in order to incorporate two 
mismatches with GYPB and GYPE and the reverse oligo was modified at the 3’ to 
incorporate a degenerate bases (G and A) in order to accommodate the presence of 
the rs4867 SNP. Also, following the sequencing results, the GA and CT extension 
oligos were modified with degenerated bases to accommodate the rs7658293 and 
rs4449373 markers (Figure 21-C). In both the GA and CT assays, the double 
heterozygote clusters disappeared leading to perfect HW and allele frequency values. 
The African American samples were perfectly incorporated to a unique heterozygote 
cluster indicating that the new reverse PCR oligo amplifies equally the A and G 
alleles (Figure 21-D). Finally, both the reverse PCR oligo and forward oligo of HPA1 
a/b and Fy a/b were corrected with degenerate nucleotides to accommodate the 
previously unknown underlying SNPs (Table 2 of the Materials and Methods 
section). 
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Figure 19: Extraction of DNA from FTA cards 
 
A) 4% agarose gel after multiplex PCR using the SNPstream PCR oligo mixes 
version 1. Typical example of multiplex PCR results obtained using 2 µL of 
DNA extracted from 1.2 mm, 2.0 mm and 3.0 mm spots sizes, undiluted and 
diluted 5, 10 and 20X respectively. DNAs from each punching technique 
were amplified in duplicate and are represented within the white boxes.  
 
B) Typical genotyping clusters of marker Fy a/b using the multiplex PCR and 
CT extension pool from version 1 and five different FTA punching techniques 
(two spots 1.2 mm, one and two spots 2.0 mm and one and two spots 3 mm). 
The actual examples pictured are the results obtained using 1/10 dilution. The 
blue cluster represents the C allele, the green represents the T allele and the 
yellow represents the CT alleles. The six samples points shown in the 
genotyping cluster of 3.0mm (two spots) represent the Coriell DNA samples. 
 
C) 1% agarose gel analysis of the CYP2D6 and APOE fragments. PCR bands are 
expected at 1.7 kb and 900 bp respectively, when positive amplifications of 
CYP2D6 and APOE are obtained. The wells 1 to 10 represent the CYP2D6 
amplification and wells 36 to 45 represent the APOE amplification. 
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Table 8: Summary results after the phase 1 genotyping optimisation 
 
The above table represents a summary of results obtained after the phase I genotyping optimisation. The following results are evaluated on 84 
samples, where 44 are from the Coriell DNA panels (15 Caucasian, 15 African American and 14 Asians) and 40 are from the FTA cards (2 mm 
punches), for a total of 24 genotyping assays (GA and CT). The phase 1 genotyping optimisation evaluated five main criteria: cluster separation, 
which evaluates the quality of the heterozygote cluster separated from both homozygote clusters, the marker call rate, representing the ratio of 
successful genotype calls over the failed calls, the genotyping call concordance, representing the percentage of samples that have identical 
genotyping results in both extension pools (F/R; Forward and reverse DNA strands), the comparison of the theoretical and experimental minor 
allele frequencies (MAF), and finally the Hardy-Weindberg evaluation (HW), which represents a statistical interpretation of normal (Passed) and 
abnormal (Failed) allele distributions.  Markers highlighted in red represent the markers that required phase II optimisation for either PCR 
condition optimisation or complete assay redesign. 
Antigens Marker ID Extension Pools Cluster Separation Call rate %
F/R 
Genotyping 
concordance
Reported MAF
(Caucasian)
Experimental
 MAF HW 
Improvement 
needed
GA Perfect Cluster Separation 100% >99% Passed
CT Perfect Cluster Separation 100% >99% Passed
GA Perfect Cluster Separation 100% >99% Passed
CT Perfect Cluster Separation 100% >99% Passed
GA Good Separation, Double Heterozygote 100% >99% Failed Assay Redesign
CT Good Separation, Double Heterozygote >97% >99% Failed Assay Redesign
GA Good Separation 100 >99% Passed
CT Good Separation 100 >99% Passed
GA Not Standard Clustering 100% >99% N/A
CT Not Standard Clustering 100% >99% N/A
GA Not Standard Clustering 100% >99% N/A
CT Not Standard Clustering 100% >99% N/A
GA Perfect Cluster Separation 100% >99% Passed
CT Perfect Cluster Separation 100% >99% Passed
GA Perfect Cluster Separation 100% >99% Passed
CT Perfect Cluster Separation 100% >99% Passed
GA Bad Cluster separation and Low Intensity 95% >99% Passed Assay Redesign
CT Bad Cluster separation and Low Intensity 95% >99% Passed Assay Redesign
GA Perfect Cluster Separation, Low intensity 100% >99% Passed Assay conditions
CT Perfect Cluster Separation 100% >99% Passed
GA Not Standard Clustering 100% N/A N/A
CT Not Standard Clustering 100% N/A N/A
GA Perfect Cluster Separation 100% >99% Passed
CT Perfect Cluster Separation 100% >99% Passed8%
4%
10%
7%
N/A
2%
16%
27%
32%
N/D
N/A
10%
48%
50%
7%
10%
50%
55%
15%
50%
35%
10%
N/D
Kap a/b rs8176059 2%
e/E
HPA1 a/b
M/N
s/S
c/C
c/C-Intron
HPA5 a/b
rs5918
 rs7682260 
rs7683365
rs1053344
109 bp insertion
rs6065
rs12075
rs1058396
rs8176058
rs609320
rs10471371
HPA2 a/b
Fy a/b
Jk a/b
k/K
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Figure 20: Phase I genotyping results optimisation 
 
A) Typical polar genotyping representation of three successful markers from the 
phase 1 optimisation. The first two genotyping results (1 and 2) represent the 
HPA2 a/b (GA pool) from the Coriell DNAs and the FTA-2 mm DNAs 
respectively, the second two results (3 and 4) represent the s/S (GA pool) and 
the last two results (5 and 6) represent the genotyping clusters from Kap a/b 
(GA pool) from the Coriell and FTA-2 mm DNAs respectively. 
Computational marker call rates, allele frequencies and Hardy-Weinberg 
calculations are represented in the upper left corner and in the lower left side 
of each genotyping cluster respectively. The blue clusters represent the 
presence of the G allele whereas the green clusters represent the presence of 
the A allele and the orange clusters represent the presence of both G and A 
alleles. Samples in gray represent the negative controls. 
 
B) Polar representation of the genotyping results obtained for the marker k/K 
with the pools GA (1) and CT (2) generated with Coriell DNAs and FTA 
DNAs (3 and 4). These results depict an assay that needed optimisation after 
using low DNA concentration as the PCR template.  
 
C) Polar representation of the genotyping results obtained for the marker Jka/b 
with the pools GA (1) and CT (2) generated with Coriell DNAs and FTA 
DNAs (3 and 4). The following results depict a typical assay that needed 
redesign due to clustering separation failure. 
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D) Cartesian representation of the genotyping results obtained for the marker 
M/N with the GA (1) and CT pools (2) generated with FTA DNAs. The blue 
circles represent the original clustering results performed by the software 
before the manual modification. The red and green circles represent the 
heterozygote subclusters 1 (less frequent) and 2 (more frequent) respectively. 
In the upper left figure, the blue, orange and green clusters represent the G, 
GA and A alleles respectively. The following results depict a typical assay 
that needs assay redesign because of the Hardy-Weindberg and allelic 
frequency failures. 
 
E) Sequencing chromatogram representation of four tested samples, two from 
the less abundant cluster (#1) and two from the most abundant cluster (#2). 
The sequences pictured in the upper side are covering around 35 bp of DNA 
sequences downstream of the M/N variation (position 233) encompassing the 
extension oligo sequence used for the SNP detection in the GA pool. The 
sequences pictured in the lower side are covering ~30 bp of DNA sequences 
upstream of the M/N SNP (position 233) including the extension oligo 
sequence used in the CT pool. The new SNPs are located at positions 221 and 
254 of downstream and upstream sequences respectively.  
 
F)  Sequencing chromatogram representation of four tested samples, two from 
the less abundant cluster (#1) and two from the most abundant cluster (#2). 
The sequences pictured in the upper side are covering around 30 bp of DNA 
sequences downstream of the starting base of the forward oligos. The oligos 
start at position 320 and finish at position 340. The sequences pictured in the 
lower side represented 30 pb of the surrounding DNA sequences of the 
reverse oligos. The reverse oligos is starting at 180 and finishing at 199 and 
the new SNP is located at position 199. 
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Figure 21: Phase II genotyping results optimisation 
 
A) Polar graph representation of the k/K genotyping after the optimisation of the 
GA extension oligo concentration (1) and the non-modified CT assay (2). 
Coriell DNAs and FTA DNAs are analyzed all together for a total of 192 
samples. 
 
B) Genotyping representation of the optimized Jk a/b assays after the complete 
PCR oligos redesign and minor modification of the GA extension oligo. 
Coriell DNAs and FTA DNAs are analyzed all together for a total of 192 
samples. 
 
C) M/N PCR and extension oligos re-design based on the sequencing results. 
The new PCR oligos are represented in red whereas the forward oligo is 
located between position 28490 and 28510 and the reverse oligo is located 
between position 28630 and 28650. The M/N marker is highlighted in green.  
 
D) Clustering representation of M/N GA (1) and CT (2) assays after PCR and 
extensions oligos optimisation. Coriell DNAs and FTA DNAs are analyzed 
all together for a total of 192 samples.  
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2. SNPSTREAM MINOR BLOOD GROUP ANTIGEN GENOTYPING 
ASSAY VALIDATION 
 
To validate the SNPstream genotyping panel version 2, two distinct groups of 
experiments were conducted. The first set of experiments was designed to evaluate 
the accuracy of the assay and the second set of experiments was designed to evaluate 
the robustness of each marker. Within the accuracy group, we evaluated the genotype 
concordance of each marker from the SNPstream panel against the Sequenom panel. 
This evaluation is called “cross-technology” concordance, where two different assays 
and chemistries are compared side-by-side on the same set of samples. Since 
Sequenom and SNPstream technologies both use single base extension techniques for 
detection, selected samples from the previous development phases were sequenced 
and then genotyped to evaluate the concordance of genotypes using two completely 
different kinds of detection technologies (Table 9). The accuracy of the assay was 
further tested by investigating the concordance of the minor blood antigens 
phenotypes inferred from the genotyping results with known minor blood antigen 
phenotypes previously characterized by the standard and accredited serological 
methodologies used at Héma-Québec. For this part of the study, 618 extensively 
phenotyped donors were selected from Héma-Québec’s regular blood donors (Table 
10). The robustness of the assay was evaluated for reproducibility, where the final 
genotyping calls from different days were compared, and also tested for inter-
technician concordance (Table 11). 
 
2.1.   Accuracy evaluation 
The cross-technology experiment was conducted on 96 Coriell samples (1/3 
Caucasian, 1/3 African-American and 1/3 Asian) and on the same 40 FTA samples 
used during the development phases. The comparison was performed analysing both 
DNA directions on both genotyping platforms. A total of 6528 genotyping calls and 
13056 inferred phenotypes were compared for this purpose. A total of 7 (0.2%) and 
16 (0.5%) genotyping calls failed the SNPstream and Sequenom experiments 
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respectively, leading to an average call rate for markers of 99.9% and 99.2%. The 
markers e/E and c/C-intron had the lowest call rates which are perfectly reasonable 
because of the “non-Standard” nature of the assays. Also, the Sequenom panel had 
the lowest overall marker call rate since no phase II optimisation had been performed 
for this panel. Excluding the failed genotypes, an average of 99.8% of genotyping 
call concordance was obtained from both DNA strands for the SNPstream and 
Sequenom platforms, and from the both DNA sources (Coriell DNAs and FTA 
samples). Finally, a concordance of 100% was observed between the results 
generated by the SNPstream and Sequenom panels for the Coriell DNAs and 97.5% 
(one discordant) for the FTA samples. These results were more than acceptable 
considering the variability of DNAs extracted from the FTA cards, and considering 
that the discordance was from the c/C-intron (Table 9).  
Out of 96 Coriell samples, six samples (NA17175, NA17275, NA17223, 
NA17294, NA17284 and NA19007) were selected for their high frequency of minor 
alleles (heterozygous and homozygous mutant) and sent for sequencing. This would 
cross-validate the genotyping results using a different detection technology, and 
definitively validate these samples for use as internal controls for the genotyping 
production. 100% concordance was achieved between the results generated by the 
genotyping and the sequencing (Table 9 and Figure 22). Only the marker c/C-intron 
has not been sequenced since not enough specific PCR amplification with acceptable 
amplicon sizes was obtained to generate clean sequencing results (results not shown). 
Since the reverse PCR oligo was specific only in the presence of the insertion, the 
resulting concordance measure was obtained by comparing the presence or the 
absence of the band on a 4% agarose gel. The presence of a band on the gel signified 
that the sample was a carrier of the insertion and should generate a positive 
genotyping call (Figure 23). 
The ultimate validation of the sensitivity of the assay was to measure how well 
the assay can predict actual donor phenotypes previously determined by Héma-
Québec. Phenotypes were determined using serological based assays, and the inferred 
phenotypes from the genotyping results were obtained using version 2 of the 
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SNPstream panel. To perform the comparison, 618 unknown blood samples were 
collected by Héma-Québec on FTA cards and DNAs were extracted from 2 mm 
punches and genotyped on both DNA strands. In addition, 32 duplicates samples 
were present in the sample collection. An average of 99.9% of call rates were 
obtained when both DNA strands assays were combined. The lowest call rates were 
seen for the c/C-Intron and e/E markers, where 99.8 % and 99.2 % was obtained, 
indicating once again that the non-standard assays performed well, especially 
considering the variability in the quality and quantity of the DNA extracted from 
FTA cards. The genotyping accuracies between both strands were also very high, 
varying from 99.8% to 100% with an average of 99.9%. The assay c/C-intron gave 
the lowest accuracy with 99.8%, corresponding to 1 discordant sample. The sample 
was not associated with general sample failure and was not border line between the 
two clusters which could explain the discordances.  
As 32 samples were in duplicate in the sample set, a reproducibility analysis 
was then performed and only two discordant calls were found, one for the e/E assay 
and one for the c/C-intron assay. For a total of 1963 different phenotypes compared, 
the concordance rate between the serological phenotypes and the inferred phenotype 
by genotyping calls was also very high, varying from 97 to 100% for 18 of the 19 
antigens. The serological data for Kp b, HPA-2a and HPA-2b were not available.   
The only exception to the otherwise excellent concordance was the antigen 
HPA-1a where only 50% concordance was achieved (3 correct samples out of 6 total 
tested samples). The genotyping results were confirmed afterwards by sequencing, 
confirming at the same time that the serological data was wrong. All other 
discrepancies (on 12 samples) were verified by an alternative technique and the 
genotyping results were confirmed for 10 of the 12 samples. With these 
confirmations, the accuracy level was in reality 99.9% and not 99.3% as reported by 
the first round of analysis. The two discordant samples were, as before, the e/E and 
c/C-intron assays (Table 10). 
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Table 9: Summary results of the accuracy validation phase 
 
Summary of accuracy results obtained after the genotyping of 96 Coriell DNAs and 
40 DNAs extracted from 2 mm FTA cards. The concordance between DNA strands 
represents the concordance between genotyping results obtained from the GA and CT 
extension pools. The SNPstream Vs. Sequenom concordance corresponds to the 
average genotyping concordance from both DNA strands between the SNPstream 
panel version 2 and the Sequenom panel. The percentage in brackets for the 
SNPstream Vs. Sequenom call concordance referred only to the DNAs from FTA 
cards. The concordance between the genotyping and the sequencing was based on six 
selected samples (NA17175, NA17275, NA17223, NA17284, NA17294 and 
NA19007).   
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Table 10: Inferred phenotypes from the genotyping results and correlation with 
the serological phenotypes  
 
* Number of samples that serological data was available 
Summary of the accuracy results obtained after genotyping of 618 DNAs extracted 
from regular blood donors. The call rate is an average of both DNA strands call rates 
and the concordance between DNA strands represents the concordance between 
genotyping results obtained from the GA and CT extension pools. The 
reproducibility was evaluated based on the 32 duplicate samples present within the 
618 test DNAs. The concordance for the phenotypes was evaluated based upon the 
phenotypes provided by Héma-Québec (serological) and the inferred phenotypes 
from the genotyping results. 
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Figure 22: Genotyping Vs. Sequencing results for the antigen M/N 
 
A) Typical example of genotyping and sequencing results concordance from 
sample NA17294 for the marker M/N. The left genotyping (1) cluster shows 
the typical SNPstream genotyping results obtained during the validation phase 
with Coriell and FTA samples. The blue circle shows the location of the 
sample NA17294. Similarly, the right genotyping cluster (2) shows typical 
Sequenom results with the NA17294 sample in the heterozygote cluster. The 
sequencing trace represents 30 bases of DNA sequence downstream of the 
M/N variants, and the cursor indicates the SNP position. 
  
A
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Figure 23: Genotyping Vs. agarose gel results of the marker c/C-intron 
 
A)  Typical agarose 4% gel results after the amplification of the c/C-intron. The 
gel results demonstrate the evaluation of six selected samples for the presence 
or absence of a band that correlates with the 109 bp insertion (amplicon size = 
155bp). The presence of the band indicates the presence of the RHCE_C 
allele (c/C or C/C) and the absence signifies the presence of RHCE_c allele 
(c/c only). The blue cluster in the genotyping graph represents the presence of 
the insertion whereas the green cluster represents the absence of RHCE_C.  
A
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2.2.   Robustness evaluation 
 
The assays were evaluated for robustness based on the reproducibility of 
results at different time points, and between technicians. The day-to-day data 
reproducibility was conducted on 176 FTA and 12 Coriell DNAs samples (all having 
known genotypes)  using the GA and CT extensions pools reactions. In total the same 
samples were genotyped three times over three consecutive days leading to a total of 
13536 different genotyping calls for comparison. The average call rate obtained per 
experiment was 99.6% and only three discordant genotyping calls were observed 
(0.07%). 100% of the discordant calls were from the marker e/E-rs609320 and 
exclusive to FTA samples (Table 11). These results are in direct line with the results 
shown earlier where the accuracy and the intra-assay reproducibility results of e/E 
were the worst of the twelve markers tested.  
The reproducibility of results between technicians was also very good with 
only one discordant result from 1,152 total genotyping calls, leading to a discrepancy 
rate of only 0.09%. For 96 FTA samples (1,152 genotyping calls), only 0.9% of 
genotype calls were failed and therefore rejected from the comparison study. The 
identified discrepancy was for the marker c/C-intron (Table 11). Both reproducibility 
measures revealed that the SNPstream panel version 2 was very robust for all 
markers, but the results also demonstrated that the two non-standard makers were the 
most susceptible to generating unreliable results. However, the high percentage of 
concordance obtained following the accuracy and robustness experiments was 
sufficient to convince Héma-Québec to move forward on a proof of concept study to 
integrate the SNPstream minor blood group antigen genotyping panel into their 
clinical operations. 
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Table 11: Summary results of the assay robustness validation phase 
 
 The day-to-day reproducibility results were obtained on three consecutive days by 
the same technician using the SNPstream version 2 panel and 188 total samples (176 
FTA samples and 12 Coriells samples). The inter-technician reproducibility results 
were obtained on two different days using 96 different FTA samples. 
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3. CLINICAL APPLICATION: PROOF OF CONCEPT STUDY 
 
In order to accurately genotype 22,000 samples over a period of one and a half years, 
the genotyping blood antigen panel had to be incorporated into standard and 
controlled process. Based upon the genotyping panel development, optimisation and 
validation processes, detailed SOPs (Standard Operational Procedure) have been 
developed and currently applied to help prepare the genotyping panel for clinical 
application (see Annexes A and B). Also, the SOPs have been adapted into our LIMS 
(Laboratory Information Management System) to ensure complete traceability from 
the sample reception to the results reporting to Héma-Québec. Essentially, as 
described in Figure 11 of the Materials and Methods, the complete turnaround 
process for a test sample encompasses five major steps: blood collection on FTA 
cards by the Héma-Québec nurses, the management of sample reception, DNA plate 
management and extraction, the genotyping of extracted DNAs, and finally results 
quality control (QC) and reporting. For each of these steps, a controlled process has 
been established to minimize the human error and make the procedure more 
automated and as accurate as possible (Figure 24).  
 
3.1. Clinical genotyping process and key results 
 
As illustrated in Figure 24-1, to ensure complete sample traceability, barcodes 
were generated from our LIMS and shipped to Héma-Québec in order to uniquely 
identify each FTA card sample with our unique identifiers. In addition to our 
barcodes, Héma-Québec also identified each sample with their own unique 
identifiers.  
Samples are received in batches of 500 at the Pharmacogenomics Centre. The 
sample list provided by Héma-Québec is downloaded from our secure share website 
folder and pasted into the “sample checker” tool (Figure 12-A; Materials and 
Methods). To match the FTA samples against the sample list sent by Héma-Québec, 
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the Héma-Québec barcode is scanned first and immediately a notification of “Passed” 
or “Failed” is seen based upon whether the sample matches the original submitted 
list. The LIMS barcode is then scanned to make the final link between the Héma-
Québec and LIMS identifiers (Figure 12-B). The final file containing all sample 
related information is created only if the previous step provides 100% “Passed” 
comments and is then uploaded into the LIMS (Figure 12-C). Afterwards, the LIMS 
associates both identifiers in their specific fields and all sample related information is 
saved into the LIMS database (Figure 25; samples screen).  
As presented in detail in the sections 9.3 and 9.4 of the annexe A (Figure 24-2), 
the FTA cards are submitted to the auto puncher (BSD, Brisbane, Australia, Duet 
600) to create the 2 mm spots that are required for the automatic extraction on the 
BiomekFX (Beckman Coulter, Fullerton, CA). The extraction is mediated by a LIMS 
procedure transforming the FTA sample type to a DNA sample type (Figures 26-A 
LIMS procedure and B DNA plate layout). A visual quality control check is 
performed after the automatic punching and after the extraction steps, respectively, to 
ensure that all wells contain only one 2 mm spot and also that all wells contain the 
expected volume of DNA at the end of the extraction process. At the time of writing, 
16,598 samples have been punched and no problems have been documented 
regarding this step, however approximately 1% of the FTA cards (5 samples out of 
every 500 samples) are randomly removed from the well by the BiomekFx tips 
during the extraction procedure.  The lost of the 2 mm FTA disk during the extraction 
procedure steps does not automatically lead to a failed genotype unless the loss 
happens before the second wash, suggesting that DNA is slowly released from the 
disk during the final stages of the extraction procedure. 
To accurately control the genotyping processes, all steps described in the 
Annexe B are also supported by the LIMS (Figure 24-3). The DNA from two 96 well 
plates is transferred in duplicate (to support forward and reverse assays) to one 384-
well assay plate for PCR amplification. This is then followed by the LIMS 
genotyping protocol (Figure 27-A). After the robotic transfer of DNA to the assay 
plate, a visual QC check is performed to make sure that the volume is uniformly 
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transferred across the plate, and all mis-transferred samples are noted in the 
genotyping  LIMS run. Mis-transfer problems happen rarely and to date less than 
0.1% of samples (~160 samples) have experienced transferred issues. When these do 
occur, they can be easily corrected by a manual transfer. Furthermore, to evaluate the 
multiplex PCR amplification efficacy, a 1 µL aliquot of twenty-four samples located 
in key positions of the assay plate (384 total PCR reactions) are loaded onto a 4% 
agarose gel to act as part of our quality control process. Different actions are taken 
for failed samples ranging from the re-extraction of test samples to re-starting the 
multiplex amplification with another master mix (Annex B, section 8.5). With more 
than 95 experiments involving 176 samples having been performed so far, only one 
experiment has been rejected because more than 4 samples failed the PCR 
amplification (Figure 27-B).   
To accurately interpret the genotyping results obtained from the SNPstream 
scanner, the raw results are transferred to our in-house quality software tool called 
“SHERPA” to perform the genotype clustering (Figure 28-A) and evaluate the 
overall experiment quality (Figure 24-4). The SHERPA software assists in reporting 
quality issues in two ways, the first one reports the issues at the assay plate level, 
where marker conversion and failure rates are graphically highlighted for better 
visual interpretation of the general experiment performance, and the second one 
reports the issues at the genotyping level, giving a good comprehension of the 
accuracy of the results. As demonstrated in Figure 28-B, a clear issue with the entire 
row K is captured by the software where only 10 markers have generated satisfactory 
genotyping results from a possible 12 markers. The highlighted failed samples were 
subsequently linked to an array spotting problem on the SNPstream hybridization 
plate that encompassed the markers Fy a/b and Jk a/b. Also, the heat map gives a 
quick representation of possible plate inversion or sample layout issues since for the 
blank samples O9 (P9), O10 (P10), O11 (P11) and O12 (P12) a null genotyping 
result is expected. 
Multiple other issues have been flagged by the SHERPA assay plate QC tool, for 
example, an inadequate plate sealing technique leading to a high percentage of failed 
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samples located at the plate extremities was identified and has since been resolved. 
Furthermore, the SHERPA software also assists in the evaluation of the accuracy of 
the results by interpreting three levels of concordance: the concordance of results 
from both DNA strands (Figure 28-C), the concordance of results from two 
independent technicians (Figure 28-D), and the concordance between the actual and 
expected results of known control DNAs (Figure 28-E). The possibility to rapidly 
check for discordances in our results has allowed the technicians to quickly identify 
and to reanalyze problematic samples and markers and correct the genotypes 
accordingly. For instance, sometimes the discordances from both DNA strands are 
generated by a contaminant fixed on the glass of the SNPstream array plate, leading 
to a bias in the fluorescence intensities and ultimately creating a call mismatch.  In 
addition to the negative heat map results given by blank samples, the concordance 
between the genotypes of known controls samples obtained during an experiment 
with the expected genotyping calls is used to flag plate inversion problems. Such 
problems have not been seen in this study to date. The known control genotypes are 
also used to evaluate the stability of the multiplex PCR and extension reagents 
batches over time. So far, no observable variation within the same reagent batches 
has been observed (more than 99.9% of concordance was observed) and the 
mismatches are not related to the age of the reagent aliquots. SHERPA also allows 
for the double reviewing of the raw genotyping data by two independent technicians. 
This greatly increases our ability to accurately call genotypes. Results of genotyping 
mismatches between technicians are rare and are easily identified and resolved by the 
more experienced technician. On averages only four samples per assay plate (~1%) 
have cross-technician genotyping mismatches. Mismatches are most often observed 
for the markers c/C-intron and e/E. Since, the clustering of these two non-standard 
markers requires technical interpretation, a manual interpretation is needed and 
therefore these generated the highest discordant rates. After reviewing and correcting 
all cross-technician discordances, the genotyping results are ultimately saved as final 
call batches. 
Based upon the predefined criteria described in Tables 1 to 4 (Annex B, appendix 
8), the software called “Area51” analyses the final genotypes saved into the SHERPA 
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database and translated the interpreted results into three comprehensive reports: 
technical, inferred phenotypes for tested samples, and concordance with known 
controls. If for any test sample, the rules described in Table 1 (Annex B, appendix 8) 
failed, the sample was automatically removed from the sample list, added to the 
failed sample section of the phenotype report, and flagged for repeat (Figure 29-A). 
Based on these criteria, only 382 samples out of 16,598 samples (2.3%) have been 
failed and subjected to a second genotyping experiment. More than 90% of all failed 
samples are associated with “> 1 discordant genotype from DNA strand assays” 
criteria, and 95% of them are associated with the c/C-intron marker. The other 5% are 
associated with the criteria E “Low intensity signals or samples outside of normal 
clustering thresholds”. These spurious samples were re-genotyped and 100% of the 
repeated samples successfully passed the Table 1 criteria.  
The criteria of Tables 3 and 4 (Annex B, appendix 8) are simultaneously 
analysed. If one of these criteria fails an automatic warning message is highlighted in 
the technical report (Figure 29-B). After analysing more than 95 assay plates using 
the above rejection criteria, only two have been rejected to date. The experimental 
failures were in both cases attributable to mismatching errors in known controls. The 
problem was tracked to an evaporation issue where samples in row P led a to a high 
failure rate of control samples.  
Ultimately, all samples that passed all of the quality control criteria were 
translated into phenotypes and reported according to HQ clinical requirements as “+ 
and –“ reports (Figure 29-C). The translation from genotypes to + and – signs is 
performed electronically following the conversion Table 12, where basically each 
genotype allele is associated with a specific antigen. For instance, if the genotype is 
heterozygous for Fy a/b markers, the inferred phenotypes are (+) and (+) for the 
antigens Fy a and b respectively, and if the genotype is homozygous for the major 
allele, the inferred phenotypes are Fy a (+) and b (-) (therefore the sample is only 
carrying the a antigen and not the b). 
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3.2. Clinical results: accuracy and robustness 
 
To date, 16,598 samples have been genotyped for a total 398,352 genotype calls 
and 365,165 inferred phenotypes. Of that number, 9.7% (35,275) of inferred 
phenotypes were already known by Héma-Québec, but the Centre was blinded to the 
results. These known phenotypes were used as a comparison to check the accuracy of 
the genotyping experiments in production. So far, only 157 discordances were 
observed (0.45%), and most of them are related to the antigens c/C (9), e/E (69) and 
Fy b (57) (Table 13). All discordant results have been submitted to a confirmation 
test to assess if either the serological or the genotyping results generated the 
discrepancies. The validation tests confirmed the initial genotyping results for eighty-
six phenotypes (55%), whereas the test confirmed the initial serological results for 
seventy-one phenotypes (45%). As previously described in the genotyping validation 
phases, the antigen C, inferred from the non-standard c/C-intron assay, and e/E gave 
the worst initial genotyping confirmation results, where 9 out of 78 total c/C and e/E 
related discordant results were observed. The discordances generated from the non-
standard assays c/C-intron and e/E explained 97.2% (69 out of 71) of all initial 
discrepancies with the serological results. Furthermore, the antigen Fy b also showed 
discordances, but in this case all of the discordances were validated for the initial 
genotyping results. These discordances were fully explainable by two silencing 
markers that are not present in either the initial serological results or the genotyping 
data but are essential for the accurate interpretation of the final Fy b phenotype. In 
addition, discordant results have been observed for antigens M, s/S, K, Fy a and Jk 
a/b. All the discrepancies have been resolved upon re-sequencing to show that the 
original genotyping results were correct, except for one Jk b result and one Fy a 
result. Moreover for accuracy evaluation, Héma-Québec wanted to evaluate the 
stability of the blood at 4⁰C before the transfer to the FTA cards, and the stability of 
FTA cards once they were spotted with bloods. To do so, they kept ten samples from 
blood donors in the refrigerator and transferred the blood in triplicate onto FTA cards 
after 6, 27 and 55 days. Subsequently the FTA cards were stored at room temperature 
for 4, 12 and 26 weeks before shipping. All samples were unknown to the Centre and 
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distributed in different shipping boxes and consequently dispersed in different 
genotyping runs. All inferred phenotypes from all replicated samples were compared 
for inter-condition robustness with 100% concordance and reproducibility (Table 13). 
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Figure 24: Clinical process flow summary and QC check points 
 
A) A detailed process flow has been established to accurately genotype 
21,000 Héma-Québec blood donors that have agreed to participate in the 
creation of a database for minor blood group antigens. The whole process 
involves four major steps: 1- sample reception, 2- FTA sample spotting 
and DNA extraction, 3- multiplex PCR amplification and 4- genotyping, 
analysis and results reporting. Each of these steps has detailed quality 
control steps in order to reduce errors and ensure the quality of results.  
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Sample 
reception
• Matching the recieved samples against the expected sample list 
• LIMS mediated association of the Hema-Quebec IDs and our in-house 
IDs
FTA spoting 
and DNA 
extraction 
• Visual inspection of the plate for missing spots or unaccurate spot 
delivery
• Visual inspection for accurate extraction procedure and final DNA 
volume delivery
Multiplex 
PCR 
amplification
• 4% agarose gel analysis of 24 samples uniformally selected from the 
assay plate
• Based upon QC criteria, the experiment is stopped or pursued
Genotyping 
and reporting
•Sherpa:
• Genotyping analysis and issue troubleshooting
• Evaluation of experiment issues
• Results concordances interpretation
•Area51:
•Translation of genotypes to phenotypes
•Evaluation of samples, markers and genotyping plate failures
•Technical reporting and reporting to Hema-Quebec 
Protocol steps              QC Steps 
A
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Figure 25: Sample reception and LIMS management 
 
A) Typical view of the information from the received FTA samples after they 
were uploaded into our Laboratory Information Management System (LIMS). 
1- Shows the side-by-side FTA IDs provided by the Héma-Québec (HQ, 
Client Sample ID) and the FTA IDs generated by our LIMS (PGx name). 2- 
Represents the most important related information for each sample, such as 
the date of sampling, reception date and its storage box identifier. 3- 
Describes specific information related to the samples, such as the storage 
location, the sample quantity and concentration. Also, handling and transfer 
information is annotated once the samples have been moved to different 
labware (i.e. new plate association) or how the samples have been 
manipulated in the lab (i.e. information about DNA extraction, genotyping or 
sequencing run (Usage)). 
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Figure 26: LIMS mediated DNA extraction protocol 
A) View of the typical output sample file obtained after performing the DNA 
extraction LIMS protocol. 1- Shows the input samples (Parent sample), its 
related output samples (Sample) and the related output sample type, quantity 
and location. 2- Shows the output plate layout 
 
B) Typical view of the output plate obtained at the end of the DNA extraction 
protocol. The final plate name and related information, such as the future 
storage location and storage container type are indicated in point 1. For the 
plate name, the nomenclature (HQB_1_00095) represents the project 
(HQB=Héma-Québec), the nature of samples contained in the plate (1 = 
DNA) and the actual plate number (DNA plate 95). Point 2 represents the 
plate layout at the wells level (wells details) and the full list at the sample 
level (sample). All future usage of the plate for either genotyping or 
sequencing will be documented in the tab (usage).  
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Figure 27: LIMS mediated genotyping protocol 
 
A) Typical view of the output plate obtained at the end of the DNA transfer step. 
The final plate name and related information, such as the future storage 
location and storage container type are indicated in point 1. The 
HQB_2_00095_00096 located in the plate name field represents the project 
(HQB=Héma-Québec), the PCR plate (_2 = PCR plate) and DNA plates IDs 
encompassed into the assay plate (00095_00096). Point 2 represents the plate 
layout at the well level (wells details) and the full list at the sample level 
(sample). The plate usage is ultimately described in the tab “usage”. 
 
B) Represents the typical 4% agarose gel QC results obtained after multiplex 
PCR. Typically only wells 10 and 12 are expected to have null PCR 
amplification. Following the criteria described in Table 1 of the annex B, the 
experiment shown here was rejected since more than four samples had failed 
the PCR amplification (wells; 3, 6, 15, 17 and 19). 
 
 
 
 
 
108
A
 
1
2
B
 
(bp) 
 
200 
100 
50 
 
 
 
109
Figure 28: Genotyping quality control assessment using the in-house 
SHERPA software 
 
A) Overall illustration of our in-house developed quality assessment software 
tool, “SHERPA”. 1- Represents the sample and the assay plate IDs generated 
by our LIMS, along with the client ID, sample types and the well positions. 2- 
Demonstrates the tabular representation of all genotype calls per tested 
antigen marker. 3- Shows the visual representation of genotype calls using 
Polar and Cartesian graphic plots. 4- Represents the overall performance of 
genotyping for the entire detection plate.  Basic statistics are performed to 
evaluate the percentage of calls per row, per column and per well. These 
statistics are used to identify failure patterns that occur during the genotyping 
procedure. 
 
B) Close-up of the SHERPA heat map view after the raw data upload from the 
SNPstream database. The highlighted columns 01, 03, 05... represent the GA 
extension SNPstream pool whereas the columns 02, 04, 06... represent the CT 
extension pool. The number represented in each well shows the actual number 
of markers that are within the passed genotyping thresholds, for instance, 11 
means that one out of twelve markers is considered failed. The percentage 
located on each row and column demonstrates the overall ratio of failed 
makers over the successful markers and the arrows indicate that an 
investigation is required to elucidate possible failure patterns. The wells O9 to 
O12 and P09 to P12 represent the blank samples. 1- Shows clear failure 
pattern that has occurred in row K and the highlighted failed samples are 
represented in the genotyping clusters 2- Fy a/b and 3- Jk a/b.  
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C) Illustration of the module that evaluates the concordance between both DNA 
strands. 1- Shows the samples with DNA strand results discordances. 2- 
Shows the actual call discordances from the GA and CT extension pools. 
 
D) Illustration of the module that evaluates the cross-technician concordance 
results. 1- Highlights the samples that experience cross-technician genotyping 
call discordances. 2- The red highlighted samples show a typical example of 
final genotyping call discordances. 
 
E) Representation of the module that evaluates the known control concordance 
between actual genotyping calls and the expected results. 1- Highlights the 
samples and number of markers with miss-matched genotyping results. 2- The 
red highlighted samples show a typical example of discordances of actual 
genotypes (XX-XY) compared to the expected results (XX-XY). 
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Figure 29: Results reporting using the in-house Area51 software 
A) Illustration of failed samples after a typical genotyping experiment. 1- 
Represents the complete list of samples that failed the criteria described in 
Table 1 of the Data Analysis and Data reporting section of the annex B. 2- 
Shows the reason for the sample failure. 
 
B) Illustration of the technical report generated after each genotyping 
experiment. Three main components are included in this report, 1- the 
experiment status, 2- genotype discordances between the technicians 1st and 
2nd analysis, and 3- the samples that failed and required further genotyping 
experiments. The actual report shows a genotyping failure because more than 
10% of the control DNAs failed. 
 
C) Representation of the + and - inferred phenotypes from successful sample 
genotypes that are reported to Héma-Québec as a final output file of results. 
1- List of Héma-Québec and PGx sample IDs reported for which genotypes 
passed all samples, markers, and plate failure criteria. 2- Inferred phenotypes 
for all test markers. RH2 (C), RH3 (E), RH4 (c), RH5 (e), MNS1 (M), 
MNS2 (N), MNS3 (S), MNS4 (s), KEL1 (k), KEL2 (K), KEL3 (Kp a), 
KEL4 (Kp b), FY1 (Fy a), FY2 (Fy b), JK1 (Jk a), JK2 (Jk b), HPA-1a (a), 
HPA-1b, (b), HPA-2a (a), HPA-2b (b), HPA-5a (a), HPA-5b (b). The – and 
+ signs indicate the absence and presence of the antigen respectively.   
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Table 12: Conversion table of the genotyping results to phenotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
Detailed strategy used by Area51 to translate the genotypes to phenotypes for each 
marker. The presence and the absence of the inferred antigens are represented with 
the positive sign (+) and the negative sign (-) respectively and are reported in a 
comprehensive table as presented in Figure 29-C.  
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Table 13: Inferred phenotypes accuracies and reproducibility results obtained 
during the clinical genotyping of blood donors. 
 
* Confirmation test were achieved by Héma-Québec using alternative molecular based experiments. 
 
16,598 DNAs from donors were genotyped and 365,156 phenotypes were inferred 
from the genotyping alleles. Out of the total number of phenotyped samples, 9.7% 
(35,275) were also characterized using serological techniques (Héma-Québec). A 
99.7% accuracy was obtained. The discordances were tested at Héma-Québec using 
alternative molecular based techniques and 55% validated the genotyping results and 
45% the initial serological data. The reproducibility was determined after the 
genotypes of ten unknown different samples were run in replicates, tested for 
different blood (6, 27, 55 days) and FTA card (4, 12 and 26 weeks) stabilities.  
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DISCUSSION 
 
Worldwide blood banking facilities have developed rapid and efficient 
serological tests to evaluate the presence of major blood antigens, such as the A, B, 
AB, O and the RhD antigens. These tests are routinely performed to avoid any major 
immune responses that can happen during blood transfusion. However, in total there 
are 30 known blood groups leading to more than 300 different blood antigens. For a 
patient receiving one or two transfusions during their lifetime, mismatches for the 
minor blood antigens pose no problem, but a patient requiring frequent blood 
transfusions (patients with leukemia, hemophilia, sickle cell disease) can develop 
strong and fatal immune responses. For many reasons, including the continual 
increase in reagent costs, unreliable serological results, and lack of tests for some 
antigens, the detection of minor blood antigens is not routinely performed on blood 
donors (Quill, 2008).  In addition, blood banking facilities have to screen dozens of 
different blood samples for specific antigens before they arbitrarily find the right 
donor. In order to efficiently match donors with patient who undergo frequent blood 
transfusions, we have developed a minor blood group antigen genotyping assay that 
can simultaneously detect 22 different minor blood and platelet antigens (c/C, e/E, 
S/s, M/N, K/k, Kpa/b, Fya/b, Jka/b, HPA-1a/b, HPA-2a/b and HPA-5a/b) in a single 
multiplex PCR reaction only using a few nanograms of DNA.  A total of 21,000 
Héma-Québec donors have been recruited for genotyping and have agreed to take 
part in the creation of a centralized database consisting of their minor blood antigen 
profiles. The creation of this database provides Héma-Québec with the instant ability 
to match patients who undergo frequent transfusions to the appropriately matched 
donors for a fraction of the cost of standard serological testing. The final, optimized 
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and validated, minor blood group antigen genotyping assay has been developed for 
the Beckman Coulter GenomeLab SNPstream platform (Fullerton, CA) and uses a 
DNA extraction method that can support FTA cards. The use of FTA cards has many 
advantages for Héma-Québec’s blood banking facility, where only one drop of blood 
is needed, and the DNA on the FTA cards is highly stable for at least a few years at 
room temperature (Belgrader et al.1995).  
Since the blood genotyping panel was developed for a clinical setting, the highest 
quality of genotyping was essential. To do so, we devoted a lot of effort into assay 
design, and optimisation. We also developed a comprehensive phased development 
and validation plan to fully convert all markers with the highest genotyping call rates, 
robustness, and accuracy. Firstly, we bioinformatically analyzed the DNA sequences 
that encompassed the selected minor antigens to fully characterize any genomic 
anomalies that could compromise our assay designs, such as gene duplications, 
underlying genetic variation and gene homology. The results obtained from this 
bioinformatics analysis permitted the rapid identification of markers that were 
suitable for routine automated assay design using the commercial assays design tools 
provided by the genotyping platform companies. For those markers that were 
assessed to contained irregular and challenging genomic regions, we performed 
manual design strategies. As shown in Table 7, high DNA sequence homologies 
around the markers c/C and e/E were found for the genes RHCE and RHD, and high 
DNA sequence homologies around the markers M/N and S/s were identified for the 
GYPA, GYPB, GYPE genes. Laboratories that only use the standard automatic design 
tools would have automatically rejected these four markers that are absolute 
requirements for our panel design, however, this would ultimately reduce the 
sensitivity of our genotyping panel and reduce its viability for clinical application. 
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Therefore, a significant amount of effort was made so that the markers M/N (GPYA) 
and S/s (GPYB) could be manually designed to optimise PCR oligos with the highest 
specificities in 3’ region of their specific locus, whilst having favorable profiles with 
regards to Tm and other compatibilities within the PCR oligo mix. Likewise, the 
genes RHCE and RHD were aligned and PCR oligos were manually optimised for the 
markers c/C and e/E.  The manual assay designs were initially based off the M/N and 
S/s standard single base extension designs generated by the automatic software 
programs, where one pair of PCR oligos and two extension probes ending one base 5’ 
of the SNPs were created. The PCR oligo designs then needed to be manually 
optimised to provide greater specificity for the PCR amplicons to overcome the 
presence of high homology flanking the SNPs. Following phase I optimisation, the 
S/s marker was completed as the assay achieved all the required acceptance criteria: 
good cluster separation, 100% call rate, >99% concordance between both DNA 
strands, accurate allele frequency calls, and accurate Hardy-Weindberg values (Table 
8). On the other hand, the marker M/N failed with respect to the expected allele 
frequency and Hardy-Weindberg values. After thorough analysis of the genotyping 
clusters, a clear double heterozygote cluster was observed for the assays on both 
DNA strands (Figure 20-D). By manually re-clustering the two heterozygous sub-
clusters, the expected allele frequencies and the HW values were returned to normal, 
which indicated that the problem resided into the PCR oligo designs (Figures 20-E 
and F). Additionally, the minor sub-cluster was composed of African-American 
samples only which suggested the possibility of a unknown underlying variation that 
was impacting the African population genotyping patterns. Upon the sequencing of 
samples from both heterozygous populations, a previously unreported G>A variation 
was discovered at the extreme 3’ of the reverse PCR oligo specific only for the 
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African-American heterozygous population cluster. This finding explained the loss of 
heterogeneity calls for the African-American samples that were carrying the variation 
at the 3’ of the reverse PCR oligo. This issue highlights the need for using control 
samples from diverse populations during the panel development and validation 
phases. This issue would never have been discovered with exclusive use of Caucasian 
samples.  
More complex genotyping designs were developed for the markers e /E and 
c/C. As described in the results sections (Section 1.2), the marker e/E was quite 
challenging to develop because it is a G>C variation and the SNPstream GenomLab 
chemistry allowed only the same extension types (GA and CT) in multiplex 
extension reactions. To bypass this issue, we detected the presence of each allele (G 
and C) using two different extension mixes, thus the allele G was detected using the 
CT extension mix and the allele C was detected using the GA extension mix (Figure 
17). The results, as explained in Table 8 and Figure 17 showed the MAF fitted 
perfectly with the expected value and ultimately no critical problems were observed 
in the phase I experiment. However, during the phase I optimisation, the assay 
performed with the GA extension mix showed very high non-specific extension 
(Figure 17-B; green cluster). This non-specific extension was expected in the GA mix 
as there was no C nucleotide available for the normal extension on the template 
containing the G allele. This led to a high potential of non-specific G nucleotide 
incorporation (Yang et al., 2002). Nevertheless, the non-specific G incorporation 
genotyping profile was constant over time, permitting the establishment of reasonable 
clustering thresholds between samples with specific and non-specific nucleotide 
incorporation (Figure 17-B). For the CT extension, some non-specific extension was 
also observed, but in this case, instead of the same C nucleotide being specifically 
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and non-specifically extended, the T nucleotide was incorporated for samples 
carrying the G allele, leading to two opposite clusters (Figure 17-B). Normally, the 
absence of a T allele template should lead to a failed cluster, but the increased 
amount of ddT in the extension mix provided an excellent source of nucleotide and 
the DNA polymerase incorporated it into a mismatched template, ultimately leading 
to non-specific extension. Since the final genotyping results have to be inferred from 
both DNA strand assays (GA and CT) we do not have the same quality control 
concordance values that we have for most of the other SNPs, however, the assay 
results for the marker e/E was consistant and accurate enough to be successfully 
incorporated to the minor blood group antigen genotyping panel. 
The marker c/C was the most challenging marker to be incorporated into the 
genotyping panel. This marker design was also conducted manually using the aligned 
sequences of the genes RHCE and RHD. The complexity of this design came from 
the very high homology of the RHCE-C allele with the RHD gene. This homology 
prevented the conventional genotyping designs for the simultaneous detection of the 
RHCE-C and RHCE-c alleles. To avoid any genotyping signal background from the 
RHD gene, which would lead to misinterpretation of the c/C antigen phenotypes, we 
optimized the PCR amplification to be specific only to the RHCE-c allele using 
sequences mismatches between the RHCE-c allele and RHD (Figure 18-A). The 
detection of the small c allele was once again not trivial. The RHCE-c allele was 
amplified, and the only possible detectable alleles were A (for the extension GA) and 
T (for the extension CT). However, in both assays (CT and GA) non-specific 
extensions were observed, similar to the issue described for e/E (CT).  The detection 
of the RHCE-C allele was obtained by designing an additional assay, which detected 
the presence of the 155 bp insertion in intron 2 of the gene RHCE. Reported by Tax 
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et al.,2002, the presence of this insertion in intron 2 is highly associated with the 
presence of RHCE-C antigen. Even if some non-specific ddG and ddT incorporation 
occurred for both DNA strand assays, the correct genotyping clustering metrics and 
expected allele frequency values obtained during the optimisation phases permitted 
the establishment of a clear clustering threshold, which allowed for the successful 
incorporation of the c/C antigens into the genotyping panel.  
 
For validation, we evaluated the minor blood group antigen genotyping panel for 
its accuracy and robustness.  According to Bell and coworkers (2002), the expected 
call rate for the SNPstream GenomeLab system is 95%. With the idea of moving the 
assay into clinical application, a 95% call rate combined with external factors 
including possible variability in blood quality, genotyping errors, possible variability 
in array hybridization plate quality was not ideal. The overall genotyping call rate 
obtained during our validation phase was 99.9% on both DNA strands. Thus, we 
concluded that the 95% call rate estimated by Bell et al. (2002) reflected only the 
average call rate that is achieved when standard automatic designs are used. 
However, our current result of 99.9% assay call rate is a clear indication that our 
design and optimisation strategy that utilizes an extensive bioinformatics evaluation 
followed by a phased development process significantly enhances the quality of 
genotyping call rates, as well as the marker conversion rate. The lowest call rates 
obtained were 99.8% and 99.2% for the markers c/C-intron and e/E respectively 
(Table 10). Our lowest call rates were expected for our non-standard marker designs, 
but regardless, the very high call rate % obtained for these assays during the 
reliability testing demonstrated a high degree of confidence for both markers. In 
 
 
 
123
addition, the minor blood group antigen panel has been tested on different days, and 
by two different technicians with a 99.9% correlation (Table 11). 
 
To determine accuracy, we cross-compared the genotyping results obtained from 
the panel developed on the SNPstream GenomeLab technology and the panel 
developed on the Sequenom platform. The data showed more than 99.8% genotyping 
call concordance from the both DNA strands on both platforms, and 100% cross 
platform concordance if we considered only the Coriell samples, and 99.8% if we 
included the DNA extracted from the FTA samples (Table 9). The discordances 
observed with the FTA samples were associated with the c/C-intron marker, which 
was not surprising since this assay demonstrated the worst sensitivity to low DNA 
concentrations. Of particular relevance from the cross-technology comparison is that, 
except for c/C-intron, e/E and M/N, all the PCR and extension oligos were different 
between the SNPstream and the Sequenom panels, further re-enforcing the validity 
and accuracy of the genotyping results obtained during this study. The high accuracy 
levels were ultimately confirmed by sequencing where 100% of the identified 
sequences were concordant with the genotyping results.   
The final accuracy test evaluated 618 well characterized FTA blood donor 
samples, where the antigen phenotypes inferred from the genotyping panel were 
cross-compared with the antigen phenotypes determined through standard serologic 
techniques (FDA and Health Canada approved). Within the 618 samples, 32 samples 
were duplicated and 99.7% concordance was seen for the replicates, indicating that 
the reproducibility of the panel is constant over a diverse source of DNA. The data 
obtained from this accuracy experiment also showed the reliability of the genotyping 
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technique, as a 97% correlation was obtained between the genotype and serological 
techniques.  
The only exception to the otherwise high accuracy rate was seen for HPA-1b 
where only a 50% correlation was found (out of 6 samples). However, all samples 
that showed discrepancies were re-tested using an alternative molecular based 
methodology and all but two of the HPA-1b results were confirmed to be accurate 
from genotyping. The two exceptions, which confirmed the serologic results, are 
associated with the two non-standard markers, c/C-intron and e/E. Despite these two 
discordant results the concordance percentage is still very high, as 99.2% and 99.5% 
concordance was obtained for the c/C-intron (C allele) and e/E (e and E alleles), and 
an overall concordance of 99.3% was obtained during this validation step. This 
confirmed the utility of the genotyping blood antigen panel for the creation of the 
Héma-Québec minor blood group antigen database.  
As a comparison, Denomme et al. 2005 performed a similar study and was unable 
to achieve an acceptable conversion rate for these markers. They obtained a 
significantly lower concordance rate, especially for the two non-standard markers c/C 
(C antigen; 87.7%) and e/E (e antigen; 73.9%), which would preclude the use of their 
panel in a clinical context. They explained the problem by the co-amplification of the 
genes RHCE and RHD during the multiplex PCR. This example clearly illustrates the 
effectiveness of our assay design efforts and highlights the need to perform a deeper 
bioinformatics analysis to accurately designing oligos that are specific to the desired 
templates. In addition, to overcome the problem of inferring the C allele, we designed 
an alternative assay with greater specificity for the presence of RHCE-C allele. 
There are many factors that could lead to a difference between the inferred 
phenotypes from the genotyping results and the phenotype determined by serological 
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techniques. First of all, it’s well known that more than one polymorphism can 
contribute to the protein conformation and ultimately affect the antigen expression. 
For example, the SNP located in the promoter region of the FY gene occurred 
because of the presence of the malarial parasite Plasmodium vivax in endemic 
African regions and therefore is mostly associated with African descent (Storry et al., 
2007). The mutation located in the GATA-1 box region (called Fy0) is erythroid 
specific, meaning that individuals with this variation lack the Fy glycoprotein. For 
most carriers this silencing mutation is located on the genomic background of the Fyb 
allele, but it was also found on the Fya allele background (Storry et al., 2007). In our 
validation phases, the alternative molecular based assays confirmed that two of our 
three samples that differed with the serological results had this Fy0 mutation.  Also 
another SNP, FyX, more prevalent in individuals of European descent (~2.0%), is 
known to produce antigens almost undetectable by most anti-Fyb reagents. These 
examples highlight the limitations of serologic testing. Storry et al. 2007 showed in 
their study that 7 out of 74 samples had both the Fy0 and Fyx variants and thus the 
RBC carried only one dose of the antigen but they appeared, by serologic testing, to 
express both antigen doses.  
Because of the high homology between the RHCE and RHD genes, particularly 
around exon 2, we had to develop a non-standard second assay. Instead of detecting 
directly any polymorphism resulting in C antigens, we detected the155 bp insertion in 
intron 2 which is cis with respect to the RHCE-C allele. The insertion is in high 
linkage for individuals of Caucasian descent, but 25% of individuals of African 
descent carry a hybrid gene (D-CE-D) containing exons 1 through 3 of RHD gene. 
These individuals express a weak RHC antigen and therefore give false negative 
results (Daniels et al., 1998 and Storry et al., 2007). As discussed above, the biggest 
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discordance in our results was observed for the HPA-1b antigen. It is well 
documented that for erythrocyte antigens, except for HPA-1a where a monoclonal 
antibody is available, the serologic detection techniques are highly variable as the 
tests require human antisera and immune fluorescence based assays (Beiboer et al., 
2005). The possible variability in the HPA-1b antigen is most likely due to poor 
reagents and not the sensitivity of our genotyping assay and could explain the initial 
50% discordance observed between our genotyping data and the phenotype data 
provided by Héma-Québec.  
In addition to the limitations of the serological assays described above, there is a 
general problem in the blood banking world regarding the accessibility to well 
characterized and reliable reagents. Many important minor antigens have to be 
assessed using polyclonal antibodies, which are often only weakly reactive. In 
addition, the Knops antigens system has been well documented to generate inaccurate 
phenotypes when serologic test are used (Storry et al., 2007). The same study 
reported an issue when using hemagglutination for the detection of the Jsa, Kpa, Cw, 
Goa, Dia and Mia minor antigens. Inconsistent serological results for these antigens 
can be very problematic as these antigens are highly clinically relevant, especially 
when used to screen specific populations where these antigens are frequent. Storry 
and colleagues (2007), have also reported an issue with using serologic assays for the 
detection of the antigens S/s. They explained that evolutionary pressure by the 
malarial parasite, Plasmodium falciparum has led in some individuals of African 
descent, to a deleted and mutated GYPB gene, which transmits a selective advantage 
against infection. This polymorphism ultimately leads to unreliable serological 
results as current testing methods cannot accurately determine the correct antigen. As 
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described in the introduction, there is a great need for correctly matched blood donors 
for individuals who have been exposed to multiple transfusions and who are now 
refractory to PLTs or RBCs because of immunological responses that have resulting 
in antibodies to a variety of antigens. This is a major concern for blood banks 
worldwide. This is particularly true for patients with diseases like sickle cell disease 
or thalassemia, which necessitate regular transfusions over long periods of time. 
Screening blood bank donations for compatible blood when the patient has a mixture 
of relatively uncommon antibodies can be difficult, sometimes impossible, because 
the reagents, rare antisera, are difficult to obtain (Anstee, 2005).   
Taken altogether, the challenges and limitations surrounding serological 
screening of rare antigens are driving the world-wide effort to develop new and 
improved methodologies. Specifically, DNA-based assays are now gaining 
acceptance for the detection of the minor blood group antigens.  This new initiative is 
currently gaining acceptance in the form of either establishing minor blood group 
antigen databases or performing greater quality control on established serological 
tests.  
Following our very encouraging results obtained with our genotyping panel 
during the validation phase, we have established a validated process starting from 
sample reception to the final generation of reports (Figure 11). We have developed 
successful standard operation procedures (SOPs) that have firstly allowed us to 
efficiently handle 21,000 test samples from their reception to the reporting stage; and 
secondly, we have developed robust quality control procedures which we have 
integrated into all aspects of the genotyping process to assess the quality of the final 
inferred phenotypes. These SOPs support all aspects of the process from sample 
reception, DNA extraction, genotyping, through to the predicted phenotype (Figures 
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24 to 29). The complete process is mediated by our custom LIMS (Laboratory 
Information Management System) and unique barcode identifiers which ensure full 
traceability of samples, reagents and experiment time. To eliminate the possibility of 
mixing up samples provided by Héma-Québec, we have developed a system that 
electronically links the client barcodes with our own unique barcodes in our LIMS. 
Even though our laboratory and this process has not yet become officially accredited 
(eg. CLIA), the process that we have develop meets GLP standards as our laboratory 
practice during the advancement of this project followed all the documentation 
required for a controlled GLP process as closely as possible. It is important to 
mention that the system was audited by two independent pharmaceutical companies, 
who were in agreement that our processes were very close to being GLP compliant.   
A critical part of our ability to perform accurate clinical genotyping on a large 
number of samples is the establishment of quality control steps. We have efficiently 
introduced a series of quality control steps from the DNA extraction through to the 
reporting of phenotypes to Héma-Québec. The main quality control steps that we 
successfully incorporated into our process were the introduction of the SHERPA 
software and the reporting tool Area51. As presented in the Results section, the 
SHERPA software has the potential to flag, at an early stage, any plate problem 
patterns that may ultimately impact on the high-throughput genotyping process. Also, 
SHERPA contributed to increasing the accuracy of the results by automatically 
interpreting the genotyping calls from two different technicians, and by interpreting 
the concordance from both DNA strands. The comparison of two independent 
genotyping results obtained from two technicians was a particularly useful quality 
control step for the non-standard marker e/E, where no comparison of both DNA 
strands was available.  
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Finally, the reporting interface Area51 has raised the quality of our results by 
automatically inferring the phenotypes from the genotype data, thus limiting the 
impact of human error during the reporting steps. In addition, Area51 is directly 
linked to the SHERPA database; consequently it is able to interpret the data, based on 
predefined rules, allowing it to report on sample failures, control failures, and 
ultimately on experimental failures. This rapid and efficient reporting has elevated 
the quality of final results by excluding samples that failed more than two markers 
(out of 24 total markers from GA and CT extension pools) and samples that had more 
than one discordant call from both DNA strands. Area51 has so far flagged two major 
problems related to control DNAs which were later tracked to a specific, fixable 
cause, but this example illustrates the robustness of Area51 to report any kind of 
issues that could contribute to decreased quality of results. By having the quality 
controls and the reporting tools in place during the project, we were able to evaluate 
to date 16,598 different frequent donors for a total of 365,156 inferred phenotypes. A 
total of 382 samples were re-genotyped because they failed the Area51 reporting 
filters and 100% of them were recovered in a second round of genotyping. This 
demonstrated that the samples failing the first round of genotyping were related to 
technical issues and not the reliability of the genotyping designs.   
The most impressive results that came out from this project were the accuracy of 
our assay over thousands of samples. Approximately 10% of the total results 
generated so far were compared with the gold standard serological assays and we 
have achieved, similar results to those obtained during the validation phase, 99.7% 
accuracy and 100% reproducibility. A total of 157 phenotypes were discordant and 
55% (86 phenotypes) were confirmed for the genotyping results using an alternate 
molecular method, whereas 45% (71 phenotypes) were confirmed to be accurate for 
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the serological assays. Interestingly, as observed during the validation phase, the 
most problematic antigens were e/E (69 discordant), Fya/b (63 discordant) and c/C (9 
discordant), which account for more than 90% of the discrepant results. In the Fya/b 
assay, the Fyb antigen generated 57 discordant calls and all were related to the Fy0 or 
FyX variants, which clearly demonstrate the limitation of the gold standard 
serological assay when silencing markers are present. In the case of the antigen c/C, 
only 3 phenotypes (C antigen) were confirmed for the serological data, which led to a 
final concordance for that antigen of 99.9%, confirming that the strategy developed to 
interpret the C allele was valuable and applicable in a high throughput genotyping 
process. The most problematic assay remains the e/E antigen, where 60 out 69 
discrepancies were positively replicated by the serological results. The discordance 
between both assays is 100% related to the non-standard design, and there is no 
double DNA strand data to test for concordance during the quality control phases 
since both strands are needed for the final phenotype interpretation.  
As expected from the validation phase, the two non-standard markers (c/C-intron 
and e/E) generated more than 97% of all serological confirmed discrepancies. 
Fortunately, 100% of the e/E discordance encountered during this project was fully 
resolvable using the Sequenom platform, where no limitations exist for the extension 
reactions of various SNPs.  
 The process that we have developed to integrate minor blood group antigen 
genotyping into our laboratory, to support Héma-Québec, was also recently used to 
support the genotyping of 10,000 samples from the Canadian Blood Services. This 
group has the same aim, which was the vision of building an informatics database of 
20 minor blood antigens. By using the same panel, with the exception of replacing 
the platelets antigens by two RHD markers, and including the Fy0 marker, we have 
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been able to complete the genotyping of 10,000 samples (from Toronto) over three 
months. We currently have no data comparing genotyping with serological 
phenotypes, but our internal results showed that only 0.4% of total genotyped 
samples failed our filters, and an overall call rate of 99.8% was achieved, which is 
significantly higher than the 95% expected by Bell et al.,2002.  
In the near future, both the Canadian Blood Services and Héma-Québec are 
interested in the expansion of the current panel. We aim to incorporate 60-70 more 
antigens into the panel using the Sequenom platform. A preliminary list has been 
created, which includes the Knops, the Dombrock, the Lutheran, and the Colton 
systems.  The addition of these extra antigen systems will significantly increase the 
amount of clinical relevant information and will ultimately provide better 
characterization of the minor blood group antigens fro each blood donor, improving 
the sensitivity of the assay the ultimate selection of suitable blood for specific patient 
needs. Moreover, we expect to incorporate some silencing mutations, such as the Fy0 
and FyX in the next generation of the panel, in order to eliminate the recurrent 
discrepancies observed for the Fyb antigen.  
With the use of the Sequenom platform, we will eliminate the extension issues 
observed for the e/E (G>C) assay obtained with the SNPstream platform, as the 
Sequenom chemistry can handle all different extension types in a single multiplex 
reaction. Even though Sequenom will eliminate most of the concerns related to the 
e/E antigens, we expect difficulties for all markers located in the RHCE, GYPA and 
GYPB genes. To overcome this homology problem for future markers, the same 
design strategy used in this work will be applied to successfully incorporate all 
crucial makers into the extended panel.  
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 In conclusion, we have successfully developed a DNA-based assay suitable 
for the creation of a minor blood group antigen database of 21,000 frequent blood 
donors for Héma-Québec. Also we have successfully integrated a GLP-like process 
dedicated to high-throughput multiplex genotyping.  To date, 16,598 donors have 
been genotyped for a total of 365,156 total inferred phenotypes with 99.7% accuracy. 
The high accuracy and reproducibility achieved during this project has proven that 
the development strategy that we have put in place in the early stage of the project 
has enhanced the quality of the genotyping results. Similar development approaches 
used in this project, have been adapted for use in the laboratory to support other 
major pharmacogenomics projects. For instance, we have used similar development 
and clinical application approaches for a project involving lipid related genes and 400 
well characterized patients that have experienced myotoxic adverse effects as a result 
of their Statin medication.  
Recently, the same slightly modified minor antigen blood panel has been used 
by the Canadian Blood Services to generate a similar minor blood group antigen 
database, where 10,000 frequent donors have been phenotyped using our panel. 
Finally, in March 2008, Elizabeth Quill cited in Science Magazine that our laboratory 
and Héma-Québec were the first blood units in Canada and one of the leaders in 
North America that were actively moving ahead in the large scale genotyping arena. 
This article demonstrated that our work has initiated a new era for blood antigens 
genotoyping. The DNA-based assay we developed here will provide significantly 
more information about each donor than previously used methods. This will reduce 
future complications in patients receiving multiple transfusions.  
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The minor blood group antigen informatics database created from this work is 
currently being used for all hospitals in Quebec and has already demonstrated great 
improvements in the selection of the right blood for the right patient. It is anticipated 
that the same usage will become common practice in additional hospitals across 
Canada. This work was the first personalized medicine application developed and 
implemented at the Génome Québec and Montreal Heart Institute Pharmacogenomics 
Centre and is paving the way for the next set of pharmacogenomic assays that are 
moving towards the clinic. 
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1. Purpose 
1.1. This SOP defines the procedure for automated DNA extraction of 
blood spots from FTA cards with the Generation DNA Purification 
Technology by Qiagen for Héma-Québec’s Project. 
2. Scope 
 
2.1. This SOP applies to DNA extraction from a 2 mm punch of FTA card 
impregnated with whole blood. 
 
2.2. This SOP applies to either automated or manual procedures of FTA card 
punching and DNA isolation. 
 
3. Abbreviations  
3.1 DCN : Document Control Number 
3.2 DNA : Deoxyribonucleic acid 
3.3 LIMS : Laboratory Information Management System 
3.4 PCR : Polymerase chain reaction 
3.5 PGx : Pharmacogenomics 
3.6 QA : Quality Assurance 
3.7 SOP : Standard Operating Procedure 
4. Contents 
9.1 Pre-Generation of FTA card PGx barcodes 
9.2 Sample Reception and Update 
9.3 Creating a Plate Layout  
9.4 Automated FTA Card punching 
9.5 Creating a run in the LIMS 
9.6 Automated DNA Extraction 
9.7 Return of FTA Cards boxes. 
5. Definitions: N/A 
 
6. Responsibilities 
 
6.1. Directors, Clinical Lab Leaders and QA representatives  
  
6.1.1. Ensure that all PGx employees required to isolate DNA from blood 
spots on FTA cards using the Generation Technology are trained and 
follow this SOP. 
 
6.1.2. Maintain and, when required, review and sign this SOP.  
 
6.1.3. Any of these responsibilities can be delegated to the appropriate 
person provided he/she was trained on this SOP. 
 
6.2. Technicians 
 
6.2.1. Follow this SOP. 
 
6.3. Reviewer 
 
6.3.1. All reviewers must have the required background in order to 
understand the content of the document. 
 
7. Supplies 
 
7.1. Equipment 
 Biomek FX Laboratory Automation workstation 
 Biomek Software 
 BSD600-Duet  Automatic puncher 
 2 mm puncher 
 Cutting mat 
 Centrifuge 
 Multichannel pipettes (20 µL and 200 µL) 
 Heating plate sealer 
 Thermocycler (96-well module) 
 Barcode reader 
 Biotracker (LIMS) 
 
7.2 Consumables 
 FTA Classic Card (Whatman) or FTA Mini Card (Whatman) 
 55 mL Reservoir Basin 
 1.2 mL 96-well plate 
 Thermo-Seal Heat Sealing Foil    
 Adhesive plastic film 
 20 uL and 200 uL sterile filter tips 
  
 Robotic Workstation 250 uL sterile filter tips 
 Robotic Workstation 200 uL conductive sterile filter tips 
 Robotic Workstation 1000 uL conductive sterile filter tips 
 Quarter Reservoir, Divided by Length, 19 mL/Section  
 Reservoir Holders  
  Waste containers 
 FTA Cardboard box  
7.3 Chemicals 
 Generation DNA Purification Solution #1 (Qiagen)  
 Generation DNA Elution Solution #2 (Qiagen)   
 Distilled water (RNase/DNase–free grade) 
8. Generalities 
8.1. Delimited zones for DNA extraction, pre-PCR and post-PCR are to be 
used accordingly to the step being performed. This will avoid any 
carry-over contamination (refer to SOP PGx-IG-016 Material Sample 
and Personnel Flow and Hygiene). 
8.2. Every technical step performed has to be documented and recorded 
in the LIMS. 
8.3. Every consumable, chemical and equipment has to be documented 
and recorded in the LIMS. 
8.4. Any observation, abnormality or incident has to be documented and 
recorded in the LIMS. Furthermore, incidents have to be reported to 
QA in order to be documented as per SOP PGx-IG-006 Deviation, 
Incident and Investigation reporting. 
8.5. Lab coat and gloves should be worn at all times.  
Exception: in order to avoid static problems and loss of samples, the hand 
that handles the 1.2 mL 96-well plastic plate during the FTA card punching 
step should always be glove-free.  
9. Procedure 
9.1. Pre-Generation of FTA card PGx barcodes 
Note: The amount of barcodes to be generated relies on Héma-Québec’s 
request. 
  
9.1.1. Open the folder R:\Commun\Biotracker\Generic sample Batch 
Import\HQA-HQB to know what the last numbers used were for 
the previous generation of FTA barcodes (e.g: 
HQ_Temporary_0001-1000). 
9.1.2. Open the template file: HQ_PreGeneration_FTA 
Barcode_3Sept08.xlsx located under: R:\Commun\Héma-
Québec\Temporaire-Sample-reception-checker. 
9.1.3. Replace the “ClientSampleID” list with a new sample list that 
corresponds to the new incremental numbers: (e.g. 
SampleUpdate1001 to SampleUpdate2000) and insert the 
location number. 
9.1.4. Save the previous file according to the corresponding new 
numbers: in the folder R:\Commun\Biotracker\Generic sample 
batch import (e.g. HQ_Temporary_1001 to 2000). 
9.1.5. Open the LIMS, and go to the “Samples” tab and again select 
“samples” in the roll down list. 
9.1.6. Select a “sample type” (FTA paper) and click on the “Import” 
button at the bottom of the screen. 
9.1.7. Retrieve the previously created file from the “Select a file” row 
and select the mapping “HQ_Import”. 
9.1.8. Click on “Import”. 
9.1.9. When all temporary samples are imported into the LIMS, save 
the new entries and select all the samples and print the 
corresponding barcodes. 
9.1.10. Send the printed barcodes to the following address: 
Care of: Josée Perreault  
Héma-Québec 
1070 avenue des Sciences-de-la-vie 
Quebec, Qc 
G1V5C3 
  
  
9.2. Sample Reception and Update 
9.2.1. Upon arrival of Héma-Québec’s FTA card boxes, create a new 
location and a barcode for all boxes with the Location Explorer of 
the LIMS (refer to the LIMS User’s manual).  
9.2.2. Print the barcodes and label the corresponding boxes. 
9.2.3. In Knowledge Tree, open the file:  /Shared/Héma-
Québec/Tools/Sample_Reception_Checker_SampleBatchUpdat
e_template_3Sep08  
9.2.4. In Knowledge Tree, open the HQ file: PGC/Clients/Héma-
Québec/Input/.  
9.2.5. Copy and paste all data from the previous file to the “File from 
HQA” tab in the Sample Reception Checker.  
9.2.6. In the “Date Received” column, document the sample reception 
date in the following format: YYYY-MM-DD. 
9.2.7. Save the previous file under: R:\Commun\Héma-
Québec\Temporaire-Sample-reception-checker following this 
nomenclature: HQA or HQB_DATE_Start PGx Barcode – Last 
PGx Barcode (e.g. HQB_07Aug2008_FT000HQB8001-
FT000HQB9000.xlsx). 
9.2.8. Open the “Step 1” tab and scan the Client Sample ID and the 
PGx barcodes on each FTA Card starting with the box that has 
the lowest barcode number.  
Note: Throughout the scanning process, verify that the status is Passed or 
Failed. Address any kind of problem (e.g. wrong FTA papers, wrong 
order, missing sample etc.) and notify the client right away. 
9.2.9. After scanning all samples, fill out Héma-Québec’s form (comes 
with the shipment) and fax it to the appropriate fax number 
shown on the document.  
9.2.10. Save again the file and make a copy available on Knowledge 
Tree: /Shared/Héma-Québec/Final_Sample Reception Checker. 
  
9.2.11. Open the “Upload to LIMS” tab from the previous file. Select 
the cells containing the info and paste (special value) them on a 
new Excel worksheet. 
9.2.12. In the “Location” column, assign the new locations that were 
previously created (see section 9.2.1) and that correspond to the 
FTA card box barcodes. 
9.2.13. Save the new worksheet in .xls format under 
R:\Commun\Biotracker\Generic sample batch update. Follow the 
same nomenclature as for the Sample Reception Checker. 
9.2.14. Open the LIMS, and go to the “Samples” tab and again select 
“samples” in the roll down list.  
9.2.15. Select a “sample type” (FTA paper) and click on the “Import” 
button. 
9.2.16. Select the “Update” option instead of the default “Import” on 
the upper portion of the window 
9.2.17. Retrieve the previously created file from the “Select a file” row 
and select the mapping “HQ_Update”. 
9.2.18. Click on “Import” at the bottom of the window.  
9.2.19. Once the new updated samples are imported into the LIMS, 
save them and close the screen. 
9.3. Creating a Plate Layout  
9.3.1. Open the template file in Knowledge Tree:  /Shared/Héma-
Québec/Tools/Plate_Maker.xlsx. 
9.3.2. Save the file in the following folder R:\Commun\Héma-
Québec\Plate_Maker. Follow the plate maker naming scheme 
to name the file (refer to Appendix 3 Naming Scheme for 
Héma-Québec’s Project). 
9.3.3. In Knowledge Tree, open the file /Shared/Héma-
Québec/REDO/redo.xlsx 
  
9.3.4. Copy the PGx Names with their corresponding Client Sample ID 
for all redoes (if there are any). 
9.3.5. In the “Plates_list” tab of the Plate Maker file, paste the redoes 
at the beginning of the FTA PGx_Barcode and ClientSampleID 
columns of Plate #1. 
9.3.6. Open in Knowledge Tree the folder /Shared/Héma-
Québec/Final_Sample Reception Checker/ and select the 
Sample Reception Checker file previously created (refer to 
section 9.2). 
9.3.7. In the “Upload to LIMS” tab of the Sample Reception Checker 
file, copy 88 PGx Names with their corresponding Client 
Sample ID. 
Note: The number of samples to be copied should correspond to 88 minus 
the number of redoes (if there are any).  
9.3.8. In the Plates_list tab of the Plate Maker file, paste the 88 
previously copied samples to the FTA PGx_Barcode and 
ClientSampleID columns of Plate #1. 
9.3.9. Repeat steps 9.3.7 and 9.3.8 with 88 new samples for Plate #2. 
9.3.10. Go to the “FTA_Plate_Layout” tab and identify the two plates 
(refer to Appendix 3 Naming Scheme for Héma-Québec’s 
Project). 
9.3.11. Also add the ID of one PGx blank FTA card under each H5 
well of the two plates. 
9.3.12. Print the Plate layout from the “FTA Plate_Layout” tab of the 
Plate Maker. 
9.3.13. Following the plate-layout, retrieve the 88 FTA Card samples, 
chosen for Plate #1, in an empty processing box. 
9.3.14. If needed, scan the PGx barcodes in the LIMS for location of 
samples and redoes. 
9.3.15. Add the corresponding PGx blank FTA Card at the end of 
every 88 samples.  
  
9.3.16. Manually identify the processing box. (Refer to Appendix 3 
Naming Scheme for Héma-Québec’s Project). 
9.3.17. Repeat the step 9.3.13 to 9.3.15 for Plate #2. 
9.4. Automated FTA Card punching 
Note: If necessary, refer to Appendix 1 Manual Punching of FTA cards. (not 
include in this Annex). 
9.4.1. Identify a 1.2 mL 96-well plate according to the plate layout. 
9.4.2. Add 1 µL of distilled water at the bottom of each well. 
9.4.3. Open the BSD Automated puncher. 
9.4.4. Enter the User name and the Password. 
9.4.5. Open the software BSD duet. 
9.4.6. Click on “Distribute Spots”. 
9.4.7. Select “OK” on the upper right. 
9.4.8. Click “Continue” twice. 
9.4.9. Select the method according to the number of plates to be 
punched (e.g. HQA_One Plate 88 Samples for one punching 
plate). 
9.4.10. Select “Samples Only” on the upper right. 
9.4.11. Click “Continue”. 
9.4.12. Scan the first 1.2 mL 96-well plate’s barcode or enter it  
manually. 
9.4.13. Insert the previous plate in the BSD Automated puncher. 
9.4.14. Click “Continue” twice. 
  
9.4.15. Scan the PGx barcode of the first FTA Card sample. 
Note: If the card is not yet punched, it is still possible to go back and scan the 
card again by clicking on the option Scan Barcode again. 
9.4.16. Bring the FTA paper to the punching holder. 
9.4.16.1. If you are using the BSD automatic punch trigger, wait 
until the punch is completed.  
9.4.16.2. If you are using the punching pedal, press on it. 
9.4.17. If there is a Punching Error, the BSD Automated puncher will 
give you options. 
9.4.17.1. Card not Punched: Click on this option if the FTA card is 
not punched. The BSD Automated puncher will then prompt 
you to punch the card again. 
9.4.17.2. Inspect Trays: Click on this option to move the plate 
forward to get a closer look at it. Verify if the spot is in its well 
or not. 
A) If the spot is in the well, click “Continue” and click on “Spot 
placed in cell” or “Spot in cell”. The BSD automated puncher 
will resume the punching. 
B) If the spot is not in the well, click “Continue” and click on 
“Spot discarded” or “Spot not found”. The BSD automated 
puncher will then prompt you to punch the card again. 
9.4.18. As long as the run is not completed, it is possible to punch 
again a sample.  
9.4.18.1. Double-click on the desired well. 
9.4.18.2. Rescan the barcode (the barcode has to be the same 
otherwise the BSD puncher will not authorize the punch). 
9.4.18.3. The BSD Automated puncher will then prompt you to 
punch the card again. 
  
9.4.19. Repeat steps 9.4.15. to 9.4.18 for every sample. 
9.4.20. At the end of the run, the “Completed Plate” screen will appear. 
Verify that all spots are present by taking out the plate and doing 
a visual check. 
Note: At this point, it is impossible to go back and punch samples again. If 
spots are missing, refer to Appendix 1 Manual Punching of FTA Card. 
9.4.21. Click on “All Spots Present”. 
9.4.22. Refer to the BSD Duet automated puncher’s manual for daily and 
weekly maintenance. 
9.5. Creating a run in the LIMS 
9.5.1. In the LIMS, go to the “File” tab and select “Experiment 
Manager”. 
9.5.2. Select the experiment name: Biomek - DNA Isolation from FTA 
Paper. 
9.5.3. Name the run following the naming scheme of the DNA plates 
(refer to Appendix 3 Naming Scheme for Héma-Québec’s 
Project). 
9.5.4. Add samples for all the plates to be extracted and add (at the 
end) the ID of the PGx blank FTA card that was used for each 
plate (Refer to the plate-layout created in section 9.3.12.). 
9.5.5. Click on “Samples” in the “Output” section of the run. 
9.5.6. Generate PGx DNA ID for all samples and FTA blanks by 
clicking on the “Auto Accession” function. 
9.5.7. With a right-click, export the table data in csv format to the folder 
R:/Commun/Héma-Québec/FTA_BA_Export. 
9.5.8. Open the previously saved file and copy BA and FTA sample ID 
corresponding to the plate maker created in section 9.3.2. 
  
9.5.9. Paste the FTA and the BA sample ID in the “FTA&BA_sampleID” 
tab of the Plate Maker file. 
9.5.10. From that same tab, copy the first 88 samples and click on the 
“FTA_BA-SamplesOrder” tab and paste them under the columns 
FTA PGx_Barcode and BA PGx_Barcode of Plate #1. 
9.5.11. Repeat the previous step with the next 88 samples for Plate #2. 
9.5.12. Go back to the “FTA&BA_sampleID” tab. Copy the FTA blank 
that corresponds to Plate #1 and paste it under the 88th sample. 
9.5.13. Repeat the previous step for Plate #2. 
9.5.14. Click on the “BA_Plate_Layout” tab and identify the plates (refer 
to Appendix 3 Naming Scheme for Héma-Québec’s Project). 
9.5.15. Print the BA plate-layout and staple it to the corresponding FTA 
plate-layout (see section 9.3.12.). 
9.5.16. Click on the “BA-SampleImport_Plate 1” tab and save the sheet 
as a csv file under R:/Commun/Héma-Québec/DNA Plate 
Management. 
9.5.17. Repeat the previous step for “BA-SampleImport_Plate 2”. 
9.5.18. In the LIMS, click on “Samples” and select “Plate Management” 
in the roll down list. 
9.5.19. Create a DNA plate for each plate previously saved and print the 
corresponding barcodes. 
9.5.20. Record the DNA Plate’s name and barcode in the “Comment” 
section of the extraction run of the LIMS.  
9.5.21. Attach the Plate Maker file to the extraction run. 
  
  
9.6. Automated DNA Extraction 
Note: If necessary, refer to appendix 2 Manual DNA extraction of FTA Cards. 
9.6.1. Empty the waste container for pod2 (the 8 pipette channels 
arm) and fill up the water tank (if necessary). 
9.6.2. Turn on the computer and the robot. 
9.6.3. Start the Biomek software. 
9.6.4. Make sure that the light on the upper left side and on the upper 
right side of the instrument is green.  
9.6.5. If the light is red, this could mean a connection error. Restart 
the computer and the instrument.  
9.6.6. If the problem persists, refer to the Biomek’s user guide to 
resolve the issue. 
9.6.7. Click on “Instrument” tab and select “Home All axes” in the roll 
down menu. 
9.6.8. At the first dialog box, read all instructions. Click “OK” if the 
Biomek meets the specifications. 
9.6.9. At the second dialog box, make sure that the span 8 does not 
have any tips. Then click on “OK”. 
9.6.10. Watch for air bubbles in the tubes and syringes. When the 
tubes and syringes are empty of bubbles, press “OK”.  
Note: If a bubble remains in a syringe after 5 min of purging, stop the robot 
and refer to the Biomek’s user guide to resolve the issue. 
9.6.11. Open the method FTA cards extraction pgx 6 
plates_span8_1000µL, in the PGx folder of the Biomek 
software. 
Note: If robotic workstation 1000 uL conductive sterile filter tips are not 
available, the method FTA cards extraction pgx 6 
plates_span8_200µL can be used.  
  
9.6.12. In a section of a Quarter Reservoir, add 22.5 mL of Generation 
DNA Purification Solution #1. The number of sections filled 
should be the same as the number of plates to be extracted. 
9.6.13. In a section of a Quarter Reservoir, add 15 mL of Generation 
DNA Elution Solution #2. The number of sections filled should 
be the same as the number of plates to be extracted. 
9.6.14. For the disposition of all materials and solutions, refer to figure 
1 “Deck Layout of the Biomek FTA cards extraction pgx 6 
plates_span8_1000µL” (or figure 2 “FTA cards extraction pgx 6 
plates_span8_200µL”). 
9.6.15. The deck layout will be slightly different if there are less than 6 
plates to be extracted. 
9.6.16. Use tip boxes lids for the 2 waste containers. 
9.6.17. Press “Run” (green arrow) to start the method. 
9.6.18. Enter the number of plates to be extracted. 
9.6.19. Make sure that the deck layout is the same as the layout 
shown on the screen. If it is the same, click “OK”. The method 
will start. 
 
Note: To immediately stop the robot, cross the UV light curtain with your 
hand. Make corrective actions if necessary. Document and record 
any observation, abnormality or incident in the LIMS. 
9.6.20. At the end of the run, do a visual check of the plates. Any 
missing spot should be considered as a failed sample. 
Document and record the event in the LIMS. 
9.6.21. Apply a Thermo-Seal Heat Sealing Foil on each plate and seal 
them using a heating plate sealer. 
9.6.22. Centrifuge the plate ~30 seconds at 2000 RPM. 
9.6.23. Put the plate into a 96-well thermocycler and run the following 
program: 
  
99ºC – 15 min  
4 ºC for ever 
9.6.24. Once the cycling program is completed, centrifuge the plate 
~30 seconds at 2000 RPM. 
9.6.25. Do a visual check of the plate. Document and record any 
evaporation or sample abnormalities in the LIMS 
9.6.26.  Label a new 1.2 mL 96-well plate as a DNA Plate with the 
barcode previously printed (see section 9.5.19). 
9.6.27. Remove very carefully the Thermo-Seal Heat Sealing Foil of 
the first extraction plate. 
9.6.28. Using a multi-channel pipette, mix the first row of samples 10 
times and transfer ~30 uL to the corresponding wells of the 
new DNA Plate. 
9.6.29. Repeat the previous step for the remaining rows of the 
extraction plate. 
Note: Make sure that there is no spot transferring on to the DNA plate. 
9.6.30.  Seal the DNA Plates with a plastic adhesive film and get rid of 
the now empty extraction plate. 
9.6.31. The plate can be stored up to three days at +4ºC. For longer 
storage, store the plate at -20 ºC. 
  
9.7. Return of FTA Cards boxes. 
Note: The FTA card boxes should be returned to Héma-Québec within a 
month following their reception.  
9.7.1. Using a cardboard box, package all FTA card boxes to be 
returned. 
9.7.2. Go to the Fedex web site and schedule a pickup. 
  
9.7.3. Print the shipment receipt 3 times and keep them with the box. 
9.7.4. Forward the package to the shipping deck of the Montreal 
Heart Institut. 
Reference Documents 
Biomek FX Laboratory Automation Workstation Quick Start Guide 
Biomek FX Laboratory Automation Workstation User’s Manual 
Biomek FX Sotfware User’s Manual 
Generation DNA purification from Blood Spots protocol supplement (now Qiagen 
BSD-Duet600 Automatic FTA puncher documentation 
Biotracker documentation (LIMS) 
Thermocycler User’s Manual  (Thermo Electron Corporation) 
Appendices 
PGx- PR-013_APP1: Appendix 1: Manual Punching of FTA 
Cards. (not included in the Annex A) 
PGx- PR-013_APP2: Appendix 2: Manual DNA Extraction 
of FTA cards. (not included in the 
Annex A) 
PGx- PR-013_APP3: Appendix 3: Naming Scheme for 
Héma-Québec’s Project 
 
 
 
 
 
  
Figure 1: “Deck layout for “FTA cards extraction pgx 6 plates_span8_1000µL” 
 
  
 
Figure 2: Deck layout for “FTA cards extraction pgx 6 plates_span8_200µL” 
 
 
 
Automated DNA Extraction of Blood Spots from FTA    
Cards Using the Generation DNA Purification Technology by Qiagen. 
Appendix 3: Naming Scheme for Héma-Québec’s Project 
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HQB_0_00001
Examples 
Punching Plates: 
HQB_0_00001, HQB_0_00002...etc. 
DNA Plates:  
HQB_1_00001, HQB_1_00002...etc. 
Genotyping Plates:  
HQB_2_00001_00002, 
HQB_2_00003_00004...etc. 
Hybridization Plates:  
HQB_3_00001_00002,  
HQB_3_00003_00004...etc. 
Plate Maker file:  
HQB_0_00001_00002,  
HQB_0_00003_00004...etc.  
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Annex B 
This Standard Operating Procedure is currently used at the Genome Quebec and 
Montreal Heart Institute Pharmacogenomics Centre as reference document for the 
clinical genotyping of the minor blood antigens. It described all steps from the 
DNA transfer to the assay plate to the results reporting to Héma-Québec. This SOP 
is referred at the Material and Methods under the clinical application section.  
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1. Purpose  
1.1.  This SOP defines the procedure for the detection of a panel of 11 nucleotide 
(22 antigens) polymorphisms (SNPs), (c/C, E/e, K/k, Fya/Fyb, Jka/Jkb, 
Kpa/Kpb, M/N, S/s, HPA-1a/1b, HPA-2a/2b and HPA-5a/5b) found within 9 
genetically polymorphic genes ((RHCE (NM020485), KEL(NM_000420), 
FY(NM_002036), SLC14A1(NM_015865), GYPA(NM_002099), 
GYPB(NM_002100), ITGB3(NM_000212), GP1BA(NM_000173) and 
ITGA2(NM_002203))  located on different chromosomes using the 
SNPstream Genotyping Platform. 
1.2. This SOP defines the Genotyping procedure for one ASSAY PLATE of 384 
total samples. If more than one ASSAY plate is processed in the same plate, 
the volume of all reagents has to be adjusted accordingly.  
2. Scope  
2.1. The variants K/k, Fya/Fyb, Jka/Jkb, Kpa/Kpb, M/N, S/s, HPA-1a/1b, HPA-2a/2b 
and HPA-5a/5b are tested in both DNA directions for calls concordance. 
2.2. Since e/E is a G/C variant, two assays need to be performed to detect the 
presence of G (using the SNPware extension mix G/A) and C (using the 
SNPware extension mix C/T). Using the analysis tool (see Appendix 8), the 
final genotype (G/G, G/C and C/C) can be associated for each sample. 
2.3. Variants c/C needs two different assays to detect the final polymorphism. 
The assay c/C detects the presence of c/c, whereas the assay c/C-Intron 
detects the presence of C/C. All samples that are not assigned C/C or c/c are 
assigned c/C. 
2.4. As with any hybridization-based assay, underlying polymorphisms in primer-
binding regions can affect the alleles being detected and thus can 
subsequently adversely affect the resulting calls being made.  
3. Abbrevitions 
3.1 PGx : Pharmacogenomics 
3.2 LIMS : Laboratory Information Management System 
3.3 DNA : Deoxyribonucleic acid 
3.4 PCR : Polymerase chain reaction 
3.5 DCN : Document Control Number 
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Contents 
8.1  Generalities 
8.2  Creating a Genotyping Run 
8.3  DNA transfer to the Assay Plate 
8.4  Multiplex PCR reaction 
8.5  Amplification Verification 
8.6  EXO-SAP Reaction 
8.7  Extension reaction 
8.8  Hybridization Reaction 
8.9  SnpStream Scanning Procedure and Data Acquisition 
8.10. Interpretation of results 
5. Definitions:  
5.1. Tipmix: Using a pipette, mix with up and down action. 
6. Responsibilities 
6.1. PGx Centre Management personnel and QA representatives.  
6.1.1. Ensure that all PGx employees having to genotype HQ samples were trained 
on the SNPstream instrument and on the full content of this SOP.  
6.1.2. Maintain and, when required, review and approve this SOP.  
6.1.3. Any of these responsibilities can be delegated to the appropriate person 
provided he/she was trained on this SOP. 
7. Safety Precaution 
7.1. Apply the hygiene and gowning requirements of SOP PGx-IG-016 Material, 
Sample and Personnel Flow and Hygiene. 
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8. Procedure 
Equipment 
 GenomeLab SNPstream Genotyping System (Beckman) 
 Biomek FX Laboratory Automation workstation 
 Biomek Software 
 Thermocycler  
 Incubator (can reach 42°C) 
 Ice Bucket 
 Vortex 
 Vacuum Pump 
 Microtube Centrifuge 
 Plate Centrifuge 
 Multichannel Pipettes (2-20 µL) 
 Multichannel Pipettes (20-200 µL) 
 Pipettes (P10, P20, P200, P1000) 
 Barcode Reader 
 LIMS 
 Egel System (Invitrogen cat. EBMO3) 
 Gel documentation system 
Consumables 
 PCR plate: 384-well format (Greiner cat.41-785201 ) 
 1.2 mL 96-well plate  
 50 ml Reservoir Basin 
 Compressed Air Can 
 15 mL and 50mL tubes 
 2.0 mL microtube  
 500 uL microtube  
 Adhesive plastic film  
 Aerosols Resistant tips for Pipettes P10, P200 and P1000  
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 Progene filter tips 50 uL for Biomek FX 
 Progene filter tips 20 uL for Biomek FX 
 Progene filter tips 10 uL for Biomek FX 
 Progene filter tips 200 uL for Biomek FX 
 Kimwipes  
Chemicals 
 Distilled water PCR grade Rnase/Dnase –free  
 Exonuclease-1 (USB: 70073X) 
 Qiagen HotStart taq enzyme 5 U/ µl  
 Trackit 50bp Ladder (Invitrogen, 10488-043) 
 Shrimp Alkaline Phosphatase (USB: 70092X) 
 70% Ethanol 
 Ice 
 4% Pre-Cast Agarose Gel (Invitrogen cat. G800804) 
 Héma-Québec panel#1 PCR oligos 
 Héma-Québec panel#1 Extension oligos 
 SNPware 12-plex T/C extension mix (10104500) 
 SNPware 12-plex G/A extension mix (10104400) 
 SNPstream SNPware Core reagent Kits (Kits A and B and 10 SNPstream array 
plates) 
 SNPstream Wash Buffer #1 (Non-Stringent Buffer) 
 SNPstream Wash Buffer #2 (Stringent Buffer) 
 Controls DNA Coriell Samples: NA17175, NA17223, NA17275, NA17284, 
NA17294, NA17282 
 Qiagen 10X PCR buffer 
 Qiagen 25 mM MgCl2 
 Invitrogen 10X PCR buffer- No MgCl2 
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8.1. Generalities 
8.1.1. Delimited zones for DNA extraction, pre-PCR and post-PCR are to be used 
accordingly to the step being performed. This will avoid any carry-over 
contamination. 
8.1.2. Every technical step performed has to be documented and recorded in the 
LIMS. 
8.1.3. Every consumable, chemical and equipment has to be documented and 
recorded in the LIMS. 
8.1.4. Lab coat and gloves should be worn at all times. 
8.1.5. Visual inspection of the plates has to be done following every step of the 
genotyping technique. Any evaporation, observation or abnormality has to be 
documented in the LIMS and the Tracking Sheet. 
8.1.6. Every automated step can be manually performed using a multichannel 
pipette. 
8.2. Creating a Genotyping Run 
8.2.1. Open a copy of the”Tracking Sheet” found in: KT/Shared/Héma-
Québec/Tools/. 
8.2.2. Open the “plate_layout” tab and fill the appropriate information using the 
corresponding Plate-Maker file (refer to SOP PGx-PR-013, section 9.3).  
Areas to be filled 
Plate Name 
Plate Barcode 
DNA PGx_ID column 
Client Sample ID column 
Sample Type 
 
8.2.3. Save the tracking sheet to: R:\Commun\Héma-Québec\Sherpa\TrackingSheet 
following the naming scheme described in PGx-PR-013_App1. 
8.2.4. In the LIMS, create a genotyping run in “Experiment Manager”. Use the 
Genotyping Assay on SNPStream Platform protocol.  
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8.2.5. Verify in the LIMS which distilled water samples (e.g. WT000PGX001) and 
diluted Coriell DNA Controls (e.g. BA000PGX0001) are available (refer to 
Appendix 1 for Coriell Control Preparation). 
8.2.6. Add samples, water and controls to the run. The samples will be associated 
to the Assay plate using the “Plate Management” option in the LIMS. 
8.2.7. Open the Assay_PlateSampleOrder tab of the Plate-Maker. Fill the green 
cells of the Assay_Plate table with the appropriate PGx barcodes (refer to 
Appendix 2 for the layout).  
8.2.8. Go to AssayPlate_Import  tab and save it as a csv file in R:\Commun\Héma-
Québec\Assay_Plate_Management. 
8.2.9. Using “Plate Management”, import the previously created file into the LIMS. 
Print the corresponding barcode. 
8.2.10. Label a PCR 384-well plate with the previously created barcode 
generated by the LIMS. Record the Assay Plate name and its barcode 
number in the “Comments” section of the genotyping run. 
8.3. DNA transfer to the Assay Plate 
8.3.1. Retrieve from storage the DNA plates and diluted Coriell controls and let 
them thaw at room temperature. 
8.3.2. Quick spin the DNA Plates (at 2000 RPM for at least 5 seconds). 
8.3.3. Vortex the plates with the Biomek robot. Use the DNA_Mix_BioRad_plate 
protocol. 
N.B.: The mixing of the samples can be done manually. To do so, tipmix gently ~5 
times before performing the DNA transfer to the Assay plate (use a pipette at 
a volume greater than 10 µL). 
8.3.4. Transfer 2 µl of each DNA samples to the Assay Plate using the Biomek 
Robot (refer to Appendix 2, 9 and 10 for the Héma-Québec Assay Plate 
layout, the BiomekFX deck layout and the DNA transfer BiomekFx script 
description respectively). 
8.3.5. Add manually to the assay plate, 2 µl of water and Coriell controls to their 
corresponding wells (refer to Appendix 2 for the Héma-Québec Assay Plate 
layout). 
8.3.6. Gently tap the PCR plate on the working bench to bring all the samples at the 
bottom of their well. Seal the plate using an adhesive plastic film. 
8.3.7. Quick spin the Assay Plate (at 2000 RPM for at least 5 seconds). 
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8.4. Multiplex PCR reaction 
8.4.1. Thaw one Multiplex PCR Master Mix. Vortex and quick spin the tube. (Refer 
to Appendix 3 for Multiplex PCR oligos preparation and Appendix 4 for 
Multiplex PCR Master Mix preparation). 
8.4.2. Add 28.8 µl of Qiagen HotStart Taq enzyme (5 U/ µl) to the Multiplex PCR 
Master Mix preparation. Tipmix gently using P1000 pipette. Avoid any 
foaming. 
8.4.3. Pour the PCR Master Mix Preparation into a reservoir basin. 
8.4.4. Using a multichannel pipette, add 3 µl of the Multiplex PCR Master Mix 
solution to each and every well of the Assay Plate. Avoid any contact with the 
DNA samples. 
N.B.: The Biomek robot can be used for the addition of the Multiplex PCR Master 
Mix solution. For time consuming reasons, the automated application is only 
optional. 
8.4.5. Gently tap the Assay plate on the working bench to bring all the samples to 
the bottom of the wells. Seal the plate using an adhesive plastic film. 
8.4.6. Quick spin the Assay Plate (at 2000 RPM for at least 5 seconds). 
8.4.7. Put the plate into a 384-well thermocycler and run the following program: 
 
8.4.8. After completion of the thermocycler program, quick spin the Assay Plate at 
2000 RPM for at least 5 seconds. 
8.4.9. Do a visual check of the plate. Document and record any evaporation or 
sample abnormalities in the LIMS and the Tracking Sheet. 
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8.5. Amplification Verification  
8.5.1. Remove the adhesive plastic film and transfer to a sample preparation plate, 
1 µl of the following PCR samples reactions (see layout below): B01, B03, 
B05, B07, B09, B11, H12, H14, H16, H18, H20, H22, J02, J04, J06, O07, 
O09, O11, O13, O15, O17, N17, N19, N21. 
8.5.2. Transfer 2 µl of the Track it 50 bp Ladder into the sample preparation plate 
(see layout below). 
8.5.3. Add respectively 14 µl and 18 µL of distilled water (PCR grade) to each 
sample and ladder. Tipmix and load 15 µL of the mixture to a 4% Pre-Cast 
Invitrogen Agarose Gel (see layout represented in the figure below). 
 
 
8.5.4. Set the time on the Egel box for 15 minutes (in EG mode). 
8.5.5.  Place the Agarose Gel under UV light and take a picture (refer to the 
documentation on the Gel Picture Acquisition System for instructions). 
8.5.6. Verify band profiles before pursuing the technique (refer to gel picture below 
for an example). Refer to Table 1 for amplification acceptance criteria.  
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Table 1: Amplification acceptance criteria 
 
Condition Description Action 
Condition 1 
All samples and controls show a 
positive amplification band profile. No 
contamination seen in the FTA blank 
(well: O09) nor in the PCR water (well: 
O11) 
Genotyping assay to be pursued 
Condition 2 
No amplification band profile for more 
than 4 samples 
Extraction and PCR on all samples and controls 
must be performed again. 
Condition 3 
No amplification band profile for more 
than 1 control (wells: O13, O15 and 
O17) 
If condition 2 is not applicable, PCR on all 
samples and controls must be performed 
again. 
______________________________________ 
If condition 2 is applicable, extraction and PCR 
on all samples and controls must be 
performed again. 
Condition 4 
Amplification band profile seen in FTA 
blank (well: O09) and not in PCR water 
(well: O11) 
Extraction and PCR on all samples and controls 
must be performed again. 
Condition 5 
Strong amplification band profile seen 
in FTA blank (well: O09) and in PCR 
water (well: O11) 
PCR on all samples and controls must be 
performed again. 
Condition 6 
Weak amplification band profile seen in 
PCR water and not in FTA blank. 
Continue genotyping assay, but record it in 
the LIMS. 
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Gel Picture 
 
 
8.6. EXO-SAP Reaction: 
8.6.1. Prepare EXO-SAP Mix as described in the table below: 
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1 B01 2 J02
3 B03 4 J04
5 B05 6 J06
7 B07 8 O07
9 B09 10 O09 Blank FTA
11 B11 12 O11 HQA-Water
13 H12 14 O13
15 H14 16 O15
17 H16 18 O17
19 H18 20 N17
21 H20 22 N19
23 H22 24 N21
EXO-SAP Reaction 1 plate
480
Reagents Lot# Vol/Sample Qte/Conc Total vol
10X PCR buffer (10X) No MgCl2 0.30 0.375X 144
MgCl2 (25mM) 0.12 0.375mM 58
SAP (1U/µl) 0.330 0.041 U/µl 158
EXO (10U/µl) 0.067 0.084 U/µl 32
PCR grade Water 2.18 1048
Total 3.00 1440
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N.B.: In the case where more than one Assay Plate is being processed, the volumes 
described in the above table should be adjusted accordingly to the number of 
Assay Plates. 
8.6.2. TipMix the EXO-SAP solution and pour into a reservoir basin.   
8.6.3. Using a multichannel pipette, add 3 µl of the EXO-SAP solution to each and 
every well of the Assay Plate. Avoid any contact with the PCR mixture. 
N.B.: The Biomek robot can be used for the addition of the EXO-SAP solution. For 
time consuming reasons, the automated application is only optional. 
8.6.4. Gently tap the Assay plate on the working bench to bring all the samples to 
the bottom of the wells. Seal the plate using an adhesive plastic film. 
8.6.5. Quick spin the Assay Plate (at 2000 RPM for at least 5 seconds). 
8.6.6. Put the plate into a 384-well thermocycler and run the following program: 
 
8.6.7. After completion of the thermocycler program, quick spin the Assay Plate at 
2000 RPM for at least 5 seconds. 
8.6.8. Do a visual check of the plate. Document and record any evaporation or 
sample abnormalities in the LIMS and the Tracking Sheet. 
8.7. Extension reaction: 
8.7.1. Thaw one G/A Multiplex Extension Oligos Mix and one C/T Multiplex 
Extension OligosMix per Assay Plate (refer to Appendix 5 for Extension 
Oligos Mix Preparation). 
8.7.2. Prepare the Multiplex G/A and C/T Extension Master Mix solutions as 
described in the following tables: 
  
EXO-SAP Program
Tº Time
37 30 minutes
99 10 minutes
4 Hold
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Table 1: GA Extension Master Mix Preparation:  
 
Table 2: CT Extension Master Mix Preparation:  
 
N.B.1: The Extension Mix SNPware 12-Plex CT and GA are light sensitive. Cover 
the reagents with aluminum foil. 
N.B.2: In the case where more than one Assay Plate is being processed, the 
volumes described in the above tables should be adjusted accordingly to the 
number of Assay Plates. 
8.7.3. Remove the adhesive plastic film from the Assay Plate.  
8.7.4. Tipmix the G/A Extension Master Mix solution and pour into a reservoir 
basin. 
8.7.5. Using a multichannel pipette, add 7.0 µl of the G/A Extension Master Mix 
solution to the corresponding wells (refer to Appendix 2 for the Héma-
Québec assay plate layout). Avoid any contact with PCR mixture. 
N.B.: The Biomek robot can be used for the addition of the G/A and C/T Extension 
Master Mix solutions. For time consuming reasons, the automated 
application is only optional. 
8.7.6. Repeat steps 8.7.4. and 8.7.5. with the C/T Extension Master Mix solution. 
8.7.7. Gently tap the Assay plate on the working bench to bring all the samples to 
the bottom of the wells. Seal the plate using an adhesive plastic film.  
HQA_Panel#1_Multiplex CT Extension Master Mix 1 Plate
240
Reagents Lot# Vol (µL)/Sample Qte/Conc Total vol (µL)
SNPware Extension Mix Diluent 3.77 6.7mM MgCl2 and 65.6mM Tris-Cl 905
Distilled Water, PCR Grade 2.95 709
 SNPware 12-plex Extension Mix CT 0.200 48
CT Multiplex Extension Oligos Mix (5 -10µM) 0.06 0.02µM-0.04µM 14
 SNPware  DNA polymerase 0.017 4.08
Total 7.00 1680 µL
HQA_Panel#1_Multiplex GA Extension Master Mix 1 Plate
240
Reagents Lot# Vol (µL)/Sample Qte/Conc Total vol (µL)/
SNPware Extension Mix Diluent 3.77 6.7mM MgCl2 and 65.6mM Tris-Cl 905
Distilled Water, PCR Grade 2.95 709
 SNPware 12-plex Extension Mix GA 0.200 48
GA Multiplex Extension Oligos Mix (5 -10µM) 0.06 0.02µM-0.04µM 14
 SNPware  DNA polymerase 0.017 4.08
Total 7.00 1680 µL
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8.7.8. Quick spin the Assay Plate (at 2000 RPM for at least 5 seconds). 
8.7.9. Put the plate into a 384-well thermocycler and run the following program: 
 
8.7.10. After completion of the thermocycler program, quick spin the Assay 
Plate at 2000 RPM for at least 5 seconds 
8.7.11. Do a visual check of the plate. Document and record any evaporation 
or sample abnormalities in the LIMS and the Tracking Sheet. 
8.8. Hybridization Reaction: 
8.8.1. Using “Plate Management”, import the Assay Plate import file previously 
created into the LIMS (see section 8.2.) to create the Detection Plate. Print 
the corresponding barcode. (Refer to PGx-PR-013_App1 for the naming 
scheme).  
8.8.2. Label a 12-Plex SNPstream array plate with the previously created barcode. 
Record the Detection Plate name and also the LIMS and SNPstream 
barcode numbers in the “Comments” section of the genotyping run.  
8.8.3. Pour in a reservoir basin ~40 ml of Non-Stringent Buffer (Buffer #1) (refer to 
Appendix 6 for the preparation of “Non-Stringent and Stringent Buffers). 
8.8.4. Transfer ~20 µl of Non-Stringent Buffer (avoid touching the plate glass) into 
the array plate wells. Tap gently on all sides of the plate to cover the entire 
well surface.  
8.8.5. Remove the buffer using a vacuum pump system. 
8.8.6. Repeat steps 8.8.4 and 8.8.5. two more times. 
8.8.7. Prepare the Hybridization solution as described in the following table: 
 
Extension Program:
T º Time
96 3 minutes
94 20 seconds
40 11 seconds
4 Hold
45 Cycles
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N.B.: In the case where more than one Assay Plate is being processed, the volumes 
described in the above table should be adjusted accordingly to the number of 
Assay Plates. 
8.8.8. Using a multichannel pipette, add 8 µl of Hybridization Solution to each and 
every well of the Assay Plate. Avoid any contact with the PCR mixture. 
N.B.: The Biomek robot can be used for the addition of Hybridization solution. For 
time consuming reasons, the automated application is only optional. 
8.8.9. Using the BiomekFX robot, transfer 14 µl from the Assay Plate to the 
SNPstream 12-plex Array plate (refer to Appendix 9 for the BiomekFX deck 
layout and Appendix 10 for the BiomekFX Liquid transfer: Genotyping on 
SNPstream).  
8.8.10. Gently tap the Detection Plate on each side in order to cover the entire 
well with liquid. 
8.8.11. Place the SNPstream 12-plex Array plate into a hermetically sealed 
humid container and put it into a hybridization oven set at 42ºC for 2 hours. 
8.8.12. Retrieve the plate from the oven and do a visual check of the plate. 
Document and record any evaporation or sample abnormalities in the LIMS 
and the Tracking Sheet.  
8.8.13. Using the vacuum pump system, remove all mixture from the 
SNPStream 12-plex Array Plate. 
8.8.14. Pour in a reservoir basin ~40 ml of the Stringent Buffer (Buffer #2). 
8.8.15. Transfer ~20 µl of Stringent Buffer (avoid touching the plate glass) into 
the array plate wells. Tap gently on all sides of the plate to cover the entire 
well surface. 
8.8.16. Remove the buffer using a vacuum pump system.  
8.8.17. Repeat steps 8.8.15 and 8.8.16. two more times. 
8.8.18. Dry the plate thoroughly using compressed air (if necessary). 
Hybridization Solution Preparation: 1 Plate
480
Reagents Lot# Vol (µL)/Sample Qte/Conc Total vol (µL)
SNPware Hybridization Solution 7.56 1.64M NaCl, 164mM EDTA, 
190.6mM MES 
3629
SNPware Hybridization Additive 0.44 211
Total 8.00 3840  (µL)
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8.8.19. Wash the back of the plate with 70% EtOH or isopropanol (if necessary). 
8.8.20. Put back the Array Plate into its aluminum pouch until ready for the 
scanning procedure. 
8.8.21. The tracking sheet should then be added to the genotyping run of the LIMS 
under the section: Output/File. 
8.9. SNPStream Scanning Procedure and Data Acquisition 
8.9.1. Refer to Appendix 7 for complete details. 
8.10. Interpretation of results  
8.10.1. For cluster analysis, data analysis and data reporting, refer to Appendix 8  
for complete details. 
9. Reference Documents 
9.1. Biomek FX Laboratory Automation Workstation Quick Sart Guide 
9.2. Biomek FX Laboratory Automation Workstation User’s Manual 
9.3. Biomek FX Sotfware User’s Manual 
9.4. BSD-Duet600 autoFTA puncher 
9.5. Biotracker LIMS software Manual 
10. Appendices 
10.1. PGx_PR-012_APP-1 Coriell Control preparation  
10.2. PGx_PR-012_APP-2 Héma-Québec Assay Plate layout. 
10.3. PGx_PR-012_APP-3 Multiplex PCR Oligos Preparation 
10.4. PGx_PR-012_APP-4 Multiplex PCR Master Mix Preparation 
10.5. PGx_PR-012_APP-5 Extension Oligos Mix Preparation 
10.6. PGx_PR-012_APP-6  SNPstream Stringent and Non-Stringent Buffers     
preparation. 
10.7. PGx_PR-012_APP-7  Raw data acquisition using the SNPstream technology 
and software 
10.8. PGx_PR-012_APP-8  Data Analysis and Data reporting 
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10.9. PGx_PR-012_APP-9  Robotic Liquid transfer: BiomekFX deck layout 
10.10. PGx_PR-012_APP-10 BiomekFX Liquid transfer: Genotyping on 
SNPstream 
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Héma-Québec Coriell Control plate preparation: Freshly prepared after 10 freeze-thaw cycles. 
 
1. Create in the LIMS two PGx ID for each Coriell control. This way, each Coriell control will have two different barcode numbers 
to facilitate data analysis. 
2. Print the barcodes and label a plate. 
3. Prepare Control samples following the plate layout below (figure 1). 
4. Prepare 12.5 ng/µl « NA » samples using distilled water (PCR grade) as diluent. Make dilution as per the following example: 
a. Prepare 110 µl of Controls samples: if stock concentrations of « NA » samples = 300 ng/µl, pipette 4.6 µl into the 
appropriate wells and add 105.4 µl of PCR grade water. Tipmix the wells A01 to A06 10 times.  
N.B.: Refer to DNA quantification in case the « NA » DNA samples concentrations are unknown. 
5. Place a silicone mat on the storage plate. 
6. The Control samples are stored at -20ºC. The plate can be freeze-thawed up to 10 times. 
 
Figure 1 : 
 
  
Control samples plate:
1 2 3 4 5 6 7 8 9 10 11 12
A NA17175 NA17223 NA17275 NA17284 NA17294 NA17282
B
C
D
E
F
G
H
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Héma-Québec assay plate layout: 
 
1. Transfer of test DNA samples to an Assay Plate 
1.1 Transfer 2 µl of DNA samples prepared as per procedure PGx-PR-013 to the Assay Plate following the scheme below. 
These samples are referred as “SAM” for the data analysis. 
1.2  Keep the wells entitled “empty” for Water and Control DNA samples (refer to appendix PGx-PR-012_APP1) for control 
samples preparation).   
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2. Transfer of Control Samples to an assay plate 
 
2.1  Transfer 2 µl of Control samples to the Assay Plate, following the scheme below (refer to appendix PGx-PR-012_APP1 for 
control samples preparation). These samples are referred as “SYN” for the data analysis.  
2.2  Transfer 2 µl of Water control samples to the Assay Plate following the scheme below. 
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Quadrants Layouts: 
The wells A01, A03… C01, C03… E01, E03… represent quadrant #1 
The wells A02, A04… C02, C04… E02, E04… represent quadrant #2 
The wells B01, B03… D01, D03… F01, F03… represent quadrant #3 
The wells B02, B04… D02, D04… F02, F04… represent quadrant #4 
3. Transfer of PCR Master Mix Preparation to Assay Plate 
3.1. Refer to the Quadrants layouts to understand transfer technique. 
3.2. Transfer 3.0 µl of PCR Master Mix preparation to the entire Assay Plate (Quadrants 1, 2, 3 and 4). 
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4. Transfer of Extension Master Mix Preparation to Assay Plate (see Figure below for visual details) 
4.1. Refer to the Quadrant layout to understand transfer technique 
4.2. Transfer 7 µl of the Extension GA Master Mix preparation to the Quadrants #1 and #2 
4.3. Transfer 7 µl of the Extension CT Master Mix preparation to the Quadrants #3 and #4 
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Héma-Québec SNPstream panel#1 PCR oligos preparation: 
 
The calculation is based on a production of 70 Assay plates.  
 
1. Prepare the Multiplex PCR oligos in a 15 mL tubes as described on the Table 1 below:  
Table 1: PCR Oligos Preparation:  
 
N.B: The needed PCR oligos volumes may change depending of the measured Oligos concentration. 
2. Mix by vortexing (~5 secondes) the PCR Oligos Preparation. 
3. Aliquot two 4300 µl into two 15 mL tubes. Identify the aliquot tubes as: Oligos_PCR_HQA-A and B. 
4. Stored the aliquots at -20ºC until used for the Multiplex PCR Master Mix Preparation. These preparations are single use. 
  
HQA_Panel#1_Multiplex PCR Oligos Mix
Mutation
Forward 
Primer ID
Forward Oligos 
Sequence
Stock 
Conc (uM)
Forw. Oligos 
Vol (µl)
Reverse 
Primer ID
Reverse Oligos 
Sequence 5' - 3'
Stock 
Conc (uM)
Reverse
 oligos Vol. (µl)
H2O
 vol (µl)
Total 
vol (µl)
Final 
conc (µM)
PCR Lenght
(Pb)
kK KelEx6K1_2-F-5 CRGATCCTTATGCTCAGCCC 200 50 KelEx6K1_2R-s2 AGGATGAGGTCCTAGGTAGGCTCTG 200 50 1 157
Kapa KelExon8Kpa_bF AGCAAGGTGCAAGAACACT 200 50 KelExon8Kpa_b-R-1 AGAGCTTGCCCTGTGCCC 200 50 1 101
sS GYPBEx4s_S-F-6 CTGGTACAGTGAAACGATGG 200 50 GYPBEx4s_S-R-6 GCACATGTCTTWCTTATTTGG 200 50 1 170
HPA2ab GPIBHPA-2a_b-F-1 CTCAGTCAAGTTGTTGTTAGCCAGAC 200 50 GPIBHA-2a_bR-S2 CTCTACCTGAAAGGCAATGAGCT 200 50 1 105
HPA1ab GPIII3HPA-1a_b-F-1 ATTCTGGGGCACAGTTATCC 200 50 GPIII3HPA-1a_b-R-5 ATAGYTCTGATTGCTGGACTTC 200 50 1 114
Fyab FYex2Fya_b-F-5 AGWCATCCAGCAGGTTACAGG 200 50 FYex2Fya_BR AAGATGTATGGAATTCTTCCTATGG 200 50 1 129
HPA5ab GPIaHPA5-F-1 gctcttggtaggtgcaccaatgt 200 50 GPIaHPA5_R ttccaaatgcaagttaaattaccag 200 50 1 148
Jkab JKa_b-F-1 CCTGCTAACTTTCAATCCCACCCTC 200 50 JKa_b_R-s3_1 TGCCAGGTGAGCGCCATGAAC 200 50 1 160
eE RHCE_e-F-1 TGGATGTTCTGGCCAAGTG 200 50 RHCE_e-R-S2 CTGTCACCACACTGACTGCTAG 200 50 1 107
cC RHCEc_C-F-1 tccccctcctccttctca 200 50 RHCEc_C-R-1 GCCAGCATGAAGAGGTTGAA 200 50 1 143
cC-intron RHCintron-F-1 cagggccaccaccatttgaa 200 50 RHCintron_R tggtagcaggcgtctgtaaaaa 200 50 1 151
MN GYPAex2M_N-F-1 TGAGGGAATTTGTCTTTTGCA 200 50 GYPAex2M_N-R-4 TCTTTGTGACTGAAGAAGAR 200 50 1 98
8800 10000
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Héma-Québec SNPstream panel#1 Multiplex PCR Master Mix Preparation: 
N.B.: The calculation is based on a production of 70 Assay plates. Two preparations of this PCR Master Mix will be 
necessary to cover the 70 Assays Plates.  
1. Please refer to PGx-PR-012_APP3 for instructions on the PCR oligos Mix Preparation. 
5. Prepare the Multiplex PCR Master Mix in a 50 mL tubes as described in the Table 1 below. 
 
Table 1: (All volumes are in µl) 
 
3. Mix the 50 mL or the 2.0 mL tube by inversion. 
4. Aliquot precisely 1411.2 µl into 35 microtubes of 2.0 mL. Label all tubes with a LIMS barcode. 
5. Stored all PCR Master Mix Tubes at -20ºC. 
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Héma-Québec SNPstream panel#1 Extension Oligos Mix Preparation: 
N.B.: The calculation is based on a production of 70 Assay plates. 
6. Prepare the Multiplex Extensions oligos in a 15 mL tube as described on the Table 1 below:  
 
7. Mix by vortexing the Extension Oligos Preparation and quick spin. 
8. Aliquot 17 µl in thirty five 500 µl microtubes and ~605 µl into one 2.0 mL microtube. When the first thirty five aliquots are used, 
freeze-thaw the aliquot of 605 µl and re-aliquot 17 µl in another thirty five 500 µl microtubes. Label all tubes with a LIMS 
barcode. Store the aliquots at -20ºC until used for the Multiplex Extension Master Mix Preparation. These preparations are 
single use.
HQA_Panel#1_Multiplex GA Extension Oligos Mix: SNPstream Assay #: 328
Mutation
GA Extension 
oligos ID
GA Extension Oligos 
Sequences 5'-3'
SNPstream 12-plex 
Array  Positions
Stock 
Conc 
(uM)
Oligos
 Vol. (µl)
Vol 
H2O (µl)
Final
 Vol. (µl)
Final 
Conc. (uM)
kK KelEx6K1_2-GA-U5 GCGGTAGGTTCCCGACATATACTCATCAGAAGTCTCAGC 3_2 100 120 10
Kapa KelExon8KGA_U1 ACGCACGTCCACGGTGATTTGCCTCAGAAACTGGAACAGCC 2_1 100 60 5
MN GYPAex2M_NGA-U2_2 GGATGGCGTTCCGTCCTATTGTGCATTGCCACMYCAGTGGTACTT 3_1 100 60 5
sS GYPBs_S-GA-U7 AGGGTCTCTACGCTGACGATAAACGATGGACAAGTTGTCCC 1_3 100 60 5
HPA2ab GPIBex2HPA2GA-U10-s3 AGATAGAGTCGATGCCAGCTGAGCTTCTCCAGCTTGGGTGTGGGC 4_3 100 60 5
HPA1ab GPIIIAex3HPA-1GAU8 GTGATTCTGTACGTGTCGCCCTTCAGGTCACAGCGAGGTGAGCCC 2_3 100 60 5
eE RHCEex5RhE_eCTU3-s3_1 CGTGCCGCTCGTGATAGAATCCTTTGGATTGGACTTCTCAGCAGAG 1_2 100 60 5
cC RHCEEx2Rhc_CGA-U9 GACCTGGGTGTCGATACCTACCCTTGGCTTGGGCTTCCTCACCTC 3_3 100 60 5
Fyab FYex2Fya_b-U11 AGAGCGAGTGACGCATACTAGATTCCTTCCCAGATGGAGACTATG 2_4 100 60 5
HPA5ab GPIaHPA5-GA-U6 GGCTATGATTCGCAATGCTTGTCTACCTGTTTACTATCAAA 4_2 100 60 5
Jkab JKa_b-U4_1 AGCGATCTGCGAGACCGTATCTCAGTCTTTCAGCCCCATTTGAG 2_2 100 60 5
cC-intron RHCintron-Gins-U12 CGACTGTAGGTGCGTAACTCGGTGCCCTTTGTCACTTCCCA 3_4 100 120 10
HQA_Panel#1_Multiplex CT Extension Oligos Mix SNPstream Assay #: 329
Mutation
CT Extension 
oligos ID
CT Extension Oligos 
Sequences 5'-3'
SNPstream 12-plex 
Array  Positions
Stock 
Conc 
(uM)
Oligos
 Vol. (µl)
Vol 
H2O (µl)
Final
 Vol. (µl)
Final 
Conc. (uM)
kK KelEx6K1_2U7 AGGGTCTCTACGCTGACGATTGGACTTCCTTAAACTTTAACCGAA 1_3 100 60 5
Kapa KelExon8Kpa_bU12 CGACTGTAGGTGCGTAACTCTTCCTTGTCAATCTCCATCACTTCA 3_4 100 60 5
MN GYPAex2M_NCTU11-s3_2 AGAGCGAGTGACGCATACTAACAGRAATTGTGAGCATATCAGCAT 2_4 100 60 5
sS GYPBEx4s_S-CT-U2-s2 GGATGGCGTTCCGTCCTATTTTGAAATTTTGCTTTATAGGAGAAA 3_1 100 60 5
HPA2ab GPIBex2HPA-2a_bCTU9 GACCTGGGTGTCGATACCTAGACCCTGCCCCCAGGGCTCCTGA 3_3 100 60 5
HPA1ab GPIIIAex3HPA1CTU8-s2 GTGATTCTGTACGTGTCGCCCTCTTTGGGCTCCTGTCTTACAGGCCCTGCCTC 2_3 100 60 5
eE RHCEex5RhE_eCTU1-s2_1 ACGCACGTCCACGGTGATTTCCTTTGGATTGGACTTCTCAGCAGAG 2_1 100 60 5
cC RHCEEx2Rhc_CctU6-s2 GGCTATGATTCGCAATGCTTTGCTCCAGCTGTGTCTCCGGAAA 4_2 100 60 5
Fyab FYex2Fya_bU4 AGCGATCTGCGAGACCGTATGGGGGCAGCTGCTTCCAGGTTGGCA 2_2 100 60 5
HPA5ab GPIaHPA5-CT-U3 CGTGCCGCTCGTGATAGAATTTAGTTTATTTTTTTTTTTTTACCT 1_2 100 60 5
Jkab JKa_b-CT-U5-s2_1 GCGGTAGGTTCCCGACATATGAAACCCCAGAGTCCAAAGTAGATGT 3_2 100 60 5
cC-intron RHCintron-CT-U10 AGATAGAGTCGATGCCAGCTGGCAGAGGCTGCAATGAGCTATGATTGTAC 4_3 100 120 10
1200360
1200420
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SNPstream Non-Stringent and Stringent Buffers Preparation: 
 
N.B.: Both preparations should be stored at -4ºC for no more than three months. 
 
1. Prepare in 1.0 L bottles as listed in the following tables: 
 
Table 1: 
 
 
 
Table 2: 
 
 
 
 
2. Invert 10 times for complete reagent re-suspension.
Non-Stringent Buffer:
Reagents Vol (mL)
SNPStream 20 X Non-Stringent Buffer: 50
ddWater 950
Total 1000
Stringent Buffer:
Reagents Vol (mL)
SNPStream 64 X Stringent Buffer: 15.6
ddWater 984.4
Total 1000
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Raw data acquisition using the SNPstream technology and software 
1. SNPstream Input Excel Tool 
 
N.B.: As guidance, every green cell in the SNPstream Input excel tool corresponds 
to a cell where information needs to be entered by the user. Other cells are 
automatically filled or locked.  
 
1.1.  From Knowledge Tree, under /Shared/Héma-Québec/Tools/, download a 
copy of SNPstream_inputFile_Format3_Template.xls.  
 
1.2. In the Sheet 1 tab, fill out the process group which should correspond to the 
Detection plate name (e.g. HQB_3_00001_00002). Write down number 3 for 
the format. Refer to Format_Viewer tab for format details. 
 
1.3. Open the corresponding plate-maker.  
 
1.4. Copy the BA PGx_Barcode columns of the FTA_BA-SamplesOrder tab and 
paste them to the corresponding PGxSampleID columns of the SNPstream 
Input Plate_Layout tab. 
 
1.5. Copy the ClientSampleID columns of the Plates_List tab of the same plate-
maker and paste them to the corresponding ClientSampleID columns of the 
SNPstream Input Plate_Layout tab. 
 
1.6. Save the file with the name of the hybridization plate in Knowledge Tree 
under /Shared/Héma-Québec/Final_SNPstream input/. 
 
1.7. Go to the Maker tab and save it as a text (.txt) file in Knowledge Tree under 
/Shared/Héma-Québec/Final_SNPstream input/. 
2. Importation of the Input file in Plate Explorer 
 
2.1. Open the Plate Explorer application of the SNPstream software.  
2.2. Click on the Upload icon. 
2.3. Select the Input (txt) file previously created in section 1. 
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2.4. Click Open and Upload. 
2.5. In the Process group list box, select the process group corresponding to your 
plate’s name. Copy the process group name and paste it in the PCR plate 
name.  
2.6. Enter the SNPware plate barcode number in the SNPware Plate section.  
2.7. Select the following marker panels for the following segments in Marker 
Panel(s) section: 
 
Seg Panel Name 
1 328 GA: HQA_GA_01OCT2007 
2 329 CT: HQA_CT_01OCT2007 
  
2.8. Click the Save to DB icon and exit Plate Explorer software.  
3. Data Acquisition 
3.1. Open the SNPstream instrument. 
3.2. Open the Run Manager application. The instrument will automatically 
initialize. If not, click on Initialize. 
3.3. Once the initialization is completed, select Manual in the Run drop down 
menu.  
3.4. Choose 12-Plex in the Plate type section. 
3.5. Choose the Twocoloradjusted_6Mai2008 in the 12-plex Method section. 
3.6. Click on Eject plate. 
3.7. Insert the hybridization SNPstream plate making sure that the SNPstream 
barcode is facing the mirror and click on Insert plate. 
3.8. Once the lasers are warmed up, click Run. 
3.9. At the end of the raw data acquisition, click on Eject Plate and retrieve the 
hybridization plate. Place it back in its aluminum pouch. 
3.1.10. Click on Insert Plate. 
4. Automatic clustering 
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4.1. Open the SNPAdmin application of the SNPstream software. 
4.2. Click on Run and select in the drop down menu Start and then Auto Run. 
The automatic raw data analysis and clustering will start.
  
Description of the analysis and reporting flow using three different software 
tools: 
1- Cluster analysis using the SNPstream GetGenos 
2- Data analysis and formatting using Sherpa software© 
3- Data reporting using Area51© 
1. Cluster analysis using the SNPstream GetGenos software 
N.B.: Two different users are required to go through cluster analysis (User1 and 
User2). 
1.1. Open the GetGenos application. Open the View tab and then select 
QCReview. 
1.2.  In the Qc Review section, click on New and select SNPplate Number as the 
category. 
1.3.  Select Plate within 5 days from the “Select by SNP Plates Number” drop 
down menu. 
1.4.  In the drop down menu of “Select Qc plate from list”, select the SNPstream 
barcode of the plate being analyzed. Choose the first segment (GA). 
1.5. The software will prompt you to adjust any grid shift if needed. If not, the 
analysis will resume at step 1.4. In the presence of grid shifts:  
1.5.1. Click Yes. Select the appropriate SNPware batch. The two grids from 
the two color lasers analysis will appear. 
1.5.2. Realign the shift grids by using the plate control spots as references 
(see figure 1 for Assay variation positions on the 12-plex Array plate). 
Click on Manual Adjust.  
1.5.3. Click on Update DB.  
1.5.4. Repeat steps 1.3.2. and 1.3.3. for each sample showing grid shifts.  
1.5.5. Select Segment 2 (CT) and verify if grid shifts are detected. If so, 
repeat steps 1.3.1. to 1.3.4.  
1.5.6. Reprocess the plate. 
1.5.6.1. Select GetGenos from DB in the Run dropdown menu.  
1.5.6.2. In the “Run on DB” tab, choose the Reprocess plate with # 
option.  
1.5.6.3. Enter the SNPware barcode and click on Retrieve plate list.  
1.5.6.4. In the “Reprocess a plate” section, click All segments if 
segments 1 and 2 have grid shifts or click on Selected Segments 
and choose the segment that needs to be reprocessed. 
1.5.6.5. Click on Run GetGenos. 
N.B.: Refer to the SNPstream Grid Shift documentation for complete instructions. 
  
1.6. Go back to segment 1 (GA) and perform a manual search for grid shifted 
samples (the software could have overlooked some grid shifts): 
1.6.1. Look for any cluster outlier for XX, XY and YY controls (see 
figure 1 for Assay variation positions on the 12-plex Array plate). 
1.6.2. Select all outlier samples and click on ‘’View Image’’. Make 
sure the correct SNPstream barcode file is open.  
1.6.3. For every observed grid shifted sample, click on ‘’Mark this 
well as grid shifted’’. If there are no grid shifts, close the images and 
resume the procedure at step 1.7. 
N.B.: Outliers can also be caused by dust particles on the array spot. If dust 
particles are visible, the decision to fail or pass the assay for that 
particular well must be taken by the most experience person between 
User1 and User2 (refer to figure 2 for an example of a dust particle on 
the array spot). 
1.6.4. When all grid shifted samples have been marked as so, click 
on “Fix Grid Shifted well in this segment” and follow steps 1.5.1. to 1.5.6. 
1.6.5. Repeat steps 1.6.1. to 1.6.4. for segment 2 (CT). 
1.7. Make a visual evaluation of the plate’s status by clicking on “View whole 
plate status” (refer to figure 3 for an example). This is an informative tool 
that could link failed samples to an assay plate pattern (e.g. genotypes 
missing for a complete row, column failure for A and G results etc.). If a 
plate pattern is present, refer to the lab manager before pursuing the 
analysis. 
1.8. Perform a cluster analysis as per cluster profiles shown below. 
  
  
 
Standard Cluster Analysis: 
 
Segment 1 (GA analysis) : 
 
a. Kapa : 
 
 
 
  
 
Normal Setting for Cluster Analysis: 
 
Polar View: 
YY => 0.00 to 01 
XY => 0.2 to 0.6 
XX => 0.9 to 1 
  
 
b. MN 
 
   
 
  
Normal Setting for Cluster Analysis: 
 
Polar View: 
 
YY => 0.00 to 0.05 
XY => 0.10 to 0.45 
XX => 0.9 to 1
 
  
 
c. eE 
 
 
 
 
 
 
 
 
 
 
Polar View:    Cartesian: 
  
Normal Setting for Cluster Analysis: 
Cartesian 
YY < 11000 (AA = ee) 
XX > 15000 (GG = eE or EE) 
  
 
d. Jkab 
 
  
Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.05 
XY => 0.08 to 0.35 
XX => 0.9 to 1
 
  
 
e. kK 
  Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.10 
XY => 0.30 to 0.75 
XX => 0.9 to 1 
 
  
 
f. HPA5ab: 
  Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.10 
XY => 0.15 to 0.50 
XX => 0.9 to 1
 
  
 
g. sS: 
  Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.05 
XY => 0.10 to 0.35 
XX => 0.9 to 1 
 
  
 
h. HPA1ab : 
  Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.10 
XY => 0.20 to 0.55 
XX => 0.9 to 1
 
  
 
i. cC : 
  Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.20 (AA= cc or cC) 
XX => 0.5 to 1 (GG = CC) 
 
  
 
j. HPA2ab : 
  Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.05 
XY => 0.16 to 0.75 
XX => 0.9 to 1 
 
  
 
k. Fyab : 
 
 
 
 
 
 
 
 
 
                                
Normal Setting for Cluster Analysis: 
 
Polar View 
YY => 0.00 to 0.05 
XY => 0.08 to 0.4 
XX => 0.9 to 1 
  
 
l. cC-intron : 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Normal Setting for Cluster Analysis: 
 
Cartesian View 
YY < 8000(AA= cc) 
XX > 11000 (GG= (cC or CC) 
  
Segment 2 (CT analysis) : 
 
a. Kapa 
 
  
Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.1 
XY => 0.3 to 0.75 
XX > 0.9 to 1
 
  
 
b. MN : 
  Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.15 
XY => 0.22 to 0.70 
XX > 0.9 to 1 
 
  
 
c. eE : 
 
 
 
 
 
 
 
 
 
                                     
Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.1(CC = ee or eE) 
XX > 0.3 to 1 (TT = EE) 
  
d. Jkab : 
  Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.12 
XY => 0.25 to 0.70 
XX > 0.9 to 1 
 
  
 
e. kK: 
  Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.10 
XY => 0.20 to 0.60 
XX > 0.9 to 1
 
  
f. HPA5ab: 
  Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.10 
XY => 0.20 to 0.65 
XX > 0.9 to 1 
 
  
g. sS : 
  Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.15 
XY => 0.75 to 0.95 
XX > 0.98 to 1 
 
  
 
h. HPA1ab: 
  Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.10 
XY => 0.30 to 0.65 
XX > 0.9 to 1 
 
  
 
i. cC: 
 
 
 
 
 
 
 
 
                          
Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.50 (CC = CC) 
XX > 0.8 to 1 (TT = cc or cC) 
  
 
j. HPA2ab: 
  Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.08 
XY => 0.25 to 0.65 
XX > 0.9 to 1
 
  
 
k. cC-Intron: 
  
Normal Setting for Cluster Analysis: 
 
Polar view 
YY > 19000 (CC = cC or CC)  
XX < 13000 (TT= cc) 
 
  
 
l. Fyab: 
  
Normal Setting for Cluster Analysis: 
 
Polar view 
YY => 0.00 to 0.08 
XY => 0.25 to 0.65 
XX > 0.9 to 1 
 
  
 
Figure 1: Position of Héma-Québec Assay variations on the 12-plex array plate: 
GA: CT: 
 
Figure 2: Example of a dust particle on the array spot: 
 
 
Figure 3: Whole Plate Status View: 
 
The figure represents an 
example of the whole plate 
status view. A clear problem for 
wells D07, D24 and H24 can be 
observed. Also, all samples 
located in the second half of the 
plate (I01 to P24) represent a 
clear assay problem. This 
problem has to be addressed 
and requires the Lab Manager 
approval before resuming 
analysis.
  
2. Data analysis and formatting using Sherpa software© 
2.1. Importing the results to Sherpa: 
N.B.: Two different users have to go through this section (User1 and User2). 
2.1.1. Login with your user name. 
2.1.2. Open the Sherpa software. 
N.B.: The user name listed in the Sherpa’s welcoming page should match the user 
ID that has performed the cluster analysis. 
2.1.3. Select Héma-Québec as the project. 
2.1.4. Select “Sherpa production Database” 
 
 
 
2.1.5. Click on “Import Data from a Database”. 
2.1.6. In the “Import Plates” window, select “SNPstream Machine Database”.  
2.1.7. Click on “Load plate list” and enter the SNPware plate barcode in the 
“plate name” cell. 
2.1.8. Check the box corresponding to the plate and click “Import”. 
 
        
 
  
 
2.1.9. While the plate is being imported, the following message should 
appear:  
 
 
 
2.1.10. After the plate has been correctly imported, the following table should 
become available:  
 
 
 
2.1.11. Click on the “Import Sample ID Information” icon and answer “Yes” to 
the pop-up question (the sample information comes from the 
Tracking Sheet file previously created in section 8.2. of SOP PGx-
PR-012):  
N.B.: Once User1 has imported the Sample ID Information, there is no need for 
User2 to repeat this step. 
 
  
   
 
 
2.1.12. Click on the “Save to database” icon  
2.1.13. After saving the data, reinitialize the genotyping clusters on the 
GetGenos (SNPstream) software. 
N.B.: Only User1 is required to perform this step. 
 
2.2. Concordance between users 
N.B.: This section applies to User 2 only, being a more experienced and 
knowledgeable technician than User 1. 
2.2.1. Login to your user name. 
2.2.2. Open the Sherpa software. 
N.B.: The user name listed in the Sherpa’s welcoming page should match the user 
ID that has performed the cluster analysis. 
2.2.3. Select the ‘’Héma-Québec project’’. 
2.2.4.  Click on the Data menu and select “Sherpa production database”. 
2.2.3. In the left lower side of the Sherpa screen, two users’ call should now 
be available. 
 
 
2.2.4. Click on “start call”. 
2.2.5. Select the “Final call” option and highlight the two users’ call batch. 
Then click OK. 
  
 
                   
2.2.6. The user-to-user discordances are now displayed. Click on the filter 
icon  to sort down all user-to-user discordant calls. 
2.2.7. Find out the discordant calls and evaluate the best clustering analysis. 
2.2.8. Click on each discordant call and make the final call. 
2.2.9. Give a reason and click “OK” (refer to table 1 for Sample Failure 
Criteria). 
2.2.10. Repeat these steps for all discordant calls. 
2.2.11. Once all discordant calls have been evaluated, click “Save Call” and 
“save database” to update the database. 
 
Table 1: Sample failure criteria 
Criteria Description Sample status 
A Sample failed over 2 different markers (evaluation made with Area51) Failed 
B 1 discordant genotyping results between both DNA strands Failed 
C EXO-SAP issue pattern (refer to SNPstream documentation) Failed 
D Complete well evaporation during the experiment Failed 
E Clear plate pattern problem (missing arrays, non-uniform array spots on the 
SNPware plate). 
Failed 
F Low intensity signal or sample outside normal clustering values (refer to 
cluster profiles) 
Failed 
G Major dust particles issue onto the hybridization plate Failed 
H No signal for the SNPstream plate controls (XX, XY and YY) Failed 
 
2.3. Control genotypes 
2.3.1. On the left end side of Sherpa screen, click on “control”. 
 
  
 
2.3.2. Look at the concordance table and check if controls match criteria 
described in table 2.  
Table 2: Control failure criteria: 
Controls Description Control 
status 
DNA 
controls 
Option1: Exact same criteria described in Table 1. 
Option2: No concordance between theoretical and actual genotypes. 
Failed 
Negative  Genotyping results are generated Failed 
 
2.3.3. Possible explanations for a majority of controls failing genotypes: 
2.3.3.1. Possible evaporation or pipetting errors. Look at the Plate 
Validation tab in the corresponding Tracking Sheet for any 
comment that could justify the problem.  
2.3.3.2. Possible grid shift that was not flagged previously. 
2.3.3.3. Possible presence of dust particle in the array plate. 
2.3.4. Possible explanations for a majority of controls discordant from 
expected genotypes:  
2.3.4.1. Wrong sample ID and/or control ID from the SNPstream Input 
file.  
2.3.4.2. Wrong sample ID and/or control ID from the Plate Maker file. 
2.3.4.3. Possible DNA contamination. Refer to the gel picture in the Plate 
Validation tab in the corresponding Tracking Sheet.  
2.3.5. If no explanation can be found, a new dilution of controls has to be 
done and the whole assay plate has to be repeated.  
3. Data reporting using Area51©: 
N.B.: The Area51 software analyzes the final calls (previously saved in the Sherpa 
database) as per acceptance criteria described in tables 1 to 4 (see above for 
tables 1 and 2; see below for tables 3 and 4). 
 
  
Table 3: Marker failure criteria 
 
Table 4: Plate failure criteria  
 
 
3.1. Type the following address in the internet browser: 
https://my.pgx.ca/session/new 
3.1.1. Login. 
3.1.2. Select Area51. 
3.1.3. Select the desired plate to be reported. 
3.1.4. Generate a technical report as well as a client report. 
3.1.5. If Area51 generates a “Plate Failure” for any reason listed in table 4, 
please address the problem to the Lab Manager or to the appropriate 
authority.       
Controls Description Control 
status 
A Call rate lower than 85% Failed 
B Unacceptable clustering patterns Failed 
Controls Description Control 
status 
Sample More than 30% of wells show no signals for the XX, XY and YY 
SNPstream hybridization plate controls.  
Failed 
Sample More than 30% of wells show poor EXO-SAP activity Failed 
Marker More than 30% of markers show less than 85% of call rate Failed 
DNA controls More than 10% of DNA controls genotypes are missing Failed 
DNA controls More than 5% of DNA controls genotypes show discordant calls 
between theoretical and actual genotypes 
Failed 
Negative 
controls 
More than half of markers show positive genotyping results (refer to 
Agarose gel for more details on possible contamination). 
Failed 
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Abstract  
  
Background. ABO and Rh(D) phenotyping of both blood donors and transfused 
patients is routinely performed by blood banks to ensure compatibility. These 
analyses are done by antibody-based agglutination assays. However, blood is not 
tested for minor blood group antigens on a regular basis because of cost and time 
constraints. This can result in alloimmunization of the patient against one to several 
minor antigens and may complicate future transfusions. Study design and Methods. 
To address this problem, we have generated an assay on the GenomeLab SNPstream 
genotyping system to test simultaneously polymorphisms linked to 22 different blood 
antigens using donor’s DNA isolated from minute amounts of white blood cells. 
Results. The results showed that both the error rate of the assay, as measured by the 
strand concordance rate, and the no-call rate were very low (0.1%). The concordance 
rate with the actual red blood cell and platelet serology data varied from 97 to 100%. 
Experimental or database errors as well as rare polymorphisms contributing to 
antigen conformation could explain the observed differences. However, these rates 
are well above requirements since phenotyping and cross-matching will always be 
performed prior to transfusion. Conclusion. Molecular profiling of blood donors for 
minor red blood cell and platelet antigens will give blood banks instant access to 
many different compatible donors through the set-up of a centralized data storage 
system. 
 
Key words : SNPs, blood groups, high-throughput screening, minor antigen 
  
Introduction 
Blood banking facilities routinely test for the presence of the major antigens ABO 
and Rh(D). These analyses are done for every blood donor by antibody-based 
agglutination assays using automated equipment. However, minor antigens are not 
currently tested on a regular basis. This limitation may result in alloimmunization of 
the patient and complicate future transfusions.1 Part of the problem is that the 
procurement of extensively phenotyped blood components to specific patients using 
agglutination-based assays is costly and labour intensive especially when the 
patient’s serum contains antibodies against several minor blood group antigens. 
Furthermore, it is often impossible to test some antigens because of reagent 
shortages. The more frequent use of supportive transfusion therapies and a better 
survival of patients indicate that the need to transfuse alloimmunized individuals will 
increase in the future. For all these reasons, the procurement of compatible blood 
represents a significant operational problem for blood banks. 
 
Cloning of blood group genes and knowledge of their molecular basis made possible 
the development of molecular typing methods, leading to identification of new 
mutations, polymorphisms and alleles. The first application of these assays has been 
for antenatal diagnosis of maternal-fetal compatibility to predict the risk of 
development of hemolytic disease of the newborn.2 Since then, genetic tests have 
been described for most of the clinically important red blood cell and platelet 
antigens. 3,4 Despite these successes, these assays are usually not suitable for massive 
testing. With the human genome project came great improvements in high-
throughput technologies (increased number of parallel reactions, automated systems 
  
to facilitate the data production and better tools for the analysis), resulting in a 
dramatic reduction in genotyping cost.  
 
These commercially available genotyping systems which can analyze multiple SNPs 
in parallel include Sequenom’s MassARRAY system,5 Beckman’s GenomeLab 
SNPstream Genotyping System,6 ABI’s SNPlex Genotyping System, ParAllele 
Molecular Inversion Probe Technology,7 Affymetrix’ GenFlex Tag Arrays8 and 
Illumina Bead-Array technology.8 In this work, we have tested the possibility of 
using a semi-automated system, the GenomeLab SNPstream Genotyping System 
from Beckman Coulter, to genotype DNA samples from blood donors. This system 
uses multiplex PCR and single-base extension to genotype up to 12 SNPs per sample 
simultaneously and can perform up to 600 000 genotypes per day. Most of the other 
high-throughput platforms use a fixed set of SNPs or need a few hundreds or 
thousands of SNPs to be cost-effective. 
 
Many recent publications have showed use of high-throughput systems to genotype 
multiple antigens at once, including a study using also the Genome Lab SNPstream 
genotyping system.10-13 Here, we present the development of an assay that can be 
used to genotype polytransfused patients and regular blood donors for 22 different 
antigens. It improves on previous reports as it needs only minute amounts of blood 
and its low no-call rate and error rate makes it suitable for use in clinic in order to 
build a registry to accelerate the quest for compatible blood.  
 
  
Materials and Methods 
Blood collection and DNA extraction 
Peripheral blood samples were collected from randomized volunteers from the 
province of Quebec after signature of an informed consent form approved by Héma-
Québec’s Research Ethics Committee. 618 samples consisted of a blood drop applied 
on an FTA card. All samples were anonymized and the FTA cards were sent to the 
Genome Quebec Innovation Centre in Montreal for genotyping. DNA was then 
extracted from the FTA cards using the GENERATION Capture Card Kit (Gentra 
Systems, Minneapolis, MN), according to the manufacturer’s specifications. A good 
proportion of the blood samples were phenotyped at Héma-Québec for the most usual 
minor blood group antigens using standard serology techniques. The 96 samples that 
were used to optimize the panels consisted of DNA isolated at Héma-Québec by the 
R&D group using the Qiagen QiaAmp DNA Blood mini kit (Qiagen, Mississauga, 
ON) according to the manufacturer's protocol. These samples are routinely used as 
controls. 
 
Genotyping 
Primer selection 
SNP flanking sequences were tested for the presence of repeats or duplicated 
regions and masked if needed using the BLAT program 
(http://www.genome.ucsc.edu). In the first round, PCR and extension primers 
were designed using the Autoprimer program (http://www.autoprimer.com). 
The program selects PCR primers that will generate products ranging between 
90 and 180 bp and an optimized single base-pair extension primer 5’ to the 
  
SNP site and assemble them into panels of 12 SNPs of the same type.6 In 
subsequent rounds, modifications were made to the primers and the panel 
composition (see Tables 2 and 3). 
PCR 
Twelve-plex PCR reactions were performed in 384-well plates (MJS 
BioLynx) in a 5 μL volume using 6 ng of DNA, 75 μM dNTPs, 0.5 U of 
AmpliTaq Gold (Perkin-Elmer), and the 24 PCR primers at a concentration of 
50 nM each in 1 X PCR buffer. Thermal cycling was performed in GeneAmp 
PCR system 9700 thermal cyclers (Applied Biosystems) using the following 
program : initial denaturation at 95°C for 5 min followed by 40 cycles of 95°C 
for 30 sec, 55°C for 55 sec, 72°C for 30 sec. After the last cycle, the reaction 
was held at 72°C for 7 min. Following PCR, plates were centrifuged briefly 
and 3 μL of a mixture containing 0.67 U Exonuclease I (Amersham 
Pharmacia) and 0.33 U Shrimp Alkaline Phosphatase (Amersham Pharmacia) 
were added to each well. The plates were sealed and incubated for 30 min at 
37°C and at 95°C for 10 min.  
Extension and hybridization  
Extension reactions and hybridizations to the Orchid UHT microarray plates 
were carried out as described by Bell et al.,6 using the SNPware UHT reagent 
kit and the appropriate extension mix kit containing two dideoxynuclotides 
labelled with either Bodipy-Fluorescein or TAMRA dye (Beckman Coulter, 
Fullerton, CA). Finally, the plates were read using the GenomeLab 
SNPstream Array Imager and fluorescence intensity was measured with help 
  
of the UHTImage software. Intensity was plotted and genotypes were called 
by the UHTGetGenos software. After visual inspection of the clusters, manual 
adjustments were made for some of the assays.  
Alternate genotyping assays 
All samples showing discrepancies between phenotype and genotype results were 
retested using different genotyping assays 14-16 or by sequencing. 
  
Results 
On the GenomeLab SNPstream system, panels of 12 SNPs can be genotyped in 
parallel for the same alleles. SNPs were prioritized based on their importance for the 
blood bank, their frequency in the Quebec population (we prioritized antigens with a 
frequency above 5%) and their allele type. Twelve antigen pairs were thus selected: 
C/c, E/e, M/N, S/s, Kpa/b, Fya/b, Jka/b, K/k, and some platelet antigens, HPA-1a/1b, 
HPA-2a/2b, HPA-4a/4b and HPA-5a/5b. For these antigens, the main causative 
polymorphism have been conclusively identified 3,4. For Rh(C/c), polymorphisms in 
strong linkage disequilibrium with the causative SNP were selected because of 
difficulties in generating good assays (see below). Panels for both strands were 
designed to increase confidence in the genotyping calls. Ninety-six DNA samples 
with known phenotypes (for about half of the antigens studied) were used to optimize 
the panels.  
 
 One obstacle in the creation of these panels was that the E/e antigens, which were 
considered essential to the panel, are caused by a C/G SNP. Since the 11 other 
antigen pairs are caused by C/T or A/G SNPs, we decided to develop two assays 
which test only one allele at a time (i.e. the C allele in the C/T panel or the G allele in 
the G/A panel; see Figures 1B and 2B). Another major issue that came up after a few 
rounds of testing was the fact that no primers could be designed to efficiently amplify 
the RHCE gene over the RHD gene near any C/c discriminating SNP. Two assays 
were then developed: one discriminates for the presence of the c antigen over C/C 
individuals (assay RHCE exon 2) and the other assay looks for the presence of an 
insertion in intron 2 of RHCE which was previously shown to be strongly associated 
with the RH(C) allele but absent from either the RH(c) allele or the RHD gene (assay 
  
RHC intron 2; see Figure 1A).17,18 11 antigen pairs are included in the final panels 
(HPA-4a/4b was removed; see Table 4).  
 
To evaluate the panels and the feasibility of the proposed approach, DNA from 618 
regular Hema Quebec's blood donors were used.  The phenotypes were not known in 
advance by the genotyping group in Montreal. In addition, 32 duplicate samples were 
present, but their identity was not transmitted to the genotyping group until after 
results were obtained. Examples of the genotyping results are shown in Figure 2. The 
call rate, as measured by combining data from both strand assays, was very high at 
99.9%, indicating that the assays are extremely robust considering the variability in 
the DNA quantity that could be extracted from the FTA cards (Table 4). The assays 
for antigens E/e had the lowest call rate at 99.2% which is more than acceptable since 
in that case genotype calls on both strands were needed to make a final call. The 
accuracy of the assays, as measured by the strand correlation or the duplicate samples 
reproducibility, was also very high with both measurements being above 99.7%. 
Only one discordant call was observed when comparing data from each strand (in the 
Rh(C/c) assays) and two discordant calls when comparing calls from each of the 
duplicate samples (in the Rh(C/c) and the Rh(E/e) assays).  
 
The concordance rate between the genotypes and the serology data was also very 
good for 18 out of 19 antigens, and varied from 97% to 100%. One exception was for 
antigen HPA-1b where the concordance was only 50% (3 correct calls out of 6 tests). 
Sequencing confirmed the initial genotyping result. All other discrepancies (12 
samples) were verified by another approach. The initial genotype was confirmed for 
  
ten of the twelve samples (which translates to a final error rate of 0.1%). The two 
discrepancies were in the RHCE gene, one for the E and one for the C antigen, and 
by looking at the raw data they could easily be explained. No serology data was 
available for antigens HPA-2a, HPA-2b and Kpb, but all observed frequencies are in 
agreement with the literature.19  
  
  
Discussion 
 
In this study, we have developed an assay that can simultaneously test the presence of 
22 different minor antigens (C/c, E/e, K/k, Fya/b, Jka/b, S/s, M/N, Kpa/b, HPA-1a/1b, 
HPA-2a/2b and HPA-5a/5b) in a DNA sample. Most of these antigens are common 
in the general population (in the population studied here, all are above 15%, except 
for K and Kpa at 6% and 4% respectively) and if they are not taken in consideration 
in transfusion medicine, major complications may arise. At the moment, blood banks 
must test dozens of different blood samples for specific antigens to find a compatible 
donor. These tests are very expensive and a compatible donor can be hard to find for 
some rare antigen combination. The molecular profiling of all donors and the creation 
of a centralized data system would give blood banks instant access to many different 
compatible donors decreasing the cost. Using the GENTRA system for DNA 
isolation from FTA cards and the Beckman Coulter GenomeLab SNPstream 
platform, the entire procedure is very fast as it takes only about three working days 
and human intervention is minimal. The use of FTA cards has many great advantages 
for implementation at a blood bank facility. Blood is very easy to collect as only one 
drop is needed. The collection can conveniently be done at the same time as the 
measurement of hemoglobin at the  registration step. Thus existing functioning 
protocols need only to be modified slightly and no additional blood tubes, which 
would add unnecessary time and cost (reagents, shipping, etc.) need to be collected. 
Also DNA is very stable on FTA cards (it can last for years) which is very 
convenient for handling, shipping and long-term storage at room temperature.20  
 
  
The missing call rate on this genotyping system has been previously evaluated at 5% 
and the error rate at 0.5%.6 In a clinical setting, any genotype information will be 
confirmed with a agglutination-based assay before the blood is transfused to the 
patient. Thus any phenotype concordance higher than about 90% would be 
acceptable. But since many factors can play a role (call rate, genotyping errors, 
phenotyping errors, additional polymorphisms, database entry errors, etc.), we 
considered that obtaining the highest genotype quality was essential. Thus, we 
developed panels on both strands in order to reduce both the no-call rate and error 
rate as two “no calls” are unlikely (provided the DNA sample is of good quality) and 
that two discordant calls will not be registered as valid. The data obtained from this 
study showed the strong reliability of the technique having an accuracy of > 99.7% 
and a call rate of more than 99%. All genotype-phenotype correlations, except one, 
were above 97%, which indicates that the panel will be suitable for clinical use. The 
only exception was for antigen HPA-1b, which showed very poor correlation (50%, 
but only 6 comparisons could be made with the phenotype database). However, all 
discrepancies between genotype and serology data except two (both in RHCE gene) 
were confirmed by another genotyping method or by sequencing indicating that the 
quality of the results generated by our assays is very high. 
 
At the time of writing this paper, a comparable study using the GenomeLab 
SNPstream platform was published.11 Although it validates the use of this platform, 
we had a very different approach using results from both strands to increase 
confidence in the genotype calls. Their assays had overall lower concordance rates 
especially for the C and e antigens (87.7% and 73.9% respectively) which would 
preclude their use in clinic. They explain that the problem originated from the fact 
  
that the RHD gene was co-amplified with RHCE during the process. As described 
above, our panels avoided this problem for the C/c antigens by using primers specific 
for the RH(c) allele and by designing an additional assay that test the presence of an 
insertion in intron 2 of RHCE which is associated with the C antigen.17,18 As for the 
E/e antigens we designed primers that successfully discriminate between both genes 
using adjacent polymorphisms.  
 
 There could be many factors that could contribute to differences between the 
observed genotype and serological data. First, more than one polymorphism can 
contribute to the protein conformation or expression. For example, it is well known 
that a polymorphism in the promoter of the FY can block its expression.21,22 This 
polymorphism is rare in white individuals, but extremely frequent in individuals of 
African descent. We confirmed that two of the three samples that differed with the 
FY serological information had that mutation. In addition, several different varieties 
of each antigen can exist (weak and partial variants) caused by additional 
polymorphisms (for example the Fyx antigen is present at a frequency of 1.5 to 2.5 % 
in the Caucasian population).23,24 These usually show a very different reactivity in a 
clinical test. Thirdly, because of the high homology between RHCE and RHD in the 
sequence in and around exon 2, we had to use a second assay which doesn't test 
directly any C antigen causing polymorphism, but which relies on the presence of an 
insertion in cis with the C allele. This is mostly true for Caucasians, but Faas et al.25 
and Daniels et al.26 have showed that for up to 25% of individuals of African descent 
the presence of a D-CE-D hybrid gene containing exons 1-3 of RHD and expressing a 
weak C phenotype will induce false negative results. Finally, in the case of HPA 1b, 
  
since no additional modifying polymorphism is known 3, the most plausible 
explanation would be an error in the phenotype database. 
 
We are aware that many false positives or false negatives for most of the antigens 
studied will be observed. Testing for all the rare polymorphisms is not feasible at the 
moment as it would make the cost prohibitive, and also because new polymorphisms 
are identified on a regular basis. Also, testing for ABO and RH(D) was not a priority 
for our panel since these tests are done automatically for every collected blood unit 
and is extremely cheap to perform. In this first panel, we decided to concentrate on 
frequent polymorphisms in our population, but eventually, they could be expanded 
with additional antigens as a drop in genotyping costs and improvements in the 
multiplexing capacities of the systems will occur (indeed our SNPstream system has 
been recently upgraded to accommodate 48-plex arrays). On the other hand, 
specialized panels for ABO, RHD and RHCE genes, which exhibit the most 
variations, could be created to facilitate clinical analysis and support serology data.  
 
Since the call rate and error rate obtained in this study were well above requirements, 
and because phenotyping and cross matching will always be performed prior to 
transfusion, such a procedure will definitely save both time and money. The 
molecular profiling of blood donors for all these antigens is much less expensive than 
the serological typing, not to mention that some tests are very labor-intensive and 
complicated to perform (platelets) or that the reagents for some antigens are in very 
short supply or extremely expensive. At the present time, blood banks must test on 
average 5-10 times more blood bags that what is required to find a compatible donor. 
  
The process can be very time-consuming for rare combinations of antigens. The 
creation of a centralized data storage system would give blood banks instant access to 
many different compatible donors. Finally, since much more information will be 
known about each donor, many future complications such as alloimmunization of 
patients receiving multiple transfusions will be reduced.  
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Table 1. PCR primers used in the panels 
Assay Primer name Sequence (5'-3') Size 
RHCE exon 5 
RHCE_e-F-s2 TGGATGTTCTGGCCAAGTG 
107 
RHCE_e-R-s2 CTGTCACCACACTGACTGCTAG 
RHC intron 2 
RHCintron-F CAGGGCCACCACCATTTGAA 
151 
RHCintron-R TGGTAGCAGGCGTCTGTAAAAA 
RHCE exon 2 
RHCEc_CF-s3 TCCCCCTCCTCCTTCTCA 
143 
289-RHCEas-HD9135 GCCAGCATGAAGAGGTTGAA 
KEL exon 6 
KelEx6K1_2F-s2 GGATCCTTATGCTCAGCCCC 
157 
KelEx6K1_2R-s2 AGGATGAGGTCCTAGGTAGGCTCTG 
FY exon 1 
FYex2Fya_bF AGTCATCCAGCAGGTTACAGG 
129 
FYex2Fya_bR AAGATGTATGGAATTCTTCCTATGG 
JK exon 9 
JKa_b_F-s3_1 CCTGCTAACTTTCAATCCCACCCTC 
150 
JKa_b_R-s3_1 TGCCAGGTGAGCGCCATGAAC 
GYPB exon 4 
GYPBEx4s_SF-s2 TTGTCAAATATTAACATACCTGGTACAGT 
170 
GYPBEx4s_SR-s2 AATATGATTAAGAAAAGGAAACCCG 
GYPA exon 2 
285-GYPAs-HD9131_1 CAACTTCTATTTTATACAGA 
98 
287-GYPAas-HD9133_1 TCTTTGTGACTGAAGAAGAA 
KEL exon 8 
KelExon8Kpa_bF AGCAAGGTGCAAGAACACT 
101 
KelExon8Kpa_bR AGAGCTTGCCCTGTGCCC 
GPIIIA exon 3 
GPIIIAex3HPA-1a_bF ATTCTGGGGCACAGTTATCC 
114 
GPIIIAex3HPA-1a_bR ATAGCTCTGATTGCTGGACTTC 
GPIB exon 2 
GPIBHPA-2a_bF-s2 CTCAGTCAAGTTGTTGTTAGCCAGAC 
105 
GPIBHPA-2a_bR-s2 CTCTACCTGAAAGGCAATGAGCT 
GPIA 
GPIaHPA5_F GCTCTTGGTAGGTGCACCAATGT 
148 
GPIaHPA5_R TTCCAAATGCAAGTTAAATTACCAG 
 
  
Table 2. Probes used in the GA panel 
Antigen Primer name Sequence (5'-3') 
C RHCintron-Gins-U12 CGACTGTAGGTGCGTAACTCGGTGCCCTTTGTCACTTCCCA 
c RHCEEx2Rhc_CGA-U9 GACCTGGGTGTCGATACCTACCCTTGGCTTGGGCTTCCTCACCTC 
e RHCE_eCTU3-s3_1 CGTGCCGCTCGTGATAGAATCCTTTGGATTGGACTTCTCAGCAGAG 
K/k KelEx6K1_2-GA-U5 GCGGTAGGTTCCCGACATATACTCATCAGAAGTCTCAGC 
Fya/Fyb FYex2Fya_b-U11 AGAGCGAGTGACGCATACTAGATTCCTTCCCAGATGGAGACTATG 
Jka/Jkb JKa_b-U4_1 AGCGATCTGCGAGACCGTATCTCAGTCTTTCAGCCCCATTTGAG 
S/s GYPBs_S-GA-U7 AGGGTCTCTACGCTGACGATAAACGATGGACAAGTTGTCCC 
M/N GYPAex2M_NGA-U2 GGATGGCGTTCCGTCCTATTGTGCATTGCCACCYCAGTGGTACTT 
Kpa/Kpb KelExon8KGA_U1 ACGCACGTCCACGGTGATTTGCCTCAGAAACTGGAACAGCC 
HPA-1a/1b GPIIIAex3HPA-1GAU8 GTGATTCTGTACGTGTCGCCCTTCAGGTCACAGCGAGGTGAGCCC 
HPA-2a/2b GPIBex2HPA2GA-U10-s3 AGATAGAGTCGATGCCAGCTGAGCTTCTCCAGCTTGGGTGTGGGC 
HPA-5a/5b GPIaHPA5-GA-U6 GGCTATGATTCGCAATGCTTGTCTACCTGTTTACTATCAAA 
 
  
Table 3. Probes used in the CT panel 
Antigen Primer name Sequence (5'-3') 
C RHCintron-CT-U10 AGATAGAGTCGATGCCAGCTGGCAGAGGCTGCAATGAGCTATGATTGTAC 
c RHCEEx2Rhc_CctU6-s2 GGCTATGATTCGCAATGCTTTGCTCCAGCTGTGTCTCCGGAAA 
E RHCE_eCTU3-s3_1 CGTGCCGCTCGTGATAGAATCCTTTGGATTGGACTTCTCAGCAGAG 
K/k KelEx6K1_2U7_CT AGGGTCTCTACGCTGACGATTGGACTTCCTTAAACTTTAACCGAA 
Fya/Fyb FYex2Fya_bU4 AGCGATCTGCGAGACCGTATGGGGGCAGCTGCTTCCAGGTTGGCA 
Jka/Jkb JKa_b-CT-U5-s2 GCGGTAGGTTCCCGACATATACCCCAGAGTCCAAAGTAGATGT 
S/s GYPBEx4s_S-CT-U2-s2 GGATGGCGTTCCGTCCTATTTTGAAATTTTGCTTTATAGGAGAAA 
M/N GYPAex2M_NCTU11-s3_1 AGAGCGAGTGACGCATACTAACAGAAATTGTGAGCATATCAGCAT 
Kpa/Kpb KelExon8Kpa_bU12_CT CGACTGTAGGTGCGTAACTCTTCCTTGTCAATCTCCATCACTTCA 
HPA-1a/1b GPIIIAex3HPA1CTU8-s2 GTGATTCTGTACGTGTCGCCCTCTTTGGGCTCCTGTCTTACAGGCCCTGCCTC 
HPA-2a/2b GPIBex2HPA-2a_bCTU9 GACCTGGGTGTCGATACCTAGACCCTGCCCCCAGGGCTCCTGA 
HPA 5a/5b GPIaHPA5-CT-U3 CGTGCCGCTCGTGATAGAATTTAGTTTATTTTTTTTTTTTTACCT 
 
  
Table 4 Genotyping results and correlation with phenotype 
1 No heterozygote calls are registered for this assay. N: number of samples for which 
serology data was available. 
 
Antigen Call rate Concordance  DNA strands Frequency Reproducibility 
Concordance 
Pheno/Geno N 
C 
99.8 % 99.8 % 
62.2 % 97 % 99.2 % 131 
c 81.5 % 100 % 100 % 323 
E 
99.2 % 100 %1 
22.9 % 97 % 99.5 %  196 
e 97.1 % 100 % 99.5 %  181 
K 
100 % 100 % 
6.1 % 100 % 100 % 22 
k 99.8 % 100 % 100 % 344 
Fya 
100 % 100 % 
62.1 % 100 % 99.2 %  130 
Fyb 85.7 % 100 % 97.3 % 75 
Jka 
100 % 100 % 
74.4 % 100 % 98.6 %  146 
Jkb 75.2 % 100 % 98.9 % 97 
S 
100 % 100 % 
58.2 % 100 % 100 %  70 
s 88.6 % 100 % 98.5 % 66 
M 
100 % 100 % 
80.4 % 100 % 98.7 %  76 
N 71.0 % 100 % 100 % 26 
Kpa 
100 % 100 % 
4.1 % 100 % 100 % 26 
Kpb 99.8 % 100 % - - 
HPA-1a 
100 % 100 % 
97.1 % 100 % 100 % 30 
HPA-1b 30.2 % 100 % 50.0 % 6 
HPA-2a 
100 % 100 % 
99.5 % 100 % - - 
HPA-2b 16.0 % 100 % - - 
HPA-5a 
100 % 100 % 
98.6 % 100 % 100 % 9 
HPA-5b 21.8 % 100 % 100 % 9 
Total 99.9 % 99.9 % - 99.7 % 99.3 % 1963 
  
Legends to Figures 
Figure 1. Detailed strategy for the detection of the two non-standard SNPs.  
A) RHCE insertion in intron 2. This insertion is present almost uniquely in C positive 
individuals. The probes in the G/A panel and the C/T panel are indicated in bold. The 
base interrogated in each panel is different B) RHCE exon 5 C/G SNP. The same probe is 
used in the C/T and the G/A panel but in each only one terminator nucleotide can be 
incorporated. However, in the C/T panel, small amounts of ddT seem to be incorporated 
in the extension product. 
Figure 2. Selected examples of genotyping results. Polar and cartesian representations 
are presented.  
A) HPA-2a/2b in the G/A panel. B) E/e in the C/T panel. The SNP tested is a C/G. Since 
no G is present in the extension mix, the T dideoxynucleotide is incorporated relatively 
well in the extension product and one can clearly see the distinction between C/C and 
C/"G" genotypes in the polar view. 
 
 
 
 
 
 
